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Foreword
The International Laboratory for Research on Animal Diseases (ILRAD) was
established in 1973 by the Consultative Group on International Agricultural
Research (CGIAR) and given a mandate to conduct intensive research leading to
the improved control of important livestock diseases in developing countries.
Research at ILRAD concentrated initially on developing novel immunological
control methods for theileriosis and trypanosomiasis.  More recently the
Theileriosis Programme has been expanded to cover other tick-borne diseases.
East Coast fever is a virulent and usually fatal disease caused by the parasite
Theileria parva.  It is estimated that about 40% of the 63 million cattle in
eastern, central and southern Africa are at risk of infection with the organism.
Theileria parva is an intracellular protozoan parasite that invades bovine
lymphocytes, causing them to proliferate in an uncontrolled manner.  Intense
destruction of lymphoid organs coupled with invasion of non-lymphoid tissues
with parasitized cells lead ultimately to the death of the majority of infected
cattle.  Those animals that recover from infection are solidly immune to
homologous challenge, and a method of vaccination is available based on
infection with a sporozoite stabilate in the face of treatment with long acting
formulations of oxytetracycline.  Major drawbacks of this form of immunization
are its dependence on an effective cold chain, and the considerable antigenic
diversity that exists between different isolates of the parasite.  The development
of a broadly protective subunit vaccine against T. parva has therefore been a
major research goal of ILRAD's Tick-Borne Diseases Programme.
Bovine trypanosomiasis affects some 50 million cattle in Africa and is
considered to be the major disease constraint on livestock production in sub-
Saharan Africa.  The disease is caused by an extracellular protozoan parasite
and is characterized by anaemia, progressive cachexia and eventual death.  The
disease has serious effects on productivity and reduces the reproductive
potential of the host.  The absence of sterile immunity following trypanosome
infection due to the parasite's ability to vary its surface glycoprotein coat led to
concern that a vaccine against trypanosomiasis may not be practical.  However
this view has been overturned by recent findings.  Certain breeds of cattle,
found mainly in West Africa, have evolved a degree of genetic resistance to the
disease and are termed trypanotolerant.  Trypanotolerant cattle appear to control
parasite numbers as well as the pathological consequences of the disease.  The
description and characterization of trypanotolerance has renewed interest in the
feasibility of designing novel immunological control methods for the disease.
The trypanosomiasis research programme at ILRAD is now largely focused on
the elucidation of mechanisms responsible for trypanotolerance.  Its major goals
are to determine if there is an immunological basis for trypanotolerance, to
ascertain how trypanotolerant cattle control their parasitaemia and to identify
the genes responsible for the trait.
The parasite systems in which ILRAD is involved are complex and present
problems similar to those faced by scientists attempting to develop improved
control measures against malaria, leishmaniasis and Chaga's disease.  Much
information has been generated in the latter systems that have altered current
perceptions of the role of immunity in protection and disease and modified
vaccine development strategies.  It was therefore considered timely that a
workshop be convened to discuss novel immunization strategies against
protozoan parasites.  The principal aim of the meeting was to review those
developments in the fields of immunology and immunoparasitology that have
relevance to the development of vaccination strategies for ECF and
trypanosomiasis.  Of relevance to the control of ECF were recent developments
in the elucidation of events that surround the induction of cytotoxic T
lymphocytes, and the role of cytokines in the control and pathogenesis of
parasitic infections.  Chief areas of interest to the trypanosomiasis programme
were disease-related perturbations of the immune system, the role of individual
T cell subsets in immunity to parasites and the involvement of cytokines in the
control and pathogenesis of parasitic diseases.  More specific discussions
focused on:
• the role of CTL in parasitic infections;
• antigen processing for class I MHC-restricted responses;
• novel technologies for identifying antigens that provoke CTL responses;
• the role of detrimental immune responses in pathogenesis;
• the role of T cell subsets and their products in the control of parasitic
diseases; and
• immunization strategies for driving immune responses towards favourable
rather than detrimental mechanisms.
Ten experts in these fields participated in the workshop, and through lively
discussions contributed to be formulation of a series of recommendations that
will be incorporated in ILRAD's immunology programmes for the next five
years.
D.J.L. Williams
Chairperson, Workshop Organizing Committee
International Laboratory for Research on Animal Diseases
Nairobi, Kenya
January, 1994.
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Research into improved means of control of trypanosomiasis of livestock has
been a part of the Laboratory's research agenda since its inception in the 1970s.
At that time, it was recognized that trypanosomiasis constituted the most
significant disease constraint on livestock development in sub-Saharan Africa.
Also at that time, rapid advances were being made in understanding the basis of
immune responses and in the development of new vaccines.  Twenty years later,
trypanosomiasis remains the most important disease constraint on livestock
development on the African continent, and to a lesser, but still important extent,
in other parts of the world where non-tsetse transmitted forms of the diseases
are prevalent.  This is particularly the case in Asia and Latin America.  It is
difficult io ascertain the real costs of the disease in direct and indirect terms, but
a generally accepted figure is $5 billion annually in sub-Saharan Africa alone.
The disease also affects man, and the number of new cases reported each year
runs into the tens of thousands, many of which prove fatal.
The trypanosomiasis research programme in the Laboratory has two broad
objectives.  First, to develop approaches and technologies which will enable
currently available control strategies to be applied more effectively and, second,
to develop novel means of control.  Trypanosomiasis control at present relies on
three basic approaches: (a) chemotherapy and chemoprophylaxis, (b) vector-
control and (c) the farming of trypanotolerant livestock.  The Laboratory has not
engaged in research on improved means of vector control, this being the
mandate of other institutions, most notably the International Centre for Insect
Physiology and Ecology (ICIPE) in Nairobi.
In support of current control options, the Laboratory has placed considerable
emphasis on the development of effective diagnostic tools to underpin disease
and disease control monitoring.  Emphasis has been given to antibody-based
systems for detecting circulating parasite antigens and these new and sensitive
diagnostic tests have been transferred to the International Atomic Energy
Agency for field validation across Africa.
In recent years, reports of apparent drug resistance have been increasing.
Given the importance of drugs in the disease controllers' armamentarium, and
the fact that all of the currently available drugs are chemically related one to
another, the emergence of drug resistance in trypanosomes is a serious concern.
The programme at ILRAD has therefore included research into the evolution of
drug resistance in the field, on the one hand, and into the molecular basis for
drug resistance, on the other. Through better understanding of the circumstances
which lead to the development of drug resistance, and with the availability of
rapid and accurate methods to detect and quantify drug resistance in field
isolates, it is hoped that chemotherapy can be sustained as an effective control
measure into the foreseeable future without the need to develop new drugs-the
latter being a very costly and unattractive proposition for the drug industry.
With respect to trypanotolerant livestock, research on the definition of the
trypanotolerance trait, estimation of heritability and development of effective
means for selection of better trypanotolerant cattle has been undertaken jointly
by ILRAD and the International Livestock Centre of Africa (ILCA).  This
research has led to the identification of selection criteria and development of
selection programmes based on field challenge and monitoring of response in
immature animals.
The Laboratory's programme on development of novel control strategies
envisages two principal outputs-vaccines and candidate trypanotolerance genes.
With respect to vaccine development, scientists at ILRAD, during its early
years were instrumental in the description of antigenic variation and
subsequently in the description of the genetic control of this phenomenon.  The
more that was understood about antigenic variation, the clearer it became that
vaccines based on immune responses to the variant surface coat of
trypanosomes would be unlikely to have an impact in the field.  However,
increased understanding of the cell biology of trypanosomes and their molecular
biology has led to the identification of parasite components and products which
may in their own right be responsible for development of disease.  This in turn
has brought the possibility of development of vaccines based on immune
responses to invariant molecules such as cystein proteases and cyclophilins,
which are produced by trypanosomes and which may be expected to contribute
to the disease process.  A further potential option for development of novel
strategies based on the immune response is the development of vaccines using
invariant antigens of the trypanosome which may be accessible to the humoral
arm of the immune system.  Work continues in this area.
This research at ILRAD, which may lead to the development of novel control
technologies, was considerably strengthened during the 1980s by the
establishment of a herd of trypanotolerant N'Dama cattle in the Laboratory,
providing scientists with the means to compare and contrast immune and
pathological responses in resistant and susceptible host genotypes, and also to
compare trypanosome growth and differentiation in the different host types.  In
this way it may be possible to identify the key features of response to infection
which impart resistance to the disease as it occurs in genetically resistant cattle,
and, at the same time, this may lead to the identification of candidate genes for
the trypanotolerance trait.
During the last few years, a second approach to the identification of genetic
regions, and ultimately genes, responsible for the trypanotolerance trait has been
developed in the Laboratory.  This has involved the breeding of a
trypanotolerant resource population based on a cross between tolerant N'Dama
cattle and susceptible Boran cattle.  Currently, an F2 population is undergoing
phenotyping.  Using the rapidly developing map of the bovine genome, it will
soon be possible to undertake a linkage analysis and search for trypanotolerance
control regions in the N'Dama genome.  If successful, this will provide animal
breeders with markers of the trypanotolerance trait which could be used to
introgress resistance genes into highly productive but susceptible genotypes, and
it may be expected to give livestock geneticists essential clues as to where to
begin the search for the individual genes.  If such genes can be identified, it may
be expected that the development of transgenic cattle will follow relatively
quickly, but, perhaps even more importantly, an understanding of the molecular
bases of this disease resistance trait should be achieved.
   It seems certain that trypanosomiasis control in the future, as in the past, will
depend on successful integration of the different options available, and the
Laboratory will therefore continue to research questions related to optimizing
integration of control strategies, whilst at the same time continuing to strive to
develop new options to replace or add to those currently available.
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The Tick-Borne Diseases Programme at the International Laboratory for
Research on Animal Diseases (ELRAD) has as its major objective the
improvement of the control of tick-borne diseases by immunological means.
The focus of its research has been a novel vaccine for Theileria parva, the cause
of East Coast fever (ECF) in 11 countries in eastern, central and southern
Africa.  Conventional control of tick-borne diseases in this region is by strict
tick control using regular application of acaricides in dips or sprays.  This
method has become less reliable because of the development of acaricide
resistance, poor management, high cost of acaricides in hard currency, civil
unrest and a growing concern about the use of environmentally damaging
chemicals.  Live vaccines exist for the complex of tick-borne diseases that occur
in association with ECF, anaplasmosis, babesiosis and cowdriosis.  However,
live vaccines have the important limitations of cold chain delivery, induction of
persistent infections and the risk of causing diseases during immunization or of
introducing pathogens that contaminate the vaccines during preparation.  In
addition, the live vaccine for T. parva, based upon ground up infected tick
stabilate inoculated simultaneously with tetracycline, is complicated by a
multitude of different antigenic parasite types.
   ILRAD's approach to the development of a new vaccine against T. parva has
been through exploring the protective immune responses in cattle.  This work
has identified CD8 + T-cell responses directed against parasite antigens on the
surface of infected lymphocytes as the major response.  In addition,
hyperimmune cattle sera and monoclonal antibodies have been shown to
neutralize the infectivity of T. parva sporozoites, the tick-derived stage
inoculated during feeding that invades and transforms lymphocytes.  Pursuing
this neutralization has identified a dominant circumsporotozite antigen of 67
kDa.  The gene for this antigen has been cloned and expressed.  Immunization
experiments with recombinant p67 have provided infection blocking protection
varying from 70-100% and its potential as a future vaccine antigen is being
explored.  In addition, ILRAD's work has attempted to develop characterization
reagents that can distinguish different Theileria parasites isolated from the field.
This latter research has yielded a range of monocional antibodies and DNA
probes that provide unique markers for individual T. parva parasites but do not
identify its antigenic nature.  These reagents are excellent epidemiological and
biological tools and have been used to show that many, if not all, field isolates
contain mixtures of parasites and that T.  parva undergoes sexual reproduction
which may further contribute to its antigenic complexity.  An important research
objective is to complete the development of these technologies as reliable and
robust diagnostic and epidemiological tools for the complex of tick-borne
diseases.
The search for schizont antigens will be concentrated on the isolation of these
antigens using peptide stripping and screening of random DNAs from parasite
libraries expressed in COS cells.  The focus of research will be maintained on T.
parva, exploring adjuvant and live vaccination systems, but will be expanded in
collaboration with other laboratories working on Anaplasma, Babesia and
Cowdria to exploit ILRAD's immunological and vaccine development expertise
to investigate the vaccine potential of candidate antigens of the other parasites.
The long-term objective is the development of antigen-based vaccines for the
major tick-borne diseases that can be designed to protect cattle in particular
challenge environments.  These vaccines will be applied where the tick-borne
disease epidemiology has been defined so that the most appropriate control
strategy is used.
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The role of class I MHC-restricted T-cell
responses in immunity to Theileria parva:
prospects for a vaccine
D.J. McKeever, E.L.N. Taracha, E. Innes* , N. MacHugh,
H. Goddeeris† and W.L. Morrison‡
*Moredun Research Institute, Edinburgh, UK
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INTRODUCTION
Disease of humans and domestic animals caused by sporozoan blood parasites
are a major hindrance to Third World development.  Human malaria affects over
300 million people each year and the increasing incidence of drug resistance in
Plasmodium species has stimulated an intense search for an effective vaccine
against the disease. Although much information on the biology and immunology
of these parasites has resulted from these efforts, an effective and practical
vaccine against human malaria has yet to be developed. Theileria parva is a
related parasite that causes East Coast fever, an acute lymphoproliferative
disease of cattle in eastern, central and southern Africa.  Although not as
devastating as malaria in human terms, the disease is a huge constraint to the
improvement of livestock production in the region and so reduces the capacity
of affected countries to feed their expanding populations.  This paper will
attempt to highlight the common features of Theileria and Plasmodium
infections and to discuss advances made in the characterization of immune
mechanisms that protect recovered cattle against subsequent challenge with T.
parva.
   Because the life cycles of Theileria and Plasmodium parasites share a number
of features, the approaches followed by scientists in the search for vaccines
against these diseases have had much in common.  However, a notable
difference has been that work on T. parva has been conducted entirely in the
target host species.  Transmitted by Anopheles mosquitoes and the
Rhipicephalus appendiculatus ticks, respectively, sporozoites of both species
invade host cells and undergo schizogenous division.  After inoculation malaria
sporozoites invade a small number of hepatocytes, which rupture after
schizogeny and release merozoites.  Clinical disease is not apparent until a
subsequent expansion of the parasite in erythrocytes.  Sporozoites of T.parva
invade all lineages of bovine lymphocytes, and unlike malaria, their
development to schizonts is associated with transformation of the infected cell.
By associating with the spindle apparatus, the parasite ensures that each
daughter cell inherits the infection (Fawcett et al., 1984).  The extensive
invasion of non-lymphoid tissues with parasitized cells that characterizes the
disease is associated with this clonal expansion of infected cells.  The pathology
is also undoubtedly contributed to by cytokine products of the transformed
lymphoblasts.
IMMUNE RESPONSES TO THEILERIA PARVA
In contrast to malaria, the immune responses to T. parva have been
characterized extensively in the host species.  Much of this information has been
derived from animals immunized against the parasite by infection with
characterized parasite stabilates in the face of treatment with long acting
formulations of oxytetracycline.  This method of immunization engenders solid
immunity against homologous challenge that lasts at least 31/2 years (Radley et
al., 1975; Burridge et al., 1972), but has many disadvantages that preclude its
widespread use as a vaccine.  These include its dependence on liquid nitrogen
for stabilate viability and the possibility of introducing vaccine strains into areas
previously free of them.  The method has however allowed scientists to
establish the basis of the immunity that it induces, as part of a rational approach
to the design of an improved T. parva vaccine.
   It was soon established that cattle immunized by infection and treatment are
protected by virtue of cellular mechanisms directed at the schizont-infected cell
(Eugui and Emery, 1981; Muhammed et al., 1975; Theiler, 1907).
Characterization of these responses was facilitated by the ease with which
parasitized cells can be cultured in vitro.  It was quickly demonstrated that
peripheral blood mononuclear cells proliferated in the presence of infected cells
and that these cultures contained killing activity (Pearson et al., 1979).  This
activity in immune cattle was restricted to autologous infected cells, an
observation that was reminiscent of cytotoxicity for virus-infected cells in
contemporary reports of murine influenza.  The MHC-restriction of murine 'flu-
specific cytotoxicity prompted an examination of the involvement of bovine
MHC products in T. parva-specific cytotoxicity.  This was made possible by the
availability of a large panel of aerological reagents that define bovine class I
MHC specificities.  In a short time it was established that cytotoxicity in these
cattle was parasite-specific and restricted to infected target cells that shared at
least one class I MHC specificity with the effector cells (Morrison et al., 1987).
In addition, it was shown that killing could be blocked by the addition of
monoclonal antibodies specific for monomorphic or appropriate polymorphic
determinants on bovine class I MHC antigens.  An interesting feature of these
experiments was the observation that the restriction of these responses were
consistently biased towards one or other haplotype and, further, that certain
class I MHC specificities seemed to dominate as restricting elements within
populations (Morrison et al., 1987).  The subsequent demonstration that
parasitespecific cytolytic activity resided in the CD8 + T-cell fraction of
peripheral blood confirmed that classical CTL responses are induced in cattle by
infection with T. parva (Goddeeris et al., 1986).
   Several features of CTL responses in T. parva-immune cattle implicate this
population as major effectors in protective immunity.  Their appearance in
peripheral blood after challenge is kinetically associated with the onset of patent
parasitosis and its subsequent clearance (Morrison et al., 1987).  Studies with
two stocks of the parasite have shown that the specificity of the CTL responses
in immunized cattle is reflected in the cross-protective properties of the stocks
(Morrison et al., 1987; Irvin et al., 1983).  More recent studies of this system
have indicated that the capacity of an immune animal to resist challenge with a
heterologous stock of the parasite appears to depend on the recognition of that
stock by its CTL (Taracha et al., 1995).  More direct evidence for the role of
CTL in immunity to T. parva has recently been provided by adoptive transfer
experiments carried out in monozygous twin calves (McKeever et al., 1994).
Ruminants provide many advantages over human and murine subjects for the
study of immune responses in vivo.  Prominent among these is the ease with
which lymphatic vessels entering and leaving lymph nodes can be cannulated
for prolonged periods of time with minimal disturbance to the animal.  By
cannulating the efferent duct of immune lymph nodes under challenge with T.
parva, it was possible by limiting dilution analysis to determine that parasite-
specific CTL constitute as many as 1 in 32 of the cells leaving the node during
the peak of the response (McKeever et al., 1994).  This frequency can be 25
times that of the same population in concurrent samples of peripheral blood.  By
eliminating cells of non-CD8 + lineages in responding lymph by complement
mediated lysis, over 1 x 1010 enriched CD8+ T cells can be prepared from an
overnight collection of lymph.  These cells can be shown to confer protection on
naive twin recipients undergoing lethal challenge with the parasite, and this
capacity is abrogated by elimination of CD8 + T cells in the transfer population.
These observations provide direct evidence that CTL play a major role in the
clearance of T. parva from immune cattle under challenge.  The induction of
these responses is clearly important for the development of an improved
vaccine.  They also support the belief of many malariologists that CTL against
the liver stages of Plasmodium parasites might be effective in clearing malaria
infections prior to the development of clinical signs.
CONCLUDING REMARKS
The potential of a vaccine against T. parva based on a recombinant sporozoite
surface antigen is discussed in a separate contribution to this volume.  In the
light of the observations presented above, and the fact that schizont-specific
immunity against T. parva is long-lasting, it is clear that an improved vaccine
against this parasite should also incorporate a schizont-derived component.  The
identification of proteins that constitute targets for CTL recognition is a difficult
task in any system, and especially so in complex intracellular parasites.  It has
been estimated that the schizont of T. parva expresses approximately 4000
antigens (Gerhards et al., 1989).  Based on analyses of the parasite specificities
of T. parva-specific CTL clones, only a few of these are likely to be CTL
targets.  Technological advances in the purification and sequencing of peptides
associated with cell surface MHC molecules have now provided a means
whereby the antigens from which these peptides are derived can be identified
(Falk et al., 1991; Hunt et al., 1992).  A malaria schizont antigen recognized by
CTL in naturally exposed individuals that express the human HLA-B53 class 1
MHC molecule has recently been identified by searching known antigenic
sequences of the parasite for a motif derived from peptides isolated from that
molecule (Hill et al., 1992).  In addition, it has recently been possible to identify
a human CTL target on a melanoma cell line by screening a CDNA library with
tumour-specific CTL (Brichard et al., 1993).  The necessary materials and
reagents for applying these techniques to T. parva are available.  Large numbers
of parasitized cells can be cultured in vitro with ease, and the analysis of CTL
responses in immune cattle, both at bulk and clonal levels, is considerably less
complicated for T. parva than for Plasmodium species.  Accordingly, intense
efforts are under way in this institute to apply these technologies to the
identification of T. parva schizont antigens that constitute targets for protective
CTL.
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The malaria parasite has a complex life cycle involving several stages of
development in its mosquito and vertebrate hosts.  In the latter, the parasite is
intracellular.  Following inoculation by a female mosquito taking a blood meal,
sporozoite forms of the parasite pass into the liver and within minutes invade
hepatocyte cells.  Here the sporozoites develop into schizont forms over a period
lasting from days to years, depending on the species of host and parasite.  The
infection is silent during this hepatic incubation: the handful of maturing
malaria parasites causes no liver damage and no illness in the host.
When the parasite's development in the liver is complete and it has multiplied
many thousand-fold, merozoite parasite forms are released from rupturing
hepatocytes into the circulation, where they readily bind to receptor molecules
on the surface membrane of erythrocytes.  The merozoites enter the red blood
cells and, over several days, develop into erythrocytic schizonts.  The rupturing
of many schizont-infected red blood cells causes clinical malaria.  Some of the
merozoites, after invading an erythrocyte, rather than multiply further
differentiate to sexual forms that can infect mosquitoes.  The life cycle is then
perpetuated when these sexual forms are ingested by a mosquito taking a blood
meal.
The behaviour of the malaria parasite in its mammalian host suggests that this
parasite has evolved a survival strategy based on minimizing its exposure to the
host's humoral immune responses.  These have been demonstrated to be
effective against the parasite: both sporozoites and merozoites are rendered non-
infective when incubated with antimalarial antibodies (Potocnjak et al., 1980;
Charoenvit   et al., 1986).
All mammalian cells except red blood cells express on their surface MHC
molecules, which are encoded by genes of the major histocompatibility
complex.  The expression of surface MHC molecules enables these mammalian
cells to present antigen to T lymphocytes of the immune system, which cause
the destruction of infected cells.  By invading red blood cells, the malaria
parasite therefore avoids recognition and attack by MHC-restricted CD4  +
(helper) and CD8  + (cytotoxic) T lymphocytes.  Other cells of the immune
system, such as natural killer cells and gammaldelta T cells, do not require that
antigen be presented in association with MHC molecules.  Although these cells
may recognize parasite antigen on the surface of infected red cells, it is unlikely
that αβ TCR T cells can attack the infected erythrocytes directly.  Rather, they
may help control infection by interacting with parasite antigens released on the
rupture of red cells, by producing systemic cytokines that will induce other
protective immune responses, and/or by inducing B-cell responses against the
parasite.  MHC-restricted T cells thus play an indirect role in controlling red-
cell infection by malaria parasites T-cell responses against the parasite are more
direct in the intrahepatic stages of malaria development.  Hepatocyte cells
express MHC class I molecules and can be induced to express MHC class II
molecules.  It is thus possible that both CD4+ and CD8+ effector cells recognize
and bind to malaria antigens. (CD4+ T cells recognize antigen presented in the
binding cleft of class I molecules; CD8+ T cells recognize antigen in the binding
cleft of class II molecules.) Under natural conditions, however, few if any
people appear to develop strong sterile immunity to the early phases of malaria.
This is perhaps because the immune system is exposed to only a handful of
sporozoites or developing liver-stage schizont forms in contrast to billions of
infected red blood cells.
Much of our knowledge of cellular immunity to the hepatic stages of malaria
was gained by infecting human (Clyde et al., 1973), rodent (Nussenzweig  et al.,
1976) and avian (Russell and Mohan, 1942) hosts with large numbers of
parasites attenuated by radiation.  A typical protocol for such immunization
involves moderately irradiating infected mosquitoes with X-rays so that the
sporozoites remain motile and able to invade their hepatocyte targets.  A host is
then infected by inoculation through bites from these mosquitoes or through
needle injection of sporozoites harvested from the irradiated mosquitoes.
Sporozoites irradiated to the point of immobility or administered through
intraperitoneal or intradermal routes provoke no protective immune responses in
the experimental hosts (Vanderberg  et al., 1968).  The number of sporozoites,
as well as boosting doses, needed to immunize a host depends on the species of
parasite and host.  For example, to protect an individual against disease caused
by Plasmodium falciparum, the person must be bitten by infected irradiated
mosquitoes more than 800 times and over a period of several months (Clyde et
al., 1975); BALB/c mice, on the other hand, can be protected against disease
caused by Plasmodium berghei by administration of a thousand irradiated
sporozoites in a single inoculation (Jaffe  et al., 1990).
In this immunization method, the irradiated sporozoites pass into the liver and
invade hepatocytes but, because the radiation has damaged their DNA, they are
unable to develop into liver-stage schizont forms.  Instead, the irradiated
sporozoites induce a lymphocytic infiltrate which is absent in hosts infected
with healthy sporozoites (Hoffman  et al., 1989).  One effect of the arrested
development of the liver-stage parasites is that a lymphocyte inhibitory factor
normally made by the hepatic-stage parasites is not produced.  Some
vaccinologists speculate that irradiated sporozoite vaccines induce T-cell
immunity by putting malaria antigens directly into the hepatic cytosol, and thus
into the class I, and possibly class II, antigen-processing pathways.
A host immunized with irradiated sporozoites is protected for a period of
months to years against disease caused by subsequent infection with up to
thousands of healthy sporozoites (Edelman  et al., 1993).  This protection takes
two forms.  In human and murine malaria, the models most commonly
employed, the immunity engendered is one of sterile protection: no blood-stage
parasites are detected in immune and protected animals.  In breakthrough cases,
blood-stage parasites appear and follow their normal patterns of growth without
alteration, leading to death or self-cure of the animal host.  The second type of
immunity induced by irradiated sporozoites, not seen in rodent malaria, was first
described in avian malaria (Nussenzweig  et al., 1967).  Young birds immunized
with irradiated sporozoites do develop blood-stage infections after rechallenge
with normal parasites, but the severity of the blood-stage infection is much
reduced and the birds do not die.  This less-studied form of avian immunity may
have similarities with natural human immunity to P. falciparum malaria in West
Africa, discussed below.
The sterile immunity to malaria engendered in mice after immunization with
irradiated sporozoites is heavily if not exclusively dependent on effector CD8+,
class I-restricted T cells.  This has been best illustrated by depleting immunized
mice of CD4+ or CD8+ T-cell subpopulations after immunization using
monoclonal antibodies (Schofield  et al., 1987; Weiss  et al., 1988).  Sterile
immunity is lost after removing the CD8+ cell population but remains if CD4+
cells are removed.  CD8+ and CD4+ T cells that react with malaria antigens can
be found in the spleens of immunized animals using in vitro assays for
proliferation and cytotoxicity.  Inbred strains of mice show a genetically
restricted immune response after immunization with some but not all murine
parasite species (Weiss  et al., 1989).  This response is partly MHC-restricted
and partly dependent on genetic factors mapping outside the MHC.
Much less is known about immunity to sporozoite and liver-stage antigens in
the human than in the mouse.  Irradiated sporozoites of both P. falciparum and
P. vivax induce protective immunity in humans.  This immunity is known to be
dependent on antigen specificity because no cross-protection occurs (Clyde  et
al., 1973).  CD8+ and CD4+ T cells reactive with sporozoite antigens have been
identified in the blood of persons immunized with irradiated sporozoites (Malik
et al., 1991) as well as in people living in areas where malaria is endemic
(Doolan  et al., 1991).  However, the relative importance of class I- and class II-
restricted T-cell responses has been difficult to assess in humans.  Our group in
western Kenya is looking for correlations between responses of CD4+ and CD8+
T cells that recognize malaria antigens and resistance to infection by
sporozoites.
Work in The Gambia has shed light on the role T cells play in human malaria.
A study of human lymphocyte antigen (HLA) types in children with severe
malaria (Hill  et al., 1991) has showed that the HLA Bw53 class I molecule and
a HLA class II haplotype were independently associated with less severe disease
outcomes during blood-stage infection.  This suggests that antigens by both
class I and class II MHC molecules are important in protecting the human host.
Interestingly, both these HLA types are common in West Africa and very
uncommon in other parts of the world, indicating that their protective effects
may have fixed them in malaria-exposed populations.
Follow-up work in The Gambia showed that the HLA Bw53 product was able
to present a fragment of a P. falciparum liver-stage antigen to CD8+ cells (Hill
et al., 1992).  This is a paradox: how can immunity to the liver stages of malaria
affect the virulence of infection once the parasite successfully leaves the liver
and invades red cells?  The question may be answered by looking more closely
at avian immunity to malaria induced by irradiated sporozoites: either an
immune response in the liver reduces the numbers of infective parasites released
into the blood or immune responses in the liver cross-react with blood stages of
human malaria.
IMMUNIZATION STRATEGIES IN MALARIA
With the understanding of the importance of class I MHC-restricted T-cell
immunity in malaria, a variety of techniques have been used in attempts to
induce immunity to sporozoite and liver-stage antigens.
Irradiated Sporozoite Vaccines
Until recently, malaria sporozoites could be grown only in live mosquitoes.
Producing sporozoites for mass immunization was thus highly impractical.
Recent breakthroughs in growing sporozoites in vitro (Warburg and Miller,
1992) may solve the problem of mass sporozoite production.  However,
immunization with irradiated sporozoites will probably continue to be
constrained by the necessity for the immunizing sporozoites to remain able to
invade liver cells.
Recombinant Live Vector Vaccines
One way to introduce malaria antigens into the class I MHC pathway is to
incorporate the genes encoding these antigens in the genetic material of other
intracellular organisms.  Researchers have successfully expressed malaria
parasite antigens in vaccinia viruses (Sedegah  et al., 1988) but no such
recombinant virus has yet been able to induce in the host protective immune
responses or cytotoxic T lymphocytes (CTLS) that specifically recognize the
antigens.  Use of recombinant attenuated bacteria to deliver antigen has shown
greater promise.  Salmonella strains with an Aro A mutation are able to invade
cells but are then unable to multiply.  In an encouraging experiment with mice,
however, the addition of a plasmid expressing the malaria circumsporozoite
antigen to a non-virulent Salmonella bacterium protected 70 per cent of the
immunized mice against a subsequent sporozoite challenge (Sadoff  et al.,
1988).  Not all vaccinations with recombinant Salmonella have protected mice
against malaria, however, despite the fact that the vaccinations induced CTL
responses (Flynn  et al., 1990).  Research in this area continues in attempts to
make a comparable, protective P. falciparum vaccine for humans.
Synthetic Peptide Vaccines to Induce Class I MHC-Restricted Immune
Responses
Attempts are being made to use chemically synthesized peptides corresponding
to fragments of malaria parasite antigens as the bases for malaria vaccines.  The
aim of most of these attempts is to induce responses from CD8 + T cells. along
with antibody and class II MHC-restricted immune responses.
   Unmodified proteins and short peptides can induce CTLs when given in very
high doses with incomplete Freund's adjuvant (Carbone and Bevan, 1989).
These techniques have been tried in the mouse malaria models, using peptides
representing a CTL epitope from the circumsporozoite protein.  Significant
CD8+ T-cell responses have been induced, but these peptide vaccines have not
protected mice against parasite challenge (W. Weiss, unpublished observations).
Modified peptides can also induce CD8 + T-cell responses and often require
much lower quantities of antigen than unmodified peptides.  Adding covalently
coupled lipids to peptides reduces one hundred-fold the amount of peptide
required to induce CTL; this has been demonstrated for the malaria
circumsporozoite antigen in the mouse (Verheul  et al. 1993).  Such modified
peptides can be further combined into particle forms, such as ISCOMs
(Takahashi  et al., 1990) or liposomes.  For example (White  et al., 1993), a
modified circumsporozoite protein from the human P. falciparum parasite with
a repeating motif deleted was incorporated into liposomes with the adjuvant
monophosphoryl lipid A. A single 10-microgram intraperitoneal injection
induced CTLS.  However, such modified peptide and protein vaccines have not
yet successfully protected mice against malaria sporozoite infection.
Induction of Class I MHC-Restricted Responses by Injection with DNA
An extremely novel technique for inducing class I MHC-restricted immune
responses has recently been described for viral antigens (Ulmer  et al., 1993)
and is also showing great promise for malaria (M. Sedegah and S.L. Hoffman,
manuscript in preparation).  Plasmids containing complementary DNA (cDNA)
sequences from influenza nucleoprotein and malaria circumsporozoite antigens
were injected intramuscularly into mice.  The plasmids were taken up intact by
muscle cells, where they resided without multiplying.  The cDNA sequences
were transcribed to make intracellular proteins corresponding to the
nucleoprotein or circumsporozoite antigens.  Although the proteins were
produced at extremely low levels, significant antibody, CD4+ and CD8+ T-cell
responses are made to these antigens.  Most excitingly, the immunized mice in
some of these experiments were protected against influenza and malaria.
Problems with Class I MHC-Restricted T Cells and Protective Immunization
Both CD8+ (Romero  et al, 1989; Weiss  et al., 1992) and CD4+ (Tsuji  et al,
1990) mouse T-cell clones that recognize particular malaria parasite epitopes
have been shown in passive transfer experiments to protect animals from
malaria.  However, when animals are immunized with constructs that induce
CD8 + responses to these same epitopes, there is no evidence that the parasite is
affected.  Ibis raises the possibility of the induction of protective immune
responses is brought about not only by the activity of CTLs but also by special
characteristics of those CTLS.
One such characteristic is the presence of the correct adhesion molecules on
the surface of the CTL.  A study of protective and non-protective CTL clones
(Rodgigues  et al, 1992) showed that the presence of CD44 and VLA on the
surface of these cells correlated with an ability to protect mice in passive
transfer experiments.  Non-protective clones did not home to their targetinfected
hepatocytes—as well as protective clones.  The reason so many immunization
strategies that induce CTL proliferation do not protect the host against malaria
infection may be that the induction does not produce class I MHC-restricted T
cells with the necessary homing characteristics.
We have recently published experimental results showing that CD4+ cell
activity is required for development of protective CD8+ cells in mice immunized
with irradiated sporozoites (Weiss  et al., 1993).  Mice depleted of CD4+ cells at
the time of immunization developed the same numbers of CD8+ cells in their
spleens and livers as did the controls but were completely unprotected against
malaria sporozoites.  Although we were not able to define the critical action
CD4+ cells provide in a protective immune response, it may be related to the
development of a special characteristic of CD8+ effector cells.
   Interactions in vivo among T-cell subpopulations are almost certainly crucial
to the success of a vaccine against malaria.  It is possible that many of the
vaccine constructs mentioned here, which successfully induce CD8+ responses
but do not protect against the parasite is that the constructs are not inducing
properly coordinated CD4+ and CD8+ T-cell responses.  The rational design of a
synthetic malaria vaccine may therefore require further study of the induction
phase of CTLs in animal models and in humans.
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INTRODUCTION
Cellular immunity mediated by cytotoxic T.cells (CTL) is an essential part of
the specific immune specific response to viruses and other intracellular
parasites.  CTL recognize a complex ligand at the surface of infected cells
comprising pathogen-derived peptide epitopes bound to glycoproteins encoded
by the class I locus of the major histocompatibility complex (class I MHC).  The
study of class I MHC at the micromolecular level, and of the peptides that are
naturally bound by them, has provided a detailed picture of the complex
recognized by CTL.
   How class I MHC molecules select peptides from a potentially large
intracellular pool of pathogen-encoded proteins is as yet unclear, and an
understanding of these selection processes is crucial to the assessment of
vaccine strategies designed to prime the class I MHC-restricted arm of the
immune system.  Selection could operate at the level of proteolysis,
translocation of peptides from the site of production to the site of their
interaction with MHC, or the MHC binding event itself.  This paper briefly
reviews what is known about each of these events with respect to their
permissiveness.
COMPLEMENTARITY BETWEEN CLASS I MHC AND BOUND  EPTIDES
By isolating class I MHC molecules and stripping them of bound peptides by
denaturation, it has been possible to purify a representative, heterogeneous
mixture of ligands bound to a number of human and murine allele products.
Sequencing of this mixture has revealed that all bound peptides are
homogeneous in length, and share common amino acids at particular positions
in the sequence—described as anchor residues (Falk et al., 1991).  Because
class I MHC associated peptides are homogeneous in length, the positions of
these anchor residues within the sequence thus defined allele-specific binding
motifs.  Examples of such motifs are shown in Figure 1.
   The molecular basis of complementarity between class I MHC and its bound
peptides was elucidated by high resolution X-ray crystallography and confirmed
by biochemical  approaches.   The two membrane-distal domains of class I
MHC
Figure 1. Peptide binding motifs for several class I MHC alleles in mouse and man.
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heavy chain form a binding groove lined with many of the polymorphic residues
and contoured in such a way as to define six pockets (Sapar et al, 1991).
Crystallographic evidence has shown that the function of four of these pockets
is to accommodate side chains of anchor residues within the bound peptide.
Hence the arginine side chain found at position 2 of all HLA-B27-binding
peptides fits into a deep 'B' pocket at the end of which is found a glutamic acid
residue(Maden, et al, 1992).  In some alleles, this pocket is obscured by a bulky
side chain at either position 67 or 45 with the result that either other pockets are
utilized, or peptides with proline at position 2 are preferred.  The pocket that
defines the 'left hand' end of the groove is lined with non-polymorphic hydrogen
bond donors such as tyrosine, and interacts with the alpha amino group of bound
peptides.  The pocket defining the 'right hand' end is similar and makes a series
of hydrogen bonds between conserved residues and the free carboxy terminus of
bound peptides.  In addition, a correlation has been noted between the nature of
the side-chain at position 116 (which forms the floor of this pocket), and the
side chain of the C-terminus residue of the bound peptide (Elliott et al.,
manuscript in preparation).  Thus, aromatic side chains are found in this
position in those alleles that prefer a C-terminal hydrophobic residue, serine is
found in alleles that prefer aromatic C-termini, and aspartic acid is always found
at position 116 of alleles that bind peptides with basic C-termini.
CLASS I MHC ASSEMBLY
Peptide binding and class I MHC assembly are linked phenomena.  A study of
the assembly of class I with peptides in vitro has shown that peptide binding of
the 'empty' heavy chain/beta 2-microglobulin heterodimer stabilizes the
interaction between the two class I MHC chains.  Furthermore, peptides binding
to free heavy chain in the absence of beta 2-microglobulin has been shown to
induce a conformational change in heavy chain leading to its native structure-in
which it binds to beta 2-microglobulin with high affinity (Elliott et al., 1991).
Either of these reactions could contribute to the selection of intracellular
epitopes since 1) Peptides of 9 amino acids bind with the highest affinity to
'empty' class I molecules (Cerundolo et al., 1991) and 2) only peptides
corresponding to naturally processed epitopes will induce the conformational
change in free heavy chains (Elliott et al., 1991).  The last of these may be
particularly important, since the alpha-3 domain of heavy chain is not required
to observe the effect, and there is some evidence to suggest that peptides of an
optimal length and sequence may actually lower the activation energy required
for correct folding of the free HC in the absence of beta 2-microglobulin (Elliott
et al., 1992a, 1992b).
PEPTIDE TRANSPORT
Current evidence supports the notion that the primary site of pathogen protein
degradation is the cytosol.  Class I MHC is synthesized and binds to peptides in
the lumen of rough endoplasmic reticulum (ER), and it was clear from an early
stage that the topological paradox which these observations pose could only be
resolved if there exists a mechanism for translocating peptides across the ER
membrane in a signal sequence-independent way.  Recently, a heterodimeric
protein encoded in the MHC class II locus has been identified that fulfils this
role.  The complex, known as TAP.(Transporter associated with Antigen
Processing, reviewed in Townsend and Trowsdale, 1993), belongs to a family of
ATP-binding cassette (ABC) proteins and has been shown to transport peptides
from the cytosolic to the lumenal side of the ER membrane in an ATP-
dependent way (Neefjes et al., 1993; Shepherd et al., 1993).  The two TAP
chains are genetically polymorphic and there is one instance in which this has
been associated with functional polymorphism (Powis et al., 1992).  Differences
in substrate specificity of TAP alleles could therefore contribute to the selection
of cytosolic peptides that could be made available for class I MHC binding in
the ER.  Studies to date clearly show that the TAP complex is not selective for
nonameric peptides, but can transport peptides up to 15 amino acids in length.
PROTEOLYSIS
The best-studied agent of protein degradation in the cytosol is a multicatalytic
complex known as the proteasome.  Two of the proteasome subunits are
polymorphic gamma-interferon inducible and encoded by the class II locus of
MHC (Martinez and Monaco, 1991).  Recent evidence shows that of the three
ATP-independent proteolytic activities of the proteasome, those which cleave
after hydrophobic and basic amino acids are augmented after interferon gamma
treatment, whereas the third, which cleaves after acidic residues is suppressed
(Driscoll et al., 1993; Gaczynska et al., 1993).  The modulation of these
activities appears to be dependent on the presence of the two MHC-encoded
subunits.  Thus, under conditions found during immune activation, the
proteasome may preferentially generate peptides with C-termini that are
compatible with all class I MHC alleles studies to date, while reducing the
generation of peptides with acidic C-termini (for which a complementary class I
MHC binding groove has not been identified).  Down regulation of the acidic
specificity would also prevent peptide epitopes containing acidic residues from
being destroyed.
   The same abundance of basic and hydrophobic residues seen at the C-termini
of peptide epitopes is not evident at the position immediately preceding the N-
termini.  Here, the relative abundance of each amino acid approximates to the
frequency with which they occur in nature, suggesting that different sets of
enzymes may be involved in generating the N-termini of peptide epitopes.  We
have recently investigated the role of enzymes resident in the ER in trimming
longer peptides containing a natural epitope (Elliott et al., 1993).  Long
precursor peptides generated by recombinant vaccinia viruses were co-
translationally transported into the ER of a mutant cell line that is unable to
expose newly synthesized class I molecules to peptides generated in the cytosol.
Although the longer peptides were shown to bind to class I MHC with a fairly
high affinity, only the 'naturally processed' nonameric peptide could be isolated
from class I MHC molecules synthesized by the infected cells.  These results
indicate that longer peptides transported into the ER (either by a TAP-dependent
mechanism, or by leader sequence-dependent mechanisms as in this experiment)
could be trimmed by ER-resident peptidases giving rise to peptides capable of
inducing tiie folding of nascent class I MHC and forming stable complexes with
them.
CONCLUSIONS
An effective vaccine should incorporate all the elements necessary for its
processing and presentation to appropriate precursor T-cell subset(s).  In
general, vaccination strategies targeted at MHC class I-restricted responses fall
within a spectrum ranging from infection/treatment to immunization with
defined epitopes.  Both of these extremes are suboptimal.  Although infection
with a pathogenic organism is likely to prime appropriate effector and
regulatory T.cells, there are obvious disadvantages to using live organisms and
the strategy is limiting to those diseases for which a suitable and reliable
treatment is available.  On the other hand, peptide vaccination strategies limit
the response to a single epitope/class I immunostimulatory complex which may
be ineffective or even detrimental if the vaccinating epitope differs in any way
between individuals (of the same haplotype) or is not produced throughout the
course of the pathogenic challenge.  In addition, there may be as yet undefined
disadvantages associated with delivering a bolus of preprocessed antigen to the
circulation.
   In the absence of detailed information regarding the processing requirements
of intracellular antigens for presentation by class I MHC, vaccination strategies
have tended to focus on attenuated live vaccines designed to deliver a number of
potentially immunogenic proteins to intracellular processing components in a
non-pathogenic form.  Though these vaccines may be effective in delivering
antigens in a way analogous to that of the wild-type pathogens, there are many
difficulties associated with the approach, not least of which is the worry over
effective attenuation.  Also, the approach is only feasible in cases where the
pathogen is simple (i.e. viruses with a small genome) and its biology is well
understood.
What remains, therefore, are strategies that draw on information derived from
the study of antigen processing and presentation.  Since this information is
currently limited, the popular strategies focus on the delivery of
immunodominant antigens to the cytosol of antigen presenting cells by, for
example, enclosing them in liposomes or making them fusogenic by some other
means.  Clearly, a more detailed knowledge of the way in which antigens are
handled by antigen presenting cells prior to their association with class I MHC,
and an understanding of the structure of the class I molecules which present
them, will enhance our ability to approach the development of effective
vaccines in a rational way.
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Cytotoxic T.lymphoeytes (CTL) recognize peptide fragments presented on the
cell surface by MHC class I molecules.  Peptides are generated by proteases in
the cytosol and transported across the membrane of the endoplasmic reticulum
where they bind to newly synthesized MHC molecules.  However, not only
cytosolic proteins can give raise to MHC presented peptides, since nuclear
(Deckhut et al., 1992) and even mitochondrial (Loveland et al., 1990) proteins
have been shown to provide MHC class I-presented CTL epitopes.  At present,
no cellular compartment is known to be excluded from the MHC class I
presentation pathway.  Indeed, CTL responses have been detected against
bacteria and parasites that reside inside cellular vacuoles (Kaufmann, 1993) and
are therefore probably not exposed to cytosolic antigen processing enzymes.  It
is currently unknown whether generation of immunogenic peptides from such
intravacuolar parasites is dependent on cytosolic proteases and peptide
transporters, or whether alternative antigen processing pathways exist.
   MHC class I binding is an essential prerequisite for peptides to function as
CTL epitopes.  Sequence analysis of MHC-bound peptides in combination with
crystallographic structures of MHC class I molecules led to the definition of
rules governing peptide-MHC interaction The peptide binding groove of class I
molecules is highly polymorphic, and this results in binding of distinct sets of
peptides by different MHC alleles.  Study of peptide-MHC interaction resulted
in determination of allele-specific peptide binding motifs (Falk et al., 1991),
which have been used successfully for accurate prediction of many CTL
epitopes (Falk and Rotzschke, 1993).  However, CTL epitope prediction based
on these observations requires protein sequence information of the target
antigen, which is often not available.  Also, not all natural CTL epitopes contain
MHC binding motifs (Sadovnikova et al., 1994) and the frequency of motif-
negative epitopes is presently unknown.
IDENTIFICATION OF CTL EPITOPES
Approaches for identification of CTL epitopes without knowledge of target
proteins have been described.  Boon's group developed a procedure that
involves generation of variant cells that have lost expression of CTL-recognized
epitopes, followed by transfection of these variant cells with genomic DNA
from epitope-positive parental cells.  This approach has led to the identification
of tumour antigens expressed by human melanoma (Traversari et al., 1992) and
murine mastocytoma cells (Sibile et al., 1990).  The drawback of this technique
is that it is extremely labour intensive, and to date it has been used successfully
in only one laboratory.
An alternative approach to identify CTL epitopes involves isolation and
purification of MHC class I-presented peptides followed by peptide
microsequencing.  However, MHC class I-presented peptides are highly
heterogeneous (estimates are that probably 3,000 to 10,000 distinct peptides are
presented per cell) requiring extensive purification before sequence of
individual CTL-recognized peptides can be obtained.  The most serious
limitation of this approach is the discrepancy in sensitivity of CTL assays and
peptide microsequencing.  The sensitivity of classical Edman degradation
sequencing is 1-10 picomole and the sensitivity of current tandem mass
spectroscopy is approximately 50 femtomole.  Estimated CTL sensitivity is 1–
10 femtomole, indicating that successful purification of CTL-recognized
peptides does not guarantee successful sequence determination.  Nonetheless,
four CTL epitopes have been microsequenced successfully in three different
laboratories to date (Udaka et al., 1992) (unpublished information).
Surprisingly, in most cases classical Edman degradation was employed for
sequence determination, while the technically more advanced tandem mass
spectroscopy was used for identification of one epitope recognized by allo-
reactive CTL specific for HLA-A2.
In our own work we have analysed peptides recognized by CTL raised against
minor histocompatibility (H) antigens.  Minor H antigens can cause tissue
transplant rejection in MHC-matched, donor-recipient combinations, due to
CTL recognition of polymorphic non-MHC antigens.  Except for two
characterized minor H antigens in mouse (Loveland et al., 1990; Speiser et al.,
1990), the nature of these antigens and the encoding genes are generally
unknown.  We have studied the murine minor Hl antigen which is recognized by
CTL in a MHC class I, H-2Kb-restricted fashion (Yin et al., 1993).  So far, we
have immunopurified Kb molecules from approximately 30 mouse spleens and
separated Kb-presented peptides by reverse phase HPLC.  Individual HPLC
fractions were collected and tested in CTL assays showing that only one or two
adjacent HPLC fractions contained peptides recognized by CTL specific for the
minor HI antigen (Yin et al., 1993).  Active fractions were subfractionated over
three different HPLC columns and CTL-recognized peptides were successfully
identified.  Subfractionation revealed that the original HPLC fractions contained
a large number of irrelevant peptides that interfere with microsequencing of
CTL-recognized peptides.  After the final HPLC purification the CTL-
recognized fractions contained approximately 1 picomole of peptide which was
sufficient to obtain some sequence information using Edman degradation.
These purification experiments were encouraging because biologically active
peptides were easily identified even after four purification steps.  Our current
effort is to use more efficient peptide isolation and separation procedures for
purification of CTL epitopes.
ISOLATION OF SURFACE PEPTIDES FROM INTACT CELLS
We have developed a peptide extraction protocol which does not require prior
immunopurification of MHC class I molecules.  This procedure is likely to
improve peptide yield because it omits potential losses associated with
immunopurification.  Also, the procedure is independent of the availability of
MHC-specific antibodies, allowing peptide isolation from many class I alleles of
different species.  Denaturation of MHC class I molecules on the surface of
intact cells is used to release MHC-bound peptides, which are subsequently
purified by HPLC.  To monitor MHC class I denaturation, cells were exposed to
buffers of pH 6.5, 5.6, 4.5 or 2.7 and then stained with conformation-dependent,
MHC class I-specific monoclonal antibodies.  Exposure of cells to pH 6.5 or 5.6
did not significantly reduce levels of class I expression, while exposure to pH
4.5 lead to a slight reduction (Figure 1).  MHC class I expression was reduced to
undetectable levels in cells exposed to pH 2.7. Exclusion of trypan blue dye by
these cells indicated that pH 2.7 exposure did not damage the integrity of the
cell membrane.  Therefore, it appeared that pH 2.7 resulted in denaturation of
class I molecules without causing detectable cell damage.  Ph 6.5 and 5.6 did
not affect MHC expression and pH 4.5 appeared to induce partial denaturation
of class I molecules.
Figure 1. Denaturation of MHC class I molecules on the surface of intact cells.  RMA
cells (H-2b haplotye) were exposed to pH-adjusted buffers (500 mM NACI and 200 mM
acetic acid) for 3.5 min at ro(,m temperature, followed by staining at 4 ?C with murine
MAbs specific for H-2Kb and Db class I molecules and second layer FITC-labelled goat
anti-mouse antibodies.  Shown is the median of the fluorescence intensity of the stained
cells as determined by FACScan analysis.  The morphology of cells exposed to low pH
was similar to that of control cells, and pH-treated cells did not show signs of cell
damage when analysed by trypan blue staining.
   Supernatant of cells exposed to the pH-adjusted buffers was collected and
tested for the presence of peptides recognized by CTL raised against the minor
H l antigen.  Supernatants of cells exposed to pH 6.5 and 5.6 did not contain any
CTL-recognized peptides, while supernatants from cells treated with pH 2.7
were efficiently recognized by CTL (Figure 2). Treatment with pH 4.5 appeared
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to lead to partial release of CTL-recognized peptides (Figure 2).  Together, these
experiments revealed a good correlation between the disappearance of MHC
class I molecules on the surface of pH treated cells, and the appearance of
peptides recognized by class I restricted CTL (see Figures 1 and 2).  Peptide
release from intact cells appeared to be efficient, since titration experiments
suggested that the concentration of pH eluted peptides is comparable to the
amount of peptide obtained from lysates of whole cells (data not shown).
Figure 2. CTL recognition of natural peptides eluted from intact cells. 2.5 x 108  RMA
cells were exposed to pH-adjusted buffers for 3.5 min at room temperature.  Cells were
removed by centrifugation and the supernatant passed through Centricon 10 filters to
isolate low molecular weight peptides which were separated by HPLC.  Fractions 26 and
27 were collected and analysed with CTL specific for the minor histocompatibility
antigen HI, which recognize peptides present in these HPLC fractions (Yin et al., 1993).
Peptides prepared from cells by lysis with 0.7% TFA served as positive control.  For
CTL assays, 1/10 of HPLC fractions 26 and 27 were used to coat RMA-S target cells
(uncoated RMA-S cells showed approximately 5% background lysis).
   Although pH 5.6 exposure did not result in MHC denaturation and release of
CTL-recognized peptides, HPLC analysis of pH 5.6 eluent revealed the presence
of several peptide peaks (not shown).  Although the origin of these peptides has
not been determined, it is possible that they are released from receptor ligand
interactions which are more ph-sensitive than MHC/peptide interaction.  For
example, it has been shown that pH 5.6 can cause dissociation of epidermal
growth factor bound to its receptor (Haigler et al., 1980).  Since omission of
such peptides should improve the purity of CTL-recognized peptides, cells were
pre-exposed to pH 5.6 to elute irrelevant peptides before MHC presented
peptides were extracted using pH 2.7. The pretreatment at pH 5.6 did not result
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in any detectable loss of CTL-recognized peptides and was therefore routinely
used for peptide preparation.
The experiments described here were designed to develop procedures for rapid
peptide extraction from a large number of MHC class I molecules.  A major
advantage of the described surface extraction procedure is the independence of
MHC-specific antibodies allowing peptide extraction from class I molecules for
which no antibodies are available.  However, peptides prepared in this way are
more heterogeneous than peptides extracted from immunopurified class I
molecules.  This is because surface extraction leads to denaturation of all MHC
molecules expressed by treated cells, and the heterogeneity of released peptides
increases with the number of expressed class I alleles.  This drawback of
increased heterogeneity is perhaps compensated by improved peptide yield and
by the experimental facility of peptide preparation.
CONCLUDING REMARKS
It is currently unknown whether peptide purification and microsequencing can
be achieved in the majority of CTL-recognized epitopes or in only a few
exceptional cases.  An important factor determining microsequencing success is
probably the level at which a CTL epitope is expressed, which in turn
determines the concentration of purified peptides.  At present there is only some
information of the minimal number of MHC/peptide complexes that are
required for CTL recognition, but no assays are available to measure the actual
concentration of a given MHC/peptide complex.  In addition to expression level
the biochemical nature of peptides is likely to affect purification and
microsequencing attempts.  To date, most peptide isolation procedures use low
pH buffers which may result in loss of some peptides that are sensitive to acidic
conditions.  This may explain our observation that acid extraction does not
always yield CTL-recognized peptides.  For example, we have generated several
H-2Kb-specific CTL clones which recognize RMA cells but not the mutant
RMA-S subline which has an MHC class I peptide loading defect.  Although
acid extraction of parental RMA cells yields peptides recognized by most CTL
clones, some clones apparently recognize epitopes that are not present in these
peptide preparations.  It is possible that peptides recognized by these clones are
unstable under low pH conditions.  Alternatively, it is conceivable that HPLC
purification may not give equally good recovery of all peptides, leading to loss
of some CTL epitopes.  Finally, different CTL may display different affinities
for peptide MHC complexes in which case lack of CTL recognition might be
caused by low affinity T-cell receptors rather than by low peptide concentration.
   Attempts to microsequence CTL epitopes are currently undertaken in many
different laboratories and within the next few years it will be possible to judge
the general feasibility of this approach.
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INTRODUCTION
The HLA region lies on the short arm of human chromosome 6 and contains
approximately 20 class I MHC heavy chain genes, pseudogenes and gene
fragments (Geraghty et al., 1992).  Three genes encode serologically detected
HLA-A, B and C antigens, which are expressed by a wide range of tissues and
function in the presentation of peptide antigens to CD8+ T.lymphocytes.
Serological typing, using alloantisera obtained from multiparous women, has
been the primary tool for characterization of HLA-A, B, C polymorphism in
human populations and remains the routine method for clinical Class I MHC
typing.  With this approach, the activities of eleven international
histocompatibility workshops have defined 27 HLA-A, 59 HLA-B and 10 HLA-
C antigenic specificities.  Because some of these specificities represent shared
public epitopes the number of serotypically defined alleles are 23 for HLA-A,
46 for HLA-B and 9 for HLA-C.
Historically, HLA studies have been carried out in the clinical context of
tissue transplantation and autoimmune disease and have therefore focused upon
Europeans and derivative populations.  The major source of anti HLA
alloantisera and of the cells used to screen them have been individuals from
these same populations.  In 1972 the fourth International Histocompatibility
Workshop focused on the diversity of human populations.  New antigens
specific to non-European populations were discovered and striking differences
in antigen frequencies between populations revealed.  For example, the numbers
of HLA-A and B antigens found in Native American populations were only
fractions of those found in Non-Native Americans (Kostyu and Amos, 1981).
Not long after the 1972 workshop the role of class I HLA molecules in antigen
recognition by T.lymphocytes began to be appreciated, stimulating study of the
HLA specificity of alloreactive and antigen-specific T.cells.  Unexpectedly,
T.cells were found to distinguish between serologically identical class I MHC
molecules.  This was first recognized with HLA-A2, and then with A3, B27,
B35, B44 and others (Biddison et al., 1980).  Primary sequence analysis showed
that the basis for these differences were amino acid substitutions in the heavy
chain sequence.  In this manner the HLA-A2 and HLA-B27 specificities were
shown to represent a collection of related alleles, which have been called
subtypes (López de Castro, 1989).  As more serologically defined antigens have
been analyzed using T.cells, isoelectric focusing and nucleotide sequencing, a
substantial number have now been dissected into subtypes.  A common feature
of subtypes is that they segregate between populations.  Hence different, HLA-
B27 subtypes derived from Africa, India, eastern Asia and Europe have been
found (Benjamin and Parham, 1990).
CORRELATING SEQUENCES AND SEROLOGY
Nucleotide sequences for all the WHO-recognized HLA-A, B and C antigens
have now been obtained (Zemmour and Parham, 1993; unpublished data).
These data enable correlation of the primary sequences with the patterns of
aerological cross-reactivity previously defined.
HLA-A
HLA-A locus antigens have been divided by aerological analysis into five cross-
reacting antigens (CREG) designated A2, A3, A9, A10 and A19 (Rodey and
Fuller, 1987).  On the basis of nucleotide sequences five families of alleles can
be defined (Kato et al., 1989; Lawlor et al., 1991) and these correspond to the
five CREG.  The exception to this rule are the A30 subtypes, which
serologically belong to the A19 group but show sequence characteristics of the
A3 group.  The structural similarities that create the aerological epitopes
sharedby A30 and the A19 family (A29, A30, A31, A32 and A33) are located
between residues 144–151 of the a2 helix.  HLA-A30 molecules are more
frequent in Africans and African Americans than in Europeans, which perhaps
explains why serology has focused on such a limited region of the A30
molecule.  If alloantisera obtained from individuals stimulated with a cross-
reactive antigen were used to define the A30 antigen then serology would focus
only on the cross-reactive determinants.
   Potential problems associated with defining antigens from one population with
alloantisera characterized in another are illustrated by an unusual and recently
discovered allele, HLA-A*8001.  In the African American population 6.7% of
HLA-A alleles type serologically negative or 'blank'.  Sequencing of such blank
alleles has revealed the A*8001 allele, which was discovered independently by
three groups of investigators (Domena et al., 1993; Starling et al., 1993; Rosen-
Bronson et al., 1992).  HLA-A*8001 is very different from other HLA-A alleles
and on the basis of nucleotide sequence comparisons defines a sixth allelic
family.  Its closest relative is A*0101 from which it differs by 34 nucleotide and
24 amino acid substitutions.  By superimposing the A* 8001 amino acid
sequence on the three dimensional structure of the class I molecule (Bjorkman
et al., 1987a, 1987b), it can be seen that substitutions distinguishing A*0101
and A*8001 are exposed on the surface of the molecule and thus expected to be
antigenic.  Given the distinctive nature of the A*8001 molecule it is remarkable
that it escaped aerological detection for so long.  This does not appear to have
been due to poor immunogenicity of the A*8001 molecule, because recent
screening of the appropriate population has revealed A*8001 specific
alloantisera (Starling et al., 1993).
HLA-B
Serological definition of HLA-B CREG has been less clear than that of HLA-A
and a similar complexity is seen in the HLA-B nucleotide sequences, which do
not easily subdivide into families like HLA-A alleles.  Variation is heavily
concentrated in exons 2 and 3 and the evolutionary lineages have become
obscured through gene conversion events which have resulted in recombination
of short sequence motifs within the region (Parham et al., 1988).
Comparison of HLA-A and B with the chimpanzee homologues shows that the
A alleles are more closely related than the B alleles (Lawlor et al., 1988; Mayr
et al., 1988).  This observation, indicates that the B locus has evolved more
rapidly than the A locus during the five million years since human and
chimpanzees diverged, and this is supported by the comparison'of HLA-A and B
within the human species (Belich et al., 1992; Watkins et al., 1992).  Moreover,
the primary difference between the two loci appears to be the frequency with
which new alleles formed by interallelic gene conversions enter the gene pool.
The degree to which aerological cross-reactivity between HLA-B molecules
reflects overall structural similarity is highly variable.  The Bw4 and Bw6
public epitopes, formed by alternative sequence motifs at residues 77–83 of the
al helix (Wan et al., 1986) are influential in determining the aerological status
of HLA-B molecules.  A series of crossreactive antigenic pairs has been
identified (B8/B59, B44/B45, B49/B50 B38/B39, B35/B53, B51/B78 and
B62/B63) in which one member of the pair has the Bw4 epitope and the other
the Bw6 epitope.  In the absence of structural information it was speculated that
these pairs of antigens would differ solely in the sequences determining the
public epitopes.  With determination of the sequences it became apparent that
the pairs divided into two groups, those that fulfilled this expectation and those
that did not.
Four of the pairs (B49/B50, B38/B39, B35/B53 and B51/B78) differed as
predicted, in the motifs at positions 77–83 (Müller et al., 1989; Hildebrand et
al., 1992; Hayashi et al., 1990; Sekimata et al., 1990; Madrigal et al., 1992).
For the other three pairs (B8/B59, B44/B45 and B62/B63) many additional
differences were found and it was not obvious from the structures why the
alleles were serologically paired (Hildebrand et al., 1992, 1993, 1994).  On the
basis of sequence B59 is more closely related to B55 than B8 (Hildebrand et al.,
1993), B45 is more closely related to B50 than B44 (Hildebrand et al., 1992)
and B63 is more closely related to B 17 than B62 (Hildebrand et al., 1994).  The
lack of congruity between serology and structure results from dominant epitopes
formed by highly localized segments of sequence and from the antigenic
specificities being defined on the basis of cross-reactivities: B59 is specific to
Japanese populations and B45 and B63 are most common in Africans and
derivative populations (Imanishi et al., 1992).
Another example of this effect emerged from analysis of HLA in the Piman
Indians.  In this population a aerological variant of the HLA-B21 antigen,
designated BN21, was defined (Williams and McAuley, 1992).  This was
intriguing because neither of the conventional B21 antigens, B49 and B50, were
found in any American Indian groups (Kostyu and Amos, 1981) and BN21 was
restricted to the Pima and certain closely related Native American populations.
The sequence of the BN21 allele proved to be highly divergent from B49
(B*4901) and B50 (B*5001), but was very similar to B*4002, an allele that is
common among American Indian groups, including the Pima, and encodes the
B61 antigen (Hildebrand et al., 1992; Domena et al., 1992).  The BN21
molecule differs from B *4002 by substitution at positions 152 (V « E) and 163
(T.« L) in the a2 helix.  At these two positions the BN21 allele, now called
B*4005, is identical to B*4901 and B*5001, which must explain the aerological
cross-reactivity.  This sequence is present in other alleles including ones found
in the P»ma, for example B*5101 and B*5102.  Therefore, the B*4005 allele
was formed by a conversion in which B*4002 was the acceptor and either
B*5101 or B*5102 was the donor.  In conclusion, a B21-like antigen was
formed by recombination between two alleles, neither of which was in the B21
family: a sort of convergent evolution.
HLA-C
Serological definition of HLA-C has proved difficult and there have been few
developments in this area in the last decade.  Similarly, the characterization of
HLA-C proteins has been hindered by the lack of either allele-specific or locus-
specific monoclonal antibodies.  The most successful of the analytical
approaches applied to HLA-C have been those directed at nucleic acids.
Analysis of HLA-C allelic sequences reveals intriguing differences from HLA-
A and B: the peptide binding site is less polymorphic, especially in the al helix,
yet there is greater variation at positions outside the peptide binding site
(Zemmour and Parham, 1992).  Many research groups are actively engaged in
the analysis of HLA-C and the emerging impression is that there is much
undiscovered polymorphism at this locus.
DNA Methods for HLA-A, B, C Typing
Until recently serology was believed to provide adequate typing of class I HLA
molecules for medical and scientific applications.  Systematic molecular
analysis of the polymorphism has however revealed limitations in the
aerological methods.  Many alleles remain undiscovered, particularly in
Africans and other non-European populations.  Even in the most extensively
studied populations new subtypes continue to emerge.  The degree of accuracy
to which alleles can be assigned serologically is variable, as is the extent to
which patterns of aerological cross-reactivity correlate with the underlying
structures of the proteins.  The problems are obvious in the case of HLA-C, but
apply similarly to HLA-A and B.
   A fundamental requirement for analysis of the effects of HLA-A, B, C type on
T-cell vaccination, whether aimed at infectious, autoimmune and malignant
diseases, or on transplantation between unrelated donors and recipients, is
typing that distinguishes all alleles with comparable levels of accuracy.  This
requirement is most likely to be met by DNA-based methods and development
and application is one goal of the next international histocompatibility
workshop.  Another goal is to focus on human populations in which the HLA
profile is poorly defined.  It is hoped that the latter effort can be integrated with
that of the Human Genome Diversity Project which proposes to provide samples
from hundreds of anthropologically characterized human populations.
HLA-A, B, C Genes and Natural Selection
In contrast to HLA-A, B and C the class I MHC pseudogenes, HLA-H and
HLA-J, show very little polymorphism (Zemmour et al., 1990; Messer et al.,
1992).  Thus function and polymorphism are correlated, suggesting that
polymorphism in the HLA-A, B and C genes is the result of natural selection.
This idea is supported by the nature and distribution of nucleotide substitutions
within the genes; coding substitutions affecting residues of the antigen
recognition site that contact bound peptides are disproportionately represented
(Parham et al., 1988; Hughes and Nei, 1988; Hedrick et al., 1991).
Furthermore, it is clear from many studies of peptide binding and antigen
presentation that amino acid changes at such 'peptide-binding positions' affect
the specificity of the binding site.  All these data are consistent with the view
that polymorphism is naturally selected to give molecules with different
specificity for the presentation of antigens.
Disease-specific Selection
Survival depends on T-cell responses against an array of micro organisms,
viruses and foreign proteins.  That individuals with any pair of HLA-A, B and C
alleles survive suggests that all the alleles present in the human population are
capable of presenting a wide range of antigens, a conjecture supported by the
diversity of endogenous peptides that are bound by the product of a single allele
(Jardetzky et al., 1991).  Over and above these basic requirements an individual
allele may offer a particular advantage under specialized circumstance, for
example, when a particular disease is a major threat to survival.  It would be
envisaged that alleles that are better at presenting peptides from the disease-
causing pathogen would be favoured under these circumstances.  The high
frequency of HLA-B53 in West African regions of endemic malaria provides an
example of such disease-specific selection (Hill et al., 1991, 1992).  In many
other parts of the world disproportionately high frequencies of particular alleles
and haplotypes are found (Imanishi et al., 1992) and are candidates for being
associated with resistance to particular disease, but the connections between
host and pathogen have yet to be made.
Overdominant Selection (Heterozygote Advantage)
Peptides bound by class I molecules are usually nine amino acids in length.  The
ends of the peptides are bound tightly through 'anchor' residues, which are often
conserved amongst the peptides bound by a particular allele (reviewed in Barber
and Parham, 1993).  In contrast the centre of the peptide is less important for
interaction with HLA and appears to define the epitope seen by the T-cell
receptor.  The peptides bound by different alleles are distinct.  For example, at
position 2 of peptides bound by B27, B7 and B60, arginine, proline and
glutamic acid residues respectively are found (Hill et al., 1992, unpublished
data).  Thus, from a given antigenic protein each of these molecules will present
a different set of epitopes to T.cells.
In view of the mechanism of peptide presentation the potential benefit of
heterozygosity is obvious.  Heterozygotes can present a greater array of peptides
than homozygotes and by inference should be capable of making a stronger
immune response against any pathogen.  The maximum twofold effect will most
closely be approached when there is no overlap between the repertoire of
peptides bound by the two alleles.  Thus one might expect a tendency for
populations to evolve alleles that are highly distinctive and to lose intermediate
forms.  This effect could explain the presence of distinctive lineages of HLA-A
alleles and the segregation of closely related subtypes amongst populations
(Kato et al., 1989; López de Castro, 1989).
Frequency Dependent Selection
So far we have considered two components of the selection upon Class I HLA
molecules. Disease-specific selection, which assesses the ability of class I
molecules to present a limited number of defined peptides, and overdominant
selection which assesses their capacity to present a universe of peptides.
Let us consider a hypothetical population in which overdominance is the only
selection and all alleles, though complementary in their binding site
specificities, are as effective in their function of antigen presentation.  Under
these circumstances selection will act to even the frequency of alleles, thereby
maximizing the proportion of homozygotes.  This same tendency will confer
selective advantage to new alieles providing they too are complementary to
existing alleles and as functionally effective.  Most new alleles are formed by
conversions that reassort clusters of substitutions between functional alleles.
They are likely to be functionally distinct and the presence of many such
products in human populations suggests they are functionally effective.  The
prevalence of previously undiscovered HLA-B alleles in South American Indian
populations (Belich et al., 1992; Watkins et al., 1992) indicates that the
appearance of new alleles is sufficiently frequent to be a significant factor in
considerations of the selection acting upon class I HLA genes.
New alleles are advantageous not because they are better than existing alleles
but because they are different; this is a frequency-dependent selection.  As the
frequency of a new allele increases under this selection its selective advantage
will decrease, eventually to zero when the new allele has reached a frequency
comparable to that of the existing alleles.  The selective advantage of a new
allele will be dependent upon the number and distribution of existing alleles,
and thus upon population size.  For large urban populations, with their many
alleles and few homozygotes, this advantage should be considerably less than
for small tribal populations with limited numbers of alleles and greater
homozygosity.
Many of the HLA-B alleles found in South American Indians are not present
in North American Indians or Japanese, two genetically related populations.
The new HLA-B alleles can be derived from HLA-B alleles found in North
American populations by single conversion events and this is probably how they
evolved.  Despite the production of new alleles the numbers of HLA-B alleles in
South American Indian populations do not appear to be greater than those in
North American Indian groups (Belich et al., 1992; Watkins et al., 1992).  Thus
the introduction of new alleles has been accompanied by the loss of the existing
alleles.  This may be due to genetic drift, which has increasing impact with
decreasing population size; modern populations of South American Indians are
small.  As a new allele increases in frequency in a population the frequencies of
the existing alleles inevitably decrease and the chance of them being lost
commensurately increases.  The replacement of old alleles by new ones could
also result from disease-specific selections and the environment of South
America certainly harbours different pathogens from that of North America.
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The possibility of IFNγ production by bovine T. parva specific CD8+ cells and
its potential role in protection was discussed.  Although secretion of IFNγ by
this population has not been examined, a direct role of this cytokine during
infection was considered unlikely.  Although in vivo and indirect effects cannot
be excluded, it has been established that recombinant IFNγ does not affect the
growth of T. parva-infected cells in vitro.  Several mechanisms were suggested
to explain the non-reciprocal cross-protective capacities of the Muguga and
Marikebuni stocks of the parasite.  The possibility of differential sensitivity of
the stocks to CTL activity was suggested but epitope dominance during the
course of the immunizing infection was considered a more plausible
explanation.  Since individual identical twins immunized with Muguga and
Marakebuni stocks can develop strain-specific and cross reactive responses
respectively, it was considered unlikely that host MHC differences can account
for this phenomenon.
The potential for peptide immunization as a means of generating of T. parva-
specific CTL was discussed.  The low affinity of CTL induced in this manner
was highlighted as a major drawback.  An additional concern was the
observation that the optimal size for the immunization is longer at 16aa than the
9aa preferred for optimal binding of peptides te the MHC binding cleft.  This
may reflect an extended half life of the longer peptides in vivo.  Other issues
raised in this context were the possibilities that the absence of CD4+ T-cell
epitopes in short peptides used to induce CTL might lead to the induction of
sub-optimal responses, and that immunization with high doses of peptide might
induce energy rather then stimulation.
The possibility that polymorphism in TAP.and proteosome molecules in
different cell types might contribute to the selection of class I MHC-bound
peptides was discussed in relation to the selection of target cells for the
identification of bovine CTL epitopes using gene transfection of heterologous
cells expressing bovine class I MHC antigens.  Glycosylation of antigens was
also relevant in this regard.  Glycosyl moieties might be expected to obstruct the
association of a given peptide with the antigen binding groove, so that removal
of glycosylation sites could result in the generation of new T-cell epitopes.
More importantly, because glycoproteins are co-translationally translocated to
the endoplasmic reticulum, they would not be expected to access the
proteosome/TAP.processing pathway.
   The use of peptides stripped from class I MHC molecules on the surface of
APC to identify CTL epitopes was discussed at length.  The type of APC used
and the dilution at which the crudely separated peptides can be used (around
103 to 104 should be considered as a minimum) were highlighted as being of
crucial importance to the success of the technique.  The use of the mouse RMA-
S mutant cell line transfected with a bovine class I MHC gene was considered a
good option for the identification of bovine CTL epitopes, since these cells
present peptides 10 times better then the parent line RMA.  Prediction of
epitopes on the basis of the presence of an MHC binding motif alone was
discouraged, even in the case of mice, since many motif-containing peptides
will bind to class I MHC molecules without constituting T-cell epitopes.
   In discussion of MHC polymorphism and its possible influence on the efficacy
of a vaccine targeted at the induction of CTL, it was emphasized that care
should be taken to maintain heterozygosity of the MHC when selecting for
particular traits in cattle populations.  This increases the chance that the
population would survive infection with previously unencountered pathogens.
The concept of selecting cattle with MHC genes that interact well with vaccine
antigens is therefore flawed.  The aim should be to produce a vaccine capable of
providing protection in cattle of many different MHC types.  It was
recommended that, once identified, a candidate vaccine antigen for the
induction of T. parva-specific CTL should be tested in a genetically diverse
population of cattle.
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An anti-disease vaccine for malaria?
J.H.L. Playfair
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UCL Medical School, London, UK
__________________________________________________________________________
Several lines of argument suggest that it might be worth considering a malaria
vaccine that operates against the disease rather than the parasite itself.  There is
a long literature devoted to the concept of 'toxins' in clinical malaria and the
development of anti-toxic immunity in endemic areas and standard vaccines
against well-established toxins (e.g. tetanus, diphtheria) are among the most
effective that exist.  More recently, attention has focussed on the possible toxic
role of cytokines, particularly tumour necrosis factor (TNF) in severe
Plasmodium falciparum malaria, and on the identification of the parasite
components that induce them.  There is also the fact that solid immunity against
the parasite is still, after decades of work, proving quite difficult to induce.
ANTI-TOXIC IMMUNITY
Early in the century, malaria was widely considered a toxic disease, and it was
recognized that not all patients with the same parasitaemias were equally ill.
Thus the simple presence of parasites was not sufficient to cause symptoms,
which must therefore be produced by indirect means.  Furthermore it was
proposed that children could become immune to these toxic effects, and thus
suffer less severe symptoms, at an earlier age than they acquired immunity to
the parasite (Sinton et al., 1931; Taliaferro, 1949; Hill et al., 1943).  More
recent studies in the Gambia confirmed that clinical 'tolerance' (defined as 'the
ability to live asymptomatically with fairly dense parasitaemia') developed by
the age of three to five despite the persistence of high parasitaemias for up to
five more years (McGregor et al., 1956).  No evidence has been produced that
this tolerance was immunological in origin and it is still possible that it
represents a reduced responsiveness to unchanged levels of some stimulating
factor, or the presence of some natural blocking factor.  However, recent work
in experimental models, reviewed below, does suggest that acquired immunity
to symptom-inducing antigens, possibly acting through TNF, might be part of
the explanation.
In considering malaria from this viewpoint, it is necessary to distinguish
several patterns of disease.  Fever, the hallmark of malaria, is prominent in both
P.falciparum and P.vivax infections, and there is quite good evidence linking it
to over-production of TNF (Kwiatkowski et al., 1993; see below).  Anaemia,
another almost universal complication, is particularly a feature of the first year
of life, whereas cerebral malaria, the major cause of mortality, tends to occur
from about a year later and is not seen in P. vivax infections.  Nor is
hypoglycaemia, which is frequent in P. falciparum infection.  Thus it is hardly
likely that a single pathogenetic mechanism is responsible for all the clinical
effects of the disease.
CYTOKINES
Nevertheless, as Clark was the first to point out (Clark, 1987; Clark et al.,
1989), there are theoretical arguments for an involvement of TNF in these and
many other complications of P. falciparum malaria, which bear a striking
resemblance to the toxic effects of high-dose TNF administration, and it is this
cytokine that has been most thoroughly studied in this regard.  There is a general
consensus that raised plasma levels of TNF are associated with severity and
mortality in cerebral malaria (Kem et al., 1989; Grau et al., 1990; Kwiatkowski
et al., 1990).  In a mouse model that somewhat resembles cerebral malaria, anti-
TNF antibody protected against cerebral disease but not against anaemia, but so
did antibodies against several other cytokines (Grau et al., 1988).  In a small
trial of anti-TNF antibody in human malaria, a reduction in fever was the only
significant effect noted (Kwiatkowski et al., 1993).  Fever and raised TNF
levels are also found in P.vivax infection (Karunaweera et al., 1992), so if TNF
is really responsible for cerebral malaria, some co-factor(s) must be involved
too; a different pattern of sequestration could clearly be one of these, or there
may be synergy with other cytokines or mediators.  Interestingly, additive or
synergistic effects are also seen in the anti-parasitic activity of TNF: killing of
gametocytes in vitro appears to require TNF plus a 'complementary factor'
(Nautunne et al., 1990).  Although there is clearly much to be learned about
both the pathogenetic and the protective activities of even this cytokine alone, it
is important trying to understand why it is over-produced in malaria.
TNF-INDUCING MOLECULES
In experiments with the mouse parasite P. yoelii, we found that parasitized red
cells incubated overnight with peritoneal macrophages induced amounts of TNF
comparable to those induced by bacterial LPS.  Both lethal and non-lethal
strains of the parasite were active.  We then found that incubating the
parasitized blood over-night yielded supernatants that themselves induced TNF
(Bate et al., 1988).  The human parasite P. falciparum behaved similarly, and
either mouse macrophages or human blood monocytes could be used
interchangeably (Taverne et al., 1988).  When injected into mice, these
supernatants induced TNF sufficient to be detectable in the serum, and were
lethal in mice that had been made hypersensitive to TNF by pre-treatment with
D-galactosamine (Bate et al., 1989).
   Evidently, then, there were molecules in or on parasitized red cells that
induced TNF production in macrophages.  One obvious possibility was that the
effect was the result of contaminating bacterial lipopolysaccharide (LPS) but,
for reasons to be summarized later, we believe that this was not the case.
However the active material did resemble LPS in certain respects; it retained
activity after boiling, digestion with proteases and deamination by nitrous acid,
but was destroyed by lipase treatment, by some types of phospholipase C, by
dephosphorylation with HF and by deacylation with NAOH.  In a two-phase
lipid extraction, it appeared in the chloroform/methanol rather than the
water/methanol phase.  When injected into normal mice at sub-toxic doses, it
induced antibody which blocked its ability to induce TNF both in vitro and in
vivo, and was predominantly IgM; we found no evidence for a memory response
or a switch to IgG on boosting (Bate et al., 1990).  Using this assay, active
material from all the species we have tested so far, including the mouse
parasites P. yoelii and P. berghei and the human parasites P. falciparum and P.
vivax, show complete cross-blocking, which is in striking contrast to the species,
strain and even variant specificity of the protein antigens commonly studied
(Bate et al., 1992a).  We concluded that parasitized red cells contain, and can
release (in vitro at least), phospholipid molecules that induce TNF and behave
as T-independent antigens.  We refer to these molecules as parasite 'exoantigens'
or 'toxic antigens' (Bate et al., 1992b).  Similar induction of TNF from human
macrophages by P. falciparum supernatants has also been reported (Picot et al.,
1990).
Further characterization of the active molecule came from studies in which we
used standard phospholipids of the type found in red cell membranes:
phosphatidylcholine (PC), phosphatidyl serine (PS), phosphatidyl inositol (PI)
and phosphatidyl ethenolamine (PE), as well as phosphatidic acid (PA) and
cardiolipin (CL).  None of these molecules induced TNF from macrophages, but
one of them, PI, completely blocked the ability of exoantigens to induce TNE
Surprisingly, the phosphated monosaccharide inositol monophosphate (IMP)
also blocked, and so did preparations of exoantigen treated with either lipase or
HF; we refer to these as 'detoxified'exoantigens (Bate et al., 1992c).  At this
point we concluded that a phosphate group and an inositol ring were somehow
involved in the TNF-triggering part of the exoantigens.  This was further
supported by the finding that antisera raised by simply immunizing mice with PI
or IMP, but not the other phospholipids, blocked TNF release.  However PC, PS
and PA incorporated into liposomes with or without cholesterol did induce
blocking antibody, but this could be absorbed out by PC liposomes, while
antibody raised to PI or IMP.could not (Bate et al., 1992d).  From this we
concluded that blocking antibodies were of two types—one specific for
phosphate groups and one additionally recognizing inositol.
DISTINCTION FROM LPS
Our exoantigens appear to differ from LPS in a number of important ways.
First, their TNF-triggering activity is not blocked by the inclusion of polymyxin
B in the cultures, while the blocking antisera, whether against the exoantigens
themselves or against PI or IMP, do not block triggering by LPS.  Second, they
stimulate macrophages from the LPS-hyporesponsive C3H/HeJ mouse strain.
Third, triggering by LPS is not abolished, as that of the exoantigens is, by
phospholipase C digestion; conversely deamination abolished the activity of
LPS but not of the exoantigens.  Fourth, neither PI, IMP.or detoxified
exoantigens block triggering by LPS, which may even suggest that different
macrophage receptors are involved.  We therefore feel safe in concluding that
LPS alone cannot account for our results.  However we cannot eliminate the
possibility that trace amounts of LPS, insufficient to stimulate on their own, are
needed as 'adjuvant' to the effects of the exoantigens, particularly where
induction of blocking antibody is concerned (Schuster et al., 1979; Banerji and
Alving, 1990); indeed there would be nothing unphysiological if this was so,
since malaria patients probably have increased amounts of circulating LPS
(Felton et al., 1980).
HYPOGLYCAEMIA
During the experiments on toxicity of exoantigens in vivo, we had noticed that
injected mice often looked ruffled and ill.  Investigating this, we found a
dramatic drop in blood sugar lasting from two until at least eight hours after
injection.  By comparison with the normal mid-morning blood sugar of 7.6
mmol/L, the four-hour value averaged 3.4 mmol/L, and values below 2 mmol/L
were quite common.  Since TNF (and other cytokines) can cause
hypoglycaemia, we attempted to inhibit this drop with repeated injections of a
monoclonal anti-TNF antibody.  Though this antibody protected D-
galactosamine pre-treated mice from death, it had no effect on hypoglycaemia.
On the other hand, a second and third injection of exoantigen at two-week
intervals induced progressively less hypoglycaemia in normal mice, but this
protection was not seen in mice with Severe Combined Immunodeficiency
(SCID mice).  We concluded that antibody against the exoantigens could protect
against hypoglycaemia.  In line with the TNF experiments described earlier, we
then showed that IMP.mixed with the exoantigens blocked their hypoglycaemic
effect, as also did antibody raised against IMP.or against a PI-BSA conjugate
(Taylor et al., 1992).
   We do not know whether the same molecules) induced both TNF and
hypoglycaemia.  Moreover we have occasionally detected low levels of 'TNF
and hypoglycaemia induction with supernatants of normal red cells, so that it
remains possible that the active phospholipids are normal red cell components
that are increased in concentration or otherwise modified by the parasite (Hsaio
et al., 1991; Vial et al., 1990).
ANAEMIA
Anaemia is recognized as one of the most severe complications of malaria,
particularly in very young children, and it is generally agreed that it cannot be
accounted for solely by red cell parasitization (Abdalla et al., 1980).  In our non-
lethal P.yoelii mouse model, the haematocrit falls to 20% of normal in 10 days,
despite the fact that the parasite is restricted to reticulocytes.  The same is true
in SCID mice, ruling out a major role for antibody.  From about day 8 of
infection, 51 Cr-labelled normal red cells are eliminated from the circulation
unusually rapidly.  Neither this effect, nor the anaemia itself, are prevented by
prior immunization with exoantigens, nor by anti-TNF antibody, though TNF
has been shown to depress erythropoiesis (Johnson et al., 1989).
RELEVANCE TO THE INFECTION
Having shown that interesting and potentially toxic molecules are released by
parasitized red cells in vitro, we wished to establish whether they were released
during the infection.  Here the evidence is incomplete.  On the one hand, we do
not detect TNF in the blood of infected mice, at least using the bioassay, and
infected mice do not develop hypoglycaemia until about one day before they
die; this might argue against a significant release of exoantigens in vivo.  On the
other hand, serum from infected mice does contain antibodies that block TNF
induction by exoantigens, and also antibodies that bind PI and other
phospholipids, which at least suggests that the immune system has been exposed
to exoantigens.  This paradox might be resolved if antibody produced early
during infection was able to block both TNF induction and hypoglycaemia, and
a detailed study in SCID mice would probably be necessary to test this.  But
another explanation that we have found attractive is that normal serum contains
non-antibody blocking factors that would be capable of binding and neutralizing
exoantigens until their concentration became overwhelming, analogous to,
though not necessarily the same as, the lipoproteins that have been reported to
inactivate LPS (Emancipator et al., 1992).  Supporting this idea, we have found
that normal mouse serum does in fact block TNF induction by exoantigens, but
only at dilutions up to about 1120; by comparison, the titres of antibody in
immunized mice frequently exceed 1/10,000.
RELEVANCE TO PROTECTIVE IMMUNITY AND VACCINATION
The analysis of exoantigens that induce TNF and/or hypoglycaemia would be
rather academic if they could not be exploited as protective vaccines.  At present
this is far from being the case, but there are some encouraging pointers.  In a
large group of genetically homogeneous Fl hybrid mice immunized with
exoantigens and challenged 13 days later with the uniformly lethal P.yoelii,
about half recovered after about three weeks with very high parasitaemias (in
some mice over 80%) without looking particularly ill.  This is, of course, what
'anti-disease' immunity would be expected to look like.  Similar protection has
been obtained in smaller groups of mice immunized with PI and IMP.  Neither
repeated boosting nor the use of adjuvants improves this level of protection, and
though preliminary experiments with exoantigens coupled to protein carriers
such as bovine serum albumin and keyhole limpet haemocyanin have yielded
substantial increases of blocking antibody, most of which is IgG, the level of
actual protection remains the same (Bate et al., 1993).  Perhaps IgM is the more
effective isotype in this case.
This may simply reflect the fact that our P. yoelii model is not really suitable
for this type of protection study.  For example, as noted above, both vaccinated
and non-vaccinated mice become extremely anaemic during infection, and it
may be that mice are dying of anaemia though 'protected' against other aspects
of pathology.  This is typical of the difficulties encountered when trying to study
'anti-disease' immunity in such a multifactorial disease.  However in a model of
cerebral malaria using C57BL mice and P. berghei, immunization with
exoantigens has been shown to give 60% protection against early ('cerebral')
mortality (Curfs et al., 1992) and a somewhat similar partial protection with
exoantigens has also been reported in a P. falciparum model in squirrel
monkeys (Ristic and Kreier, 1984), and in cattle with babesiosis (James, 1989).
RELEVANCE TO THE HUMAN DISEASE
Our hypothesis, then, is that the 'anti-toxic' immunity observed in human
populations is due to the development of immunity against exoantigens,
probably mediated by antibody which blocks their ability to induce TNF,
hypoglycaemia etc.  This will be hard to prove, but one could make certain
predictions.  'Tolerant' children with high parasitaemia but mild or no symptoms
ought to have blocking antibody in their blood; we are beginning to test this.  In
immune adults who leave the endemic areas, clinical immunity (IgM?) might be
expected to wane more rapidly than immunity to the parasite itself (IgG?), and
this does often seem to be the case.  If we are right about the conserved nature
of the toxic exoantigens, anti-toxic immunity should show a wider degree of
cross-protection than anti-parasite immunity, but this is still controversial
(Jeffery, 1966).  Finally, antibody against the relevant exoantigens ought to
correlate with clinical protection.  One such exoantigen, a TNF-inducing
molecule found in P.falciparum culture supernatants and originally named
Antigen 7 by its discoverers, fits the latter criterion since levels of antibody to
this antigen peak in Gambian children at about the age of five, which is when
clinical immunity develops; antibody to most other exoantigens peaks
considerably later (Jakobsen et al., 1991).  Moreover, T-cell responses to
Antigen 7, assayed by IFNG release, correlate with clinical severity, which
might be important in view of the synergy between IFNG and TNF-inducing
molecules (Riley et al., 1991).  Unfortunately the best correlation with clinical
immunity in individual patients was with antibody to another exoantigen
(Antigen 2).  This kind of analysis is further complicated by the fact that several
of these antibodies also seem to affect parasitaemia.  Careful and substantial
studies of TNF and other cytokine responses to a range of exoantigens, in the
presence of sera from both immune and non-immune patients, will be necessary
before the existence of true 'anti-toxic' immunity in man can be established.
Nonetheless whether or not it exists in the natural state, the ability to induce it
by immunization could be of great potential value.
RELEVANCE TO HUMAN VACCINES
As compared to the candidate vaccines already under study, the anti-disease
approach has both advantages and disadvantages.  In its favour is the fact that it
aims to deal with what really matters—disease.  Also, the apparent lack of
antigenic variation noted in the mouse experiments might suggest that a whole
series of species and variant-specific antigens would not be needed.  Moreover
by acting against cytokine-inducing antigens rather than against the cytokines
themselves, as, for example, antibody to TNF or soluble TNF receptors do, it
might exert an effect on other cytokines induced at the same time, such as IL1,
and thus avoid the need for a complex 'cocktail' of inhibitors.  Against it is the
lack of T-dependent antibody, with memory, IgG etc., in the mouse experiments
which, if translated directly into the field, would mean a vaccine injection every
few weeks, or at best a 'tourist' vaccine.  Another theoretical danger is that the
phospholipid antigens responsible for disease might turn out to be genuine
autoantigens, or at least cross-react with host molecules; the vaccine would then
induce autoimmunity.  We are currently attempting to confer T-dependence on
the relevant antigen, in the hope that this might possibly overcome both these
problems.
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INTRODUCTION
Activation of cells from the monocyte/macrophage lineage during African
trypanosomiasis has been reported for experimental model infections in inbred
mouse strains (Grosskinsky et al., 1983) and tsetse-transmitted infection in
cattle (Flynn and Sileghem, 1991; Sileghem et al., 1993).  Although the exact
impact of this macrophage (MO) activation on the immune system is not
entirely understood, it has been suggested that it might be responsible for a
variety of immune disorders including immunosuppression and polyclonal
activation (Askonas, 1985; Sileghem et al., 1989).  Furthermore, activation of
MO might also have a direct impact on the disease.  Cachexia, a state of
exhaustion attributed to MO-derived cytokines (Beutler and Cerami, 1986;
Franks et al., 1991) is a prominent feature of trypanosomiasis (Rouzer and
Cerami, 1980; Morrison et al., 1981) and uptake of erythrocytes by activated
MO has long since been accepted as a major cause of anaemia associated with
the disease (Connal, 191 1; Fiennes, 1954; Murray and Dexter, 1988).  MO
activation during African trypanosomiasis would thus appear to have deleterious
rather than a beneficial effect for the host.
   In a variety of disease models, erythrophagocytosis, dyserythropoiesis,
cachexia and polyclonal activation have been attributed to tumour necrosis
factor a (TNFα) (Clark and Chaudri, 1988; Miller et al., 1989; Beutler and
Cerami, 1986; Macchia et al., 1993), a cytokine that is predominantly secreted
by cells of the monocyte/macrophage lineage.  TNFα has also been implicated
in the immunosuppression that is characteristic of African trypanosomiasis
(Lucas et al., 1993).  Production of TNFα might thus represent a central
mechanism through which activated MO can mediate a variety of the effects
reported during trypanosomiasis.  It was, therefore, important to determine
whether TNFα production is induced during bovine trypanosomiasis and
whether or not production is correlated with disease.
PRODUCTION OF TNFα DURING BOVINE TRYPANOSOMIASIS
PRODUCTION OF TNFα DURING BOVINE TRYPANOSOMIASIS
To measure TNFα during infection in cattle, we have developed a capture
immunoassay (EIA) using a mouse-anti bovine TNFα monoclonal antibody for
capture (BC9, Sileghem et al., 1992) and a rabbit polyclonal anti-bovine TNFα
antiserum for detection.  TNFα production was studied in cattle infected with T.
vivax IL2337 by tsetse fly inoculation (Moloo et al., 1987).  This isolate induces
acute anaemia and marked erythrophagocytosis in cattle (Anosa et al., 1992).
Plasma TNFOC was measured weekly by the EIA using recombinant bovine
TNFα (rTNFα) diluted in pooled pre-infection plasma as a standard.  The limit
of detection was defined as three times the standard deviation of the optical
density from the background (pooled pre-infection plasma), which was 200
pg/ml.  Small amounts of the cytokine were recorded only on days 14 to 21 pi
(Figure 1).  In cattle, plasma TNFα titres have been shown to be increased
within hours of intravenous administration of bacterial lipopolysaccharide (Peel
et al., 1990) or of intratracheal infusion of Pasteurella haemolytica (Pace et al.,
1993).  However, plasma TNFcc titres remained negative throughout Gram
negative septicaemia (Peel et al., 1990).  Circulating cytokines represent the
excess of cytokine synthesis and therefore may not accurately reflect the
production of a given cytokine during disease (Cavaillon et al., 1992).  We have
therefore resorted to ex vivo measurements of TNFα activity.  Peripheral blood
mononuclear cells (PBMC) were sampled from three animals prior to, and
following, tsetse fly transmitted infection of T.vivax IL2337.  Monocytes were
purified by adhesion to plasma-coated gelatine (Goddeeris et al., 1986) and
cultured.  TNF in 5 hr and 24 hr culture supernatants was measured using a
modification of the EIA described in which standards were diluted in culture
medium instead of plasma.  The use of culture medium instead of plasma as a
negative control resulted in a decrease of detection limit to 100 pg/ml.  TNF was
present in 5 hr supernatants derived from all three animals studied (Figure 2A)
although titres varied considerably from individual to individual.  Production
was maximal at day 17 pi and fell rapidly thereafter; the cytokine was not
detected in the 24 hr supernatants (data not shown).
   Because cytokine production ex vivo does not necessarily reflect the amount
produced in vivo, care should be taken in interpreting the results.  However, ex
vivo titrations can indicate the capacity of cells to produce cytokines and have
been useful in relating production of interleukin-1 to various human disease
states (reviewed by Dinarello, 1991).  In our experiments, monocytes prepared
at various time points were all cultured in the same batch of medium.
Therefore, the absence of TNFα production in monocytes prepared before
infection and those isolated after week 4 pi would argue against these results
being an in vitro artefact and would suggest that the production of TNF ex vivo
is due to in vivo macrophage activation.
Figure 1. TNFα titres in plasma from Boran cattle infected with T.vivax IL2337
by tsetse fly transmission.  At weekly intervals, blood from four animals was
sampled into ethylene-diaminetetra-acetate tubes for preparation of plasma and
the samples were stored at -70 ?C until use.  TNFα was titrated by a capture EIA
using a mouse monoclonal anti-bovine TNFα antibody (BC9) and, for detection,
a rabbit polyclonal anti-bovine TNF antiserum.  The rabbit antibody was
detected by incubation with biotin-conjugated donkey anti-rabbit
immunoglobulin (Amersham International, Amersham, Bucks, UK), and
streptavidin-conjugated horseradish peroxidase (Amersham).  Following
addition of 2,2?-azino-bis(3-ethylbenz-thiazoline -6-sulfonic acid) (ABTS), the
optical densities were determined at 414 nm in a Titertek Multiskan MCC 340
(Flow Laboratories).  Pooled pre-infection plasma was used as the negative
control and bovine rTNFα, diluted in pooled pre-infection plasma, was used to
generate a standard curve.  The limit of detection, defined as the optical density
from the negative control + 3 times the standard deviation, was 200 pg/ml.  The
four bars represent four individual animals.
ASSOCIATION OF TNFα PRODUCTION WITH SEVERITY OF  DISEASE
When monocytes were purified from cattle infected with T.congolense ILNat
3.1 (Nantulya et al., 1984) rather than T.vivax IL2337, no ex vivo TNFα
production was detected (Figure 2B).  These parasites were selected for this
study because of the marked difference in anaemia associated with the
infections they induce.  The T.vivax stock IL2337 causes acute anaemia, early
severe erythrophagocytosis and a progressive reduction in packed cell volume
(PCV) that  reaches  a  minimum  around  week  2 to 3  pi  (Anosa et al., 1992).
At that
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Figure 2.TNFα titres in culture supernatants of monocytes.  At weekly intervals
following infection by tsetse fly inoculation, blood was sampled from three
Boran cattle infected with T. vivax IL2337 (A) and from three Boran cattle
infected with T. congolense ILNat 3.1 (B).  The different bars represent
individual animals.  The blood was collected into Alsever?s solution, PBMC
were prepared by density centrifugation on Ficoll-Paque (Pharmacia, Uppsala,
Sweden) and monocytes purified from the PBMC by adhesion to plasma-coated
gelatin surfaces.  The monocytes were cultured in 100 µl aliquots in 96 well flat
bottomed plates (Costar, Cambridge MA) at a concentration of 106/ml in RPMI
1640 (Flow Laboratories, Irvine, UK) supplemented with 5% heat-inactivated
foetal calf serum (Flow Laboratories), 2mM L-Glutamine and 50 units/ml
penicillin-streptomycin (culture medium).  The cells were incubated for 5 h at
37 ÉC in a humidified atmosphere containing 5% CO2.  The supernatants were
stored at -70 ºC until use.  TNFα was titrated by a capture EIA as described in
Figure 1 with the only modifications being the use of culture medium as a
negative control and bovine rTNFα diluted in culture medium instead of plasma
to prepare the standard curve.  The limit of detection was 100 pg/ml
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time, some animals seem to overcome the acute anaemia, and their PCV values
increase.  Many animals, however, require trypanocidal drug treatment to avoid
death from anaemia.  In contrast, erythrophagocytosis is less marked during
infection with T. congolense ILNat 3. 1, and the PCV is generally stable until
week 2 pi, when it begins to fall reaching a minimum around week 6 to 7 pi.  At
this point, some animals recover and proceed to the chronic stage of the disease.
Most animals, however, require treatment (Paling et al., 1991).  Anaemia is thus
observed during infection with both parasites, but is much more acute and
severe during infection with T .vivax IL2337.
   Although it is not clear whether the differences in TNFα production between
the two infections are quantitative or qualitative, our data demonstrate
unambiguously that ex vivo TNFA secretion by monocytes is higher during
infection with T.vivax IL2337 than during infection with T.congolense ILNat 3.
1. To establish whether the ex vivo observations were a true reflection of the in
vivo situation, RNA was extracted from monocytes purified on magnetic beads
through negative selection to avoid activation.  TNFα mRNA was then detected
using bovine TNFα-specific oligonueleotide primers in a 35 cycles reverse
transcriptase polymerase chain reaction.  TNFα message was detected in
monocytes from both T.congolense- and T.vivax-infected animals, but was much
higher in the T.vivax-infected animals early in infection (Table 1).  Thus, the
differences between the two groups are apparent at the mRNA level, but are
quantitative rather than qualitative.
   In conclusion, TNFα production is induced during bovine trypanosomiasis
and is higher in T.vivax IL2337 infection than in T.congolense ILNat 3.1
infection.  This difference is observed at the level of ex vivo protein secretion
and at the level of in vivo mRNA expression.  Since TNFα has been proposed as
the cause of erythrophagocytosis in murine malaria (Clark and Chaudri, 1988),
it is interesting that a correlation is found between TNFα production and
erythrophagocytosis in bovine trypanosomiasis.  This does not establish a
causative role for TNFα in erythrophagocytosis, but the association of TNFα
production with the severity of anaemia and erythrophagocytosis makes this
cytokine a clear candidate for future research into the pathogenesis of bovine
trypanosomiasis.
Table 1. TNFα mRNA expression in monocytes isolated from Trypanosoma
vivax IL2337 and T.congolense ILNat 3.1 infected cattle.
____________________________________________________________
Pre-infection               Day 3 pi                  Day 10 pi
____________________________________________________________
T.congolense ILNat3.1
BJ296 - - -
BJ300 - - -
BJ301 - - ++
BJ349 - - ++
T.vivax IL2337
BJ249 + ++ ++
BJ250 - ++ ++
BJ344 - ++ ++
BJ352 - ND ++
____________________________________________________________
Blood was sampled from eight Boran cattle prior to and following tsetse fly-transmitted infection
with either T.vivax IL2337 or T.Bongo ILNat3.1 and collected into Alsever's solution.  PBMC
were purified by density centrifugation on Ficoll-Paque.  T.cells were removed using magnetic
beads (Dynal, Oslo, Norway) coated with anti-CD2, anti-CD4 and anti-CD8 monoclonal
antibodies, γδ T.cells using beads coated with an anti-WCI antibody and B cells using an anti-lgm
monoclonal antibody.  The negative population was found to contain over 80% monocytes (IL-
A24-positive).  RNA was extracted by the one-step method of Chomezynsky and Sacchi (1987)
and 1 µg was reverse transcribed into single stranded(ss) cDNA using AMV reverse transcriptase
and oligo(dt)15 as the primer (Promega, Madison, WI), according to the manufacturer's directions.
One tenth (5 µl) of the total cDNA mix was used as a template in a PCR reaction containing 1.5
mM M9Cl2, 15 pM of each primer, 2.5 U Taq Polymerase and 200 µM of each dNTP.  The
primers used were CATCAACAGGCCTCTGGTCAG sense and
GAGTCCGGGCAGGTCTACTTTGGGATCATTGCCCTGTGA antisense.  The 498 bp product
was amplified through 35 cycles wiTh1 minute denaturing at 95°C, 1 minute annealing at 55°C
and 2 minutes extension at 72°C.  All samples were tested for the presence of beta actin prior to
the TNFα analysis to ensure that cDNA synthesis and amplification was possible from all the
samples.  A negative control containing all components except cDNA and a positive control of
LPS stimulated alveolar macrophages was included in every analysis.  The PCR products were
evaluated by electrophoresis through an ethidium bromide containing 1.2% agarose gel.  This
figure represents a composite of a visual analysis of the agarose gels.
INDUCTION OF TNFα PRODUCTION IN VITRO BY RYPANOSOMAL
ANTIGENS
When monocytes and tissue macrophages from uninfected cattle were
stimulated in vitro with bacterial lipopolysaccharide (LPS), tissue macrophages
were found to secrete high titres of TNFα whereas the secretion of TNFα by the
monocytes fluctuated around the detection limit of our assay.  However, when
the monocytes were primed with bovine interferon g prior to stimulation with
LPS, secretion of TNFα was up to 2000 times higher than background levels.
Monocytes therefore proved more suitable indicators of the macrophage-
activating potential of parasite fractions than tissue macrophages since they
allowed the distinction of priming and trigger functions.
   When a T .congolense lysate was added to freshly isolated monocytes no
TNFα production was induced.  The lysates were then tested in the presence of
erogenous triggers or priming agents to further assess their MO activating
potential.  After being cultured for 24 to 48 h with a trypanosome lysate,
monocytes failed to respond to an external trigger.  However, when monocytes
were primed by incubation with interferon γ for 24 h, a strong TNFα secretion
was observed after the addition of T. congolense lysate.  These results indicate
that T. congolense lysates are unable to prime monocytes but are able to trigger
primed cells.  The parasite factors responsible for this stimulation are currently
being purified.
CONCLUDING REMARKS
African trypanosomes live free in the bloodstream where they are a direct target
for the host antibodies.  Since antibodies are predominantly directed to the
surface coat, the capacity of the parasite to change its coat provides it with a
powerful mechanism to escape immune elimination.  In addition, the vertebrate
host does not acquire an immune status after parasite clearance through drug
treatment.  Since African trypanosomes infect a variety of domestic and wild
animals that form a reservoir from which new infections can be established, it is
clear that drug treatment cannot provide a long-term solution to
trypanosomiasis.  For these reasons, the need for prophylactic measures has
often been put forward.
   Due to the extreme variability of the exposed epitopes of VSG molecules, the
development of a conventional anti-parasite vaccine based on the induction of
anti-surface coat antibodies is not a feasible option.  Therefore, alternative
strategies for disease control are being explored such as the development of
anti-disease vaccines.  Our observations that T. congolense molecules directly
activate macrophages to produce TNFA and that TNFα production during
disease might be correlated with severity of anaemia provide new options for
the design of alternative control measures.  Whether preventing TNFα
production would be sufficient to protect infected animals from the disease and
whether the TNFα-inducing molecule will ever be suitable as a vaccine
candidate still remain open questions.  Nonetheless the development of an anti-
disease vaccine based on TNF-inducing factors clearly deserves further
exploration.
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INTRODUCTION
The trypanosome surface coat is composed almost entirely of a homogeneous
array of molecules known as variable surface glycoproteins (VSG).  These
molecules are highly immunogenic and elicit a strong antibody response in the
infected host.  Antibodies against the surface-exposed epitopes of a particular
VSG mediate the destruction and clearance of trypanosomes expressing that
variant (Morrison et al, 1982).  As those parasites are cleared, they are replaced
by others expressing antigenically different VSG molecules, which in turn
provoke specific antibody responses.  Trypanosome infections are therefore
characterized by waves of parasitaemia followed by waves of VSG-specific
antibody.
   It is known that trypanotolerant N'Dama cattle infected with Trypanosoma
congolense have significantly lower levels of parasitaemia than the more
susceptible Boran cattle (Paling et al, 1991 a).  It has been suggested that this
reflects a more effective VSG-specific antibody response in the N'Damas
(Murray et al., 1982).  We have tested this hypothesis by examining VSG-
specific antibody responses in N'Dama and Boran cattle during experimental
infection with T.congolense.
RESULTS AND DISCUSSION
Eleven cattle of each species were infected using tsetse flies (Glossina
morsitans centralis) that had fed on a goat infected with T.congolense ILNat 3.
1, according to the method of Dwinger et al. (1987).  The course of infection
was monitored by measuring percentage packed red cell volume (PCV) and
estimating parasitaemia by dark ground/phase contrast microscopy (Paris et al.,
1982) and serum samples were collected from each animal at weekly intervals.
Cattle whose PCV fell to 15% were treated with diminazene aceturate.
   All cattle became parasitaemic between 10 and 12 days after infection (dpi).
The average parasitaemia in the Boran group during the eight-week monitoring
period was higher than that of the N'Dama group, whereas the mean PCV of the
Borans was lower than that of the N'Damas.  Although the PCV fell to 15% in
eight of the eleven Borans, that of all N'Damas remained above this value
throughout the experiment.
   Serum antibodies to VSG epitopes exposed on the surface of the parasite were
measured in a complement lysis assay using live T. congolense ILNat 3.1
parasites.  Lytic antibodies were detectable in serum from all cattle by day 21 of
infection, and in one Boran animal had appeared by day 14.  Antibodies
persisted until conclusion of the analysis at day 42.  There was no significant
difference in lytic activity of sera from the two groups.
The isotype distribution of antibodies specific for surface-exposed epitopes of
VSG was determined in sera from four N'Damas and four Borans, by FACS
analysis of live trypanosomes incubated with heat inactivated bovine test sera
and stained with monoclonal antibodies (MAb) specific for bovine
immunoglobulin isotypes.  Specific antibodies of IgM, IgG, and IgG2 isotypes
were present in all sera, and the kinetics of their appearance and their titres were
similar in both groups.  Highest titres of IgM antibodies were observed on day
21 in all eight cattle and these had disappeared by day 35 of infection.
Antibodies of IgG1 and IgG2 isotypes were first detected 21 dpi and were still
present in sera taken on day 49.
Formalin fixation disrupts the trypanosome surface coat and reveals epitopes
on VSG molecules that are not accessible on the surface of living parasites.
Antibodies that bound to formalin fixed trypanosomes were measured using an
ELISA technique (Voller et al., 1975; Williams et al., 1990).  A trypanosome-
specific IgM response was observed using this assay in both N'Damas and
Borans that peaked at day 21 and declined thereafter.  No significant difference
was apparent between the two groups in the intensity of this response.  Although
trypanosome-specific IgG, was also detected in both groups from day 14, titres
were significantly higher in the N'Dama group.  No specific antibodies of IgG2
isotype were detected in either group of cattle.
To examine the development of non-specific antibody responses in cattle
following infection with T. congolense, antibodies specific for Escherichia coli
b-galactosidase were measured in sera from each group using an ELISA assay.
No b-galactosidase-specific antibodies were detected in sera collected from the
N'Dama cattle at any time.  In contrast, responses to this antigen were detected
in the Borans between days 14 and 35 after infection, with highest titres being
observed on day 21; these antibodies were all of the IgM class. b-galactosidase-
specific IgM was prepared from the sera by affinity chromatography with MAb
ILA30 (Naessens et al., 1988) followed by a second chromatography step using
a b-galactosidase affinity column.  By testing the bound and unbound fractions
in the trypanosome ELISA described above, it was established that the b-
galactosidase specific antibodies in these sera bind trypanosome antigens.
CONCLUSIONS
The results of these experiments demonstrate that antibody responses made by
N'Dama and Boran cattle against surface-exposed epitopes of VSG during
primary infection with T. congolense are quantitatively and qualitatively similar.
Trypanotolerance in N'Dama cattle is therefore not related to a more effective
antibody response against the trypanosome surface coat.
   Further analysis revealed that although Boran cattle make strong IgM
responses to non-conformational epitopes of VSG, IgG1 responses to these
specificities were poor in comparison to those observed in the N'Dama group.
In addition, IgM responses in the Boran cattle appeared polyspecific in nature.
These observations are indicative of a defect in isotype switching and affinity
maturation in Boran cattle that is not apparent in the trypanotolerant N'Damas.
Since both of these functions are T-cell dependent, our results are consistent
with a poor helper T-cell response in T. congolense-infected Boran cattle.
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INTRODUCTION
Analysis of serum antibody responses in cattle experimentally infected with
Trypanosoma congolense suggested that antibody responses of
trypanosusceptible Boran cattle are less efficient in isotype switching and
affinity maturation than those of trypanotolerant N'Dama cattle (see preceding
report by Williams et al.; Authie et al., 1993).  Briefly, high levels of
polyspecific IgM are produced by Boran cattle while N'Dama cattle have higher
titres of IgG specific for certain trypanosome antigens.
   Further characterization of these differences required determination of the
frequency and phenotype of antibody secreting cells (ASC), as well as the
specificity of the antibody and the isotype secreted in response to infection.  A
method was therefore developed to maintain bovine B cells in culture and
stimulate them to differentiate into ASC.  B cells were examined for the
expression of the transferrin receptor and the CD5 antigen using fluorescence
activated cell sorter (FACS) analysis and the number of ASC was determined
using an ELISpot assay.
We compared B-cell activation and the frequency of ASC between six
Trypanosoma congolense-infected cattle and three uninfected controls.
Peripheral blood lymphocytes (PBL) were analysed before and after in vitro
culture for three and six days with combinations of lipopolysaccharide (LPS),
pokeweed mitogen (PWM) and recombinant bovine interleukin-2 (rboll 2).
Splenic lymphocytes from T. congolense-infected cattle were compared with
PBL from the same animals.
CHARACTERIZATION OF B CELLS
The total number of B cells and their expression of the transferrin receptor and
the CD5 antigen was determined by FACS analysis.  The percentage of B cells
in freshly isolated PBL was significantly higher in infected (60.1%) than in
uninfected animals (25.6%) (Figure 1).  After three days in vitro stimulation the
percentage of B cells present in cultures from uninfected animals was
unchanged under all culture conditions.  However, the percentage of B cells was
significantly higher in cultures from infected animals stimulated with LPS
(79.0%) and LPS plus rboIL 2 (72.8%), than those maintained with medium
alone (47.5%). The expression of the transferrin receptor on B cells from PBL
of uninfected and infected animals was 4.0 and 3.3% respectively (Figure 2).
The percentage of transferrin receptor positive B cells was significantly greater
than the medium control in cultures from cells of infected animals stimulated for
three days under all conditions.  The highest expression (44.1%) was seen in
cells stimulated with LPS plus rboll 2.
   The level of transferrin receptor expression was compared between B cells
derived from PBL and spleen of infected animals.  The mean percentage of total
B cells derived from the PBL (54.1%) was not significantly different from that
found in the spleen (48.8%). However, the level of transferrin receptor
expression on B cells from the spleens (22.7%) was significantly higher than
from PBL (5.6%).
DIFFERENTIATION OF NON-SECRETING B CELLS TO ANTIBODY-SECRETING
CELLS
The number of ASC was determined by ELISpot assay.  No ASC were ever
detected in freshly isolated PBL.  PBL from uninfected animals had a very low
frequency of ASC after in vitro stimulation for three days (Figure 3).  B cells
from infected animals differentiated to ASC when stimulated for three days with
LPS (0.32%), LPS plus rboll 2 (0.17%), rboIL 2 (0.06%) and PWM (0.05%).
The percentage of ASC decreased significantly when rboIL 2 was included with
PWM (0.0 1 %).  After six days in vitro stimulation all responses were
enhanced, particularly among the uninfected animals, where frequencies
approached those seen with infected animals (data not shown).
   Unlike B cells from PBL, fresh splenic B cells secreted antibody ex vivo
(Figure 4).  In addition, three days stimulation was sufficient to obtain the
maximum number of ASC as opposed to six days for the PBL.
Figure 1. Mean percent of B cells measured by MAb IL-A 30 (anti-IgM) in the
peripheral blood of uninfected (n=3) and Trypanosoma congolense-infected (n=3) Boran
cattle before (PBLs) and after three-day in vitro culture under various conditions.
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Figure 2. Mean percent of transferrin receptor-positive B cells measured by MAb IL-
A77 and IL-A30 in the peripheral blood of uninfected (n=3) and T. congolense-infected
(n=3) Boran cattle before and after three-day in vitro culture under various conditions.
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Figure 3. Mean percent antibody secreting cells from peripheral blook of uninfected
(n=3) and T. congolense-infected (n=6) Boran cattle after three-day in vitro culture under
various conditions.
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Figure 4. Mean percent antibody secreting cells from spleens of T. congolense-infected
(n=4) Boran cattle before and after three- and six-day culture under various conditions.
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CONCLUSIONS
The use of LPS, PWM and IL2 to stimulate B cells to secrete antibody in vitro
and detection of ASC by an ELISpot assay has been thoroughly described in the
mouse and human systems.  However, information on the activation of bovine B
cells is limited.  There are reports of stimulating bovine B cells with PWM or
human IL2 (Olobo and Black, 1989; Lutje and Black, 1992; Collins and
Oldham, 1993).  In these cases activation of B cells was measured either
through the Ig content of the culture supernatants or plaque assays measuring
responses to sheep red blood cells.  Here we have described a comparative
analysis of in vitro stimulation of bovine peripheral blood and splenic
lymphocytes from healthy  and trypanosome-infected cattle.  The differentiation of
B cells with respect to expression of an activation marker, the transferrin
receptor, and their ability to secrete immunoglobulin, was quantitated using
FACS analysis and an ELISpot assay.
   An increase in the number of circulating B cells during trypanosome infection
in cattle has previously been reported by Williams et al . (1991).  Cattle infected
with T. congolense  have a higher frequency of circulating B cells that can be
stimulated in vitro to express the transferrin receptor and secrete antibody than
uninfected cattle.  LPS and LPS plus IL2 were the most potent stimulators of
both transferrin receptor expression and antibody secretion.  Stimulation with
either PWM or IL2 alone resulted in an increase in the number of ASC;
however when both stimulators were present there were fewer ASC compared to
activation with either stimulus alone.  This phenomenon was also observed for
human peripheral blood cells by Sauerwein et al . (1986).
   The level of activation of B cells found in the spleen differed from those
found in peripheral blood.  A greater number of B cells from the spleen
expressed the transferrin receptor and some are capable of secreting antibody ex
vivo without further stimulation.  When stimulated in vitro, splenic B cells
require only three days for the maximum number of cells to differentiate to ASC
as opposed to six days for B cells from the peripheral blood.
    This work will now be extended to compare the isotype and specificity of
antibody produced by trypanotolerant and trypanosusceptible breeds of cattle in
response to trypanosome infection.
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INTRODUCTION
Infections of cattle with tsetse-transmitted Trypanosoma congolense are
accompanied by antibody responses to the variable surface glycoprotein (VSG)
and to two major invariant antigens, a member of the hsp70 family (B oulang6
and Authié,1994) and a 33 kDa cysteine protease (CP; Authié et al ., 1992).
During primary infection, trypanotolerant N'Dama (Bos taurus) cattle exhibit
higher levels of IgGl to CP than susceptible Borans (Bos indicus; Authié et al,
1993a).  Boran cattle, on the other hand, have high levels of IgM to irrelevant
antigens.  During rechallenge infections, N'Dama cattle have higher levels of
IGGI to hsp70 while Boran cattle exhibit high titres of IgM to this antigen.
Although Boran cattle do generate high titres of IgM te hsp70, N'Dama cattle
develop higher levels of specific IgG antibody (Authi6 et al., 1993b).  These
observations are consistent with a possible dysfunction in isotype switch from
IgM to IgG in Boran cattle.  Because of the central role of T helper cells in
induction of Ig isotype switch, the difference in antibody responses between
N'Dama and Boran cattle might reflect defective T helper cell function in the
susceptible breeds during infection.
   We undertook a study to analyse T-cell function in cattle during infection with
T. congolense .  T-cell proliferative responses to a recombinant form of the
hsp70 (R63), cysteine protease and VSG were measured in a group of Boran
cattle following primary challenge with T. congolense .  The role of CD4+ and
CD8+ cells in the response was also investigated.
RESULTS
No proliferative responses to the CP, R63 or VSG were detected in cultures of
PBL from cattle infected with T. congolense  ILNat 3.1 up to 45 days post-
infection (data not shown).  However, in three animals tested on day 4, 11 and
19 post-challenge, respectively, all cells obtained from lymph nodes draining the
site of infection proliferated in the presence of all three antigens (Figure 1).
Figure 1. Proliferative responses of LN cells from three Boran cattle at different stages of primary
infection with Trypanosoma congolense to the cysteine protease (cpE64), recombinant 63 kDa
protein (R63) and VSG.
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Proliferative responses to the CP, R63 and VSG were highest in LN cells from
animal BJ30 1, which was tested 11 days after challenge.  When LN cells from
another animal, BJ349, were tested 19 days after challenge, significant
proliferative responses to the CP and to R63 were detectable.  This experiment
was repeated in a different group of animals and similar results were obtained,
with highest proliferative responses observed in LN cells from day 11 post-
infection (data not shown).
The role of CD4+ and CD8+ cells in the response was analysed by their
selective depletion through FACS sorting after staining with specific MAbs.  No
proliferative responses to the CP or R63 were detected after depletion of either
CD4+ or CD8+ T cells from whole LN cell populations (Figure 2).  The response
to the VSG was abrogated by the depletion of CD4+ cells but unaffected by the
removal of CD8+ cells.
Figure 2. Role of CD4+ and CD8+ LN cells in the proliferative response to Trypanosoma
congolense antigens.
DISCUSSION AND CONCLUSIONS
In this study we demonstrate, for the first time, that T cells respond to three
immunodominant antigens of T. congolense , i.e. cysteine protease, hsp70 and
VSG, in lymph nodes from Boran cattle undergoing primary infection.  A
previous study (Flynn et al ., 1992) reported that no proliferation to
trypanosome antigens could be detected in bovine lymph node cells during
primary challenge.  However, whole trypanosome lysate was used as an antigen,
and only one animal per week post-infection was tested.  Interpretation of that
study may therefore have been complicated by variation in the intensity of
individual animal responses.  Furthermore, in our hands, T-cell responses to
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trypanosome lysate were generally poorer than those observed with the defined
antigens under discussion (data not shown).
   By depletion of T-cell subsets, we showed that bovine cell responses to VSG
involve mainly CD4+ T cells.  Whereas both CD4+ and CD8+ cells are required
for the response to cysteine protease and hsp70.  T-cell responses to VSG have
not been detected so far in cattle following infection and have only recently
been described in mice infected with Trypanosoma brucei rhodesiense
(Schleifer et al ., 1993).  The response in mice is only found in peritoneal T
cells, which secrete TH1-like cytokines (gamma-interferon and IL2) but do not
proliferate to VSG (Schleifer et al, 1993).  T cells responding to a cysteine
protease of Trypanosoma cruzi have recently been detected in chagasic patients
(Arnholdt et al, 1993) and have been characterized as CD4+ and T helper 1 -type
(TH1).  In our study, proliferative responses to cystein protease and invariant
hsplo antigens were abrogated by the depletion of both CD4+ and CD8+ T cells.
It is not clear as yet whether both CD4+ and CD8+ T cells are responding to
these invariant antigens or whether they are mutually regulated by cytokine
production.  The difference in T-cell types responding to VSG and to two
invariant antigens might be attributed to differences in antigen presentation.
Further experiments are needed to clarify these issues.
   The study reported here provides the first evidence of T-cell responses to
defined antigens of T. congolense  in cattle following tsetse-transmitted
infection.  We are currently undertaking more detailed experiments involving
production of T-cell lines and cytokine analysis, in order to analyse the quality
of T-cell help provided to B cells during infection, and to determine whether
differences exist between T-cell responses of trypanotolerant and
trypanosusceptible breeds that might account for differences in antibody isotype
switch between the two breeds.
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Although specific immunoglobulin (Ig) and B-cell responses are suppressed
during infections with African trypanosomes, a general activation of the
humoral wing of the immune system is observed.  The changes that occur in the
humoral immune system during these infections have been reviewed (Sileghem
et al, 1993) and can be summarized as follows:
• an increase in cellularity of the spleen and in the proliferative status of
spleen cells;
• an increase in the numbers of circulating B cells;
• an increase in the levels of circulating Ig, particularly that of the IgM class;
• the appearance of increased titres of antibodies specific for antigens of
non-trypanosome origin (heterophylic Abs, non-specific Abs);
• the presence of auto-antibodies and immune complexes.
   The massive increase in the numbers of circulating B cells, Ig and the
occurrence of antibodies to apparently unrelated antigens could be explained by
polyclonal activation of B cells such as that provoked in murine B cells by
bacterial lipopolysaccharide.  Many studies have been undertaken to find which
trypanosome product might be responsible for the polyclonal B-cell stimulation
and the generation of non-specific antibodies (reviewed in Sileghem et al .,
1993).  Although purified trypanosome fractions can be shown to induce
antibodies to non-trypanosome antigens, no general consensus has been reached
over which parasite antigen gives rise to the polyclonal B-cell activation seen
during infection.
   However, a subset of B cells known as the B-1 subpopulation, the majority of
which express the Ly-1 or CD5 leukocyte differentiation antigen, has been
described (reviewed in Herzenberg and Cantor, 1993; Haughton et al., 1993)
that is functionally associated with some of the features seen in trypanosome
infection.  B-1 cells are largely responsible for normal secretion of IgM and the
secretion of autoantibodies and the subset is expanded during certain
autoimmune diseases and chronic infections.  We have therefore analysed the
expression of CD5 by bovine B lymphocytes during the course of Trypanosoma
congolense infections (Naessens and Williams, 1992).
   In normal uninfected cattle CD5+ B cells represent about 20% of mononuclear
leukocytes in peripheral blood, 5-10% of those in the spleen, and 1-2% of lymph
node cells.  The population has not been observed in Peyer's patches, and no
CD5+ B cells have been detected in foetal blood and spleen.  CD5+ B cells of
cattle have the same surface phenotype as their CD5- counterparts, apart from a
higher mean concentration of membrane IgM, and are therefore similar to
human and murine B-1 cells.  As in mouse and man, bovine CD5+ B cells can be
shown to express the integrin CD11b (Mac-1).  CD5+ B cells are slightly larger
than classical B cells, and show higher forward and side scatter profiles on the
flow cytometer.
In monitoring CD5+ B-cell numbers in T. congolense -infected cattle, a sharp
increase in the proportion of total circulating B cells was observed at around
week 3 of infection, approximately one week after parasites were first detected
in peripheral blood.  The numbers of CD5+ B cells rose steadily until they
constituted 60-80% of the peripheral blood B-cell population.  Analysis of the
relative proportions of CD5+ and CD5- B cells in these animals revealed that
expansion in B-cell numbers was almost entirely due to the increase in CD5+
component.  The tissue-distribution of CD5+ B cells remained the same as
before infection with the largest numbers occurring in blood, somewhat fewer in
the spleen, very few (less than 5%) in lymph node, and none being detectable in
Peyer's patches.  A significant difference in the behaviour of CD5+ B cells
during infection was not observed between susceptible Boran and resistant
N'Dama cattle breeds.  An increase in numbers of CD5+ B cells has also been
observed in cattle infected with T. vivax.
The raised numbers of CD5+ B cells were kinetically associated with the
observed increase in total serum IgM.  It is therefore tempting to speculate that
it is the expansion of the CD5+ B population during infection that leads to the
secretion of large amounts of IgM.  By analogy with human and murine CD5+ B
cells, they may also be responsible for secretion of polyspecific Ig and
autoantibodies and may explain the occurrence of high titres of antibodies with
non-trypanosome specificities.  It is therefore important to determine why these
cells are preferentially amplified during trypanosome infections, and what
signals, from parasite or host, contribute to their expansion.
It is important to note that it has not yet been shown definitively that bovine
CD5+ B cells are homologous to B-1 cells, and a number of observations may
dispute the hypothesis.  Prominent among these is that it has not been possible
to demonstrate the expression of IgD by bovine B cells, using
immunoprecipitations with monoclonal antibodies specific for IgM and Ig light
chain on lymphocytes derived from a number of tissues.  Because their lack of
IgD distinguishes B-1 cells from classical B cells in mouse and man, this feature
provides a difficulty in making a similar distinction in cattle.  A further anomaly
is that CD5 has not been found on B cells in the bovine foetus, whereas CDS+B
B cells constitute the largest B-cell population of human and murine foetal
tissue.  It remains a possibility that ruminants possess only B cells of the B - 1
class; this is known to be the case for the rabbit, in which all B cells express
CD5.  In this situation, it is possible that CD5 behaves as an activation marker.
In the light of these observations, it is clearly important to establish whether
CD5+ B cells in cattle do behave as B-1 cells and give rise to the secretion of
IgM and high titres of antibodies with non-trypanosome specificity during
infection with African trypanosomes.
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This session consisted of eight presentations on the perturbations of the immune
system caused by immune response to parasite antigens.  In the introduction, Dr.
D. Williams (ILRAD) outlined two different areas of research concern to the
trypanosomiasis program.  One goal was to identify trypanosomal antigens
responsible for the immunopathogenesis of the disease by determining how the
infection of cattle with trypanosomes affects their immune system.  A second
goal was to identify protective immune responses that might be targeted at the
parasite itself or at the mechanisms through which it causes disease.  The first
presentation by Dr. John Playfair (University College, London) focused on the
anti-disease approach to a vaccine for malaria.  In this type of a vaccine, parasite
molecules, identified as phospholipid exoantigens, responsible for over-
production of TNFα in murine malaria, were shown to protect against the
clinical symptoms of the disease.  He pointed out that while TNFα was
responsible for fever and other complications of malaria, studies with injections
of TNFα anti-serum in mice infected with P. chabaudi greatly reduced their
parasitaemia.  TNFα could in this model play both a protective and pathogenic
role.  A similar approach to an anti-disease vaccine for trypanosomiasis was
presented by Dr. Maarten Sileghem (ILRAD).
   He showed that T. congolense  lysates contain macrophage-activating factors
that are capable of suppressing T-cell proliferation in cattle.  On the other hand,
the membrane form of VSG, specifically the phosphatidyl inositol anchor, was a
potent inducer of the cytokine TNFα, whose levels were shown to be positively
correlated with the severity of anaemia.  There were several presentations that
centered on the role of the humoral response to trypanosomiasis (Dr.  D.
Williams, ILRAD), and especially on the importance of B-cell activation (Ms.
K. Taylor, ILRAD) and the CD5+ B-cell function both in trypanosomiasis and in
Chaga's disease (Dr.  J. Naessens, ILRAD; Dr. P. Nfinoprio, Institut Pasteur,
Paris).  Inefficient isotype switching and affinity maturation of antibodies, as
well as a predominantly polyspecific IgM response to selected antigens were
shown to be a characteristic of trypanosome infections in trypanosusceptible
Boran cattle.  Dr. Minoprio's presentation on the role of the two lymphocyte
subsets, CD3 gamma-delta and CD5+ B lymphocytes, showed clearly that they
were involved in the autoimmune phenomena in the chronic phase of infection
with T cruzi.  Similarly, an increase in CD5+ B cells during a trypanosome
infection was demonstrated to occur in cattle by Dr. J. Naessens (ILRAD).  The
presentation by Dr. E. Authié (ILRAD) which highlighted differences between
the two breeds of cattle in their immune response to two immunodominant
trypanosome antigens, hsp70 and the 33 kDa cysteine protease (CP), identified
two parasite antigens that could contribute to the pathogenesis of this disease.
Data on T-cell function of trypanotolerant and trypanosusceptible cattle using
defined T. convene antigens was presented by Dr. V. Lutje (ILRAD) who
showed that depletion of CD4+ T cells or MHC class II+ cells abrogated the
proliferative response of lymph node cells to VSG in vitro, while depletion of
either CD4+ or CD8+ cells abrogated the response to CP.
There were brief discussions following each presentation and the salient points
were then summarized in a general discussion after the afternoon session.
Chimaeric twins with bone-marrow derived cells originating partly from
N'Dama and Boran breeds are an important resource at ILRAD for the analysis
of mechanisms involved in trypanotolerance.  A lengthy discussion followed as
to how these animals could best be utilised for this purpose.  One suggestion
was that they would be useful for examining immunoglobulin class switching,
since the capacity to effect this during infection might segregate with class II
MHC type of the thymus-educated bone marrow cells.  Since the chimaeras are
stable and the twins are generally similar, varying only with the proportion bone
marrow-derived cells of each genotype that they carry, it was considered that it
might also be useful to isolate N'Dama and Boran CD5+ B cells educated in the
same environment to evaluate their respective function.  Although 20–25 % of
peripheral blood mononuclear cells in newborn cattle are CD5+ B cells, very
little is known about the function of this population, other than that its
proportion increases to approximately 80% in adult cattle undergoing chronic
infections.  Since the immunoglobulin produced by these cells is polyspecific
and of low affinity, it was suggested that they could conceivably serve as the
first line of defence in a trypanosome infection, or as one of the earliest antigen
presenting cells.
An attempt was made to identify the currently known differences in immune
response between the breeds.  The group concurred that in Boran cattle
parasitaemia was always more marked, PCV was consistently lower, leukopenia
was more pronounced; and that there was no IgG response to the cysteine
protease (CP).  These cattle also mount an IgM response to β-galactosidase,
which is probably a reflection of polyspecific activation, while the N'Dama do
not.  Discussion then centered on identifying which traits or differences are not
influenced by parasite load.  Only the immune responses to the cysteine protease
antigen and isotype class switching seemed to be candidates.  Classical genetic
studies on F2 generation of cattle using microsatellite markers to study linkage
should eventually pinpoint these traits.  The question was raised whether
trypanotolerance results from a difference in parasite load or from different
distribution of the parasite in the microenvironment.  If the trait is reflected in a
real difference in parasite load then control of growth of the parasite should be a
focus of molecular vaccine research.  A comment was made regarding the
ability of buffalo to resist trypanosome infections.  Like the N'Dama they appear
to be able to mount a strong CP-specific response and, in addition, a host factor
has been identified that is capable of lysing trypanosomes.
   The major questions that arose from these presentations can be summarized as
follows:
• Can trypanotolerance be explained in terms of parasite load or does it
reflect breed differences in immune responses to trypanosome infection?
• Are perturbations of immunelcytokine networks the result of toxic
molecules of the parasite or are they due to direct damage to host
molecules and cell membranes?
• How does the quality of antibody responses in infection compare with that
seen in response to purified antigens; can we alter specific responses to
render them more appropriate to protection?
• By studying cytokine expression, antibody responses and toxic molecules
of the parasite during infection, can we devise strategies to balance the
immune system between suppression and exacerbation of pathology, or
distinguish protective immune mechanisms from those that are detrimental
to the host mechanism?
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INTRODUCTION
The conventional approach to vaccine design is the identification of dominant
antigenic epitopes associated with protective immune responses and the
construction of synthetic or recombinant versions of these epitopes in a form
suitable for artificial immunization.  This approach has been very successful in
the design of vaccines against viral infections but has been less successful in
protozoan infections, mainly because of the complexity of the responses against
eukaryotic cells and the ability of the parasites themselves to manipulate the
immune response for their own survival.  Parasitic infections present their hosts
with enormous immunological problems largely because of their antigenic
complexity and complicated life cycles in which the various stages frequently
differ antigenically from one another Parasites have also evolved numerous
ways of evading the consequences of immune attack.  Parasitic infections
therefore tend to be chronic and accompanied by varied and unsuccessful
immunological responses on the part of the host that frequently lead to
immunopathological damage and immunosuppression.  Until recently, our
understanding of the immunity and immunopathology of parasitic infections has
been hindered by the lack of a comprehensive and stable conceptual framework
within which to work.  This situation has been deterred by a number of
discoveries that have led to the realization that both immunity and pathology are
controlled by cytokines.
   The first important discovery was that mouse CD4+ lymphocytes could be
divided into two functional subsets with distinct cytokine profiles-Thl largely
dominated by the production of interferon-gamma, eliciting cell-mediated
immunity, and Th2 largely dominated by the production of IL-4, IL-5 and IL-10,
eliciting antibody-mediated immunity (Mosmann and Coffman, 1989).  In
parasitic infections these two immunological pathways are often mutually
antagonistic with one being protective and the other counter-protective (Cox and
Liew, 1992).  Although the initial observations were made using inbred strains
of mice it is now clear that analogous subsets occur in humans (Romagnani,
1991) and a search is on for similar T-cell populations in other species.
   A general scheme of the basic features of cytokine activation that has stood
the test of time is shown in Figure 1. Essentially, 711 cells produce two
important cytokines-IL-2 that activates cytotoxic T cells and other lymphokine
activated cells such as natural killer (NK) cells, and interferon-gamma that
activates macrophages.  Th2 cells produce IL-4, IL-5 and IL-10 that are
responsible for the growth and differentiation of B cells and the production of
antibody.  There is a certain amount of cross cooperation, with the Thl product
IL-2 being involved in the production of IgG2a, as well as antagonism with
interferon gamma-inhibiting the production of antibodies and IL-4 and IL-10
inhibiting the activity of interferon gamma.  However this simple pattern is
continually being revised and added to as our understanding of the parts played
by cytokines in infections increases and this has led to the creation of complex
diagrams (Cox and Liew, 1992; Powrie and Coffman, 1993) and comprehensive
charts (Burke et al ., 1993).  Unfortunately, the demarcations between CD4+ and
CD8+ activities and the roles of Th l and Th2 cells are breaking down as it
becomes apparent that Th2 cytokines suppress the generation of CD4+ cytotoxic
cells and that CD8+ cells regulate the production of Thl and Th2 cytokines.  In
parasitic infections, there is an additional complication in that cytokine profiles
may vary during the course of an infection and even from host to host infected
with the same parasite.  Nevertheless, in parallel with investigations into the
immunology of other infections, including AIDS, and cancers it is essential that
both the general patterns and the complexity of the interactions between T-cell
subsets and cytokines should be understood in parasitic infections.
CYTOKINES IN PARASITIC INFECTIONS
Although most of what we know about the role of cytokines in parasitic
infections is derived from helminth infections (Finkleman et al ., 1991).  This
discussion will focus only on the general principles that apply to protozoal
infections.
Protozoa that Live in Macrophages
Leishmania major infection of mice can be regarded as the basic model for
these parasites and has provided the most information on the influence of
cytokines in resolving and fulminating infections.  It has also served as a
baseline against which all other infections can be compared.  In L. major
infections in mice, interferon-gamma is clearly associated with recovery and/or
resistance and IL-4 and IL-10 with exacerbated infections and/or susceptibility
(Titus et al ., 1992; Liew and O'Donnell, 1993).  In human infections, there is
clear evidence that similar patterns occur.  In L. braziliensis infections,
interferongamma  predominates  in  localized  infections  and  IL-4  in
destructive  mucocutaneous
Figure 1. The overall pattern of cytokine involvement in defence against parasites.  Activation is
indicated by solid lines and inhibition by dashed lines.
forms of the disease (Pirmez et al., 1993).  In patients infected with L.
aethiopica, those experiencing diffuse cutaneous leishmaniasis exhibit poor
levels of IL-2 (Akuffo, 1992), suggesting an association with a defect in the Thl
pathway.  There is also evidence that interferon-gamma is indicative of disease
limitation in L. aethiopica infections and that different parasite antigens elicit
different patterns of cytokine response (Laskay et al ., 1991).  In L. chagasi
infections, patients with acute disease have lower levels of the protective
cytokine interferon-gamma than those that were infected but showing little
evidence of infection (Holaday et al ., 1993).  In patients infected with L.
donovani, the presence of IL- 10 correlates with the pathogenesis of the disease
(Karp et al ., 1993).
Immunity of mice to Toxoplasma gondii also involves the Thl pathway and the
production of interferon gamma (Beaman et al ., 1992).  In humans, IL-2 and
lymphokine activated natural killer cells are involved (Subauste et al ., 1992)
suggesting that the Thl pathway is also important in human infections.  However
the development of a commercial live vaccine against toxoplasmosis in sheep
based on the stimulation of antibody production (Buxton, 1993) only serves to
indicate how much more information is required before a really effective and
acceptable vaccine can be contemplated.
The situation in Trypanosoma cruzi infections is very confusing.  IL-2 and IL-
2 receptors seem to be the key molecules (Pakianathan and Kuhn, 1992) and
CD8+ T cells are important in controlling the infection at the cellular level (Sun
IFN-
 γ
Cytotoxicity
TNF
ROI
Antibody
LAK
TC
M
B
M
(APC)
TH1
TH2
IL-1
IL-1
IFN- γ
IL-4
IL-2
IL-2
IL-5
and Tarleton, 1993).  There is also synergism between interferon gamma and
tumour necrosis factor that results in the activation of trypanocidal mechanisms
in the host macrophages (Munoz-Fernandez et al., 1992).  All this evidence
supports a dependence on the Thl pathway, but IL-4, which might be thought to
have an inhibitory counter-protective effect, also appears to play an important
role in protection (Wirth et al 1989).  An antigen specific IgGl response
(suggesting a Th2 pathway) also seems to be important (Cerban et al.,1992).
Taken together these observations, are difficult to explain in terms of the
concepts outlined above.
Blood Parasites
The exhaustive studies of immunity to malaria has revealed no clear pattern of
cytokine activity.  Tumour necrosis factor and nitric oxide, both products of the
Th1 pathway, appear to have a role in protection (Rockett et al .1992) but so do
antibodies, which are products of the Th2 pathway.
The overall situation in animals infected with Theileria spp. is also unclear.  It
is widely accepted that CD8+ cytolytic cells are important effector cells in
recovery and immunity, and there are indications that helper and cytolytic CD4+
cells may also be involved (Baldwin et al .1992).  There is also evidence that
macrophages, but not natural killer cells, are involved in immunity to T annulata
(Fell and Preston, 1993).
Among the African trypanosomes, T. b. brucei stimulates CD8+ cells that
produce interferon gamma but also stimulate growth of the parasites (Olsson et
al ., 1992).  On the other hand, T. b. brucei and T. b. gambiense are susceptible
to attack by activated macrophages (Vincendeau et al ., 1992).
This brief overview of the role of cytokines in protozoal infections, which has
been drawn from some of the more recent literature, shows how little we
understand the patterns of cytokine activity that occur during these infections
and how difficult it is to make any all-embracing deductions.  However, it
should be possible, by systematically investigating both T-cell subsets and
cytokine profiles, to obtain a very good idea about which components of the
host reaction to protozoa are essential and protective and which are counter
protective.
EFFECTOR MOLECULES
Examination of cytokine profiles in parasitic infections have provided
information on the effector molecules involved.  Antibodies, particularly IgM
and IgGl, characteristic of Th2 cell activation, are involved, to a greater or lesser
extent, in all infections except leishmaniasis.  The effector molecules associated
with the Thl pathway are mainly macrophage products, such as reactive oxygen
intermediates, nitric oxide, and tumour necrosis factor; these molecules also
contribute to the pathology associated with various parasitic infections (Cox and
Liew, 1992).  It is becoming clear that nitric oxide, with or without synergism
with other cytokines or reactive oxygen intermediates, is a key molecule in
parasite killing.  The production of nitric oxide is controlled by an inducible
enzyme, NO synthase, which is under the control of various cytokines;
interferon-gamma and tumour necrosis factor enhance its production and IL-4
and IL-10 inhibit it (Liew and O'Donnell, 1993)
RELEVANCE OF CYTOKINES
The study of cytokines is now central to our understanding of the immunology
and immunopathology of parasitic infections; it is essential that we are able to
distinguish between those cytokine responses that are protective and those that
are deleterious.  The results of such studies should lead to the possibility of the
immune response towards protection and away from pathology and to the
rational development of vaccines.  This approach has already been suggested for
non-parasitic infections and is well summarized in this quotation:
'Cytokines mediate communication within the immune system and between
immune and other cell types.  In contrast to antibody therapy, where a single
agent can have a single defined effect, cytokine therapy relies on the subtle
manipulation of the complex cytokine network, therefore presenting a major
research challenge' (Gallagher et al ., 1993).
This challenge has already been taken up in general terms by Powrie and
Coffman (1993) and it should now be possible for parasitologists to employ a
rational approach to developing vaccines that elicit protective responses but not
counter-protective or damaging ones.
CYTOKINES AND VACCINE DEVELOPMENT
We suggest a strategy for vaccine design which starts from the response itself
and not the antigen.  As pointed out above, immune responses are controlled and
directed by various cytokines acting in concert or antagonistically and every
infection induces a plethora of cytokines some of which are desirable and some
of which are not.  We now know that it is possible to characterize such cytokine
profiles and to determine which are protective and which are harmful.  Using
this kind of information, it is possible to identify the T-cell subsets that are
involved and so examine the actual nature of antigen presentation and
processing that precedes the response.  As particular epitopes drive the immune
system towards either Th1 or Th2 responses, vaccines can be designed to
facilitate an appropriate response.
The recognition of a particular epitope by the antigen-presenting cells which
occurs as the result of interactions between the antigen-MHC complex and T-
cell receptors is of considerable relevance to the design of successful vaccines.
For example, transient carbonyl-amino condensations (Schiff base formation)
between cell surface ligands occur and these can be finely tuned for the
recognition of particular epitopes (Zeng et al ., 1992).  Having identified
desirable epitopes, amine-reactive carbonyl groups could therefore be
manipulated to enhance the response to such epitopes at the expense of less
desirable ones.  It might also be possible to achieve the same ends by the
selective use of adjuvants (Gordon, 1993).
Figure 2. The involvement of cytokines in the regulation of nitric oxide production.
Nitric oxide synthesis is stimulated by cytokines such as interferon-gamma and tumour
necrosis factor and inhibited by cytokines such as IL4 and IL-5.  After Liew and
O'Donnell, 1993.
Novel vaccines should, therefore, take into account the immunogenicity of the
epitope and the way it is recognized and processed, the pathways by which
subsets of T cells are activated and the resulting cytokine profiles.  So far, most
information is available from studies on L. major but the principles derived
from such studies can be applied to infections with Plasmodium, Babesia,
Theileria, Toxoplasma and Trypanosoma.  New approaches to vaccines might
even overcome the inherent problems of antigenic variation in African
trypanosomes and autoimmunity in Chagas disease.  There is a number of ways
in which this might be achieved but all depend on a detailed understanding (not
just knowledge) of the whole pattern of events that occur when an animal is
infected with a protozoan parasite.  It should be possible, for example to drive
an immune response towards protection and away from counter protection by
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introducing a particular cytokine at the same time as a vaccine.  This has been
demonstrated experimentally in mice infected with L. major in which a disease
enhancing antigen has been converted into a protective one by introducing
tumour necrosis factor at the same time as the antigen (Liew et al ., 1991).
Vaccines of the future will have to be designed to take into account the
cytokine profiles produced and it will no longer be acceptable simply to aim for
a protective immune response without considering any possible adverse effects.
It may be that protective vaccines that induce sterile immunity are unattainable
and that what is necessary is to prevent disease rather than infection.  This
approach is being pioneered by Prof.  Playfair and his colleagues for malaria but
it may be appropriate for other infections also.  For example, monoclonal
antibodies directed against particular cytokines or their receptors could be used
to ameliorate a potentially damaging response.  Future progress will also require
a willingness to accept mathematical modelling as a means of analysing and
understanding the complex networks of cytokine interactions that occur during
an infection; a start has already been made in this direction (Schweitzer and
Anderson, 1992; Schweitzer et al ., 1993).  A cytokine-based approach to
developing new vaccines and control strategies will therefore require several
changes of emphasis and thinking, but there is no easy route to the successful
prevention of disease.
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INTRODUCTION
Infections with Leishmania parasites, which live only in macrophages of
mammalian hosts, represent a spectrum of diseases dependent upon the species
of the parasite and the immune response of the host.  Clinical manifestations of
human cutaneous leishmaniasis can be reproduced in mice of different inbred
strains following infection with Leishmania major Although the majority of
inbred strains of mice (e.g. C57BL/6, CBA, C3H) are resistant to infection, a
few strains, such as BALB/c, are susceptible to infection, develop severe
cutaneous lesions and do not become immune to re-infection (Howard et al.,
1980).
   There is no evidence that antibodies play a role in the elimination of the
intracellular Leishmania spp.  The clearance of these intracellular organisms
requires the development of effective T cell-mediated immunity capable of
activating infected macrophages to a microbicidal state.
CD4+ T-CELL RESPONSES AND PATTERN OF DISEASE FOLLOWING
EXPERIMENTAL INFECTION WITH LEISHMANIA MAJOR
Using the murine model of infection with L. major, resistance and susceptibility
to infection was correlated with the expansion of CD4+ T cells from unctionally
distinct subsets (Heinzel et al ., 1991).  Thus, during infection with L. major,
susceptible BALB/c mice mount a polarized Th2-type response (e.g. an IL4,
IL5, IL 1 0 producing CD4+ T-cell response [Mosmann et al., 19861]), whereas
resistant C57BU6 or C3H mice develop mainly athl-type response (e.g. an IFNγ,
IL2 producing CD4+ T-cell response) (reviewed in Locksley and Scott, 1991).
Furthermore, susceptible BALB/c mice rendered resistant by administration of
anti-CD4 or anti-IL4 MAbs at the onset of infection mounted a predominantly
Th1-like response (Heinzel et al 1991).  This concept of a strict correlation
between virtual absence of Th l-type CD4+ T-cell response and susceptibility to
infection should be amended in the light of recent reports that IFNγ mRNA was
detected in similar levels in lymph nodes draining lesions in strains of mice
covering the entire range of susceptibility to L. major (Morris et al 1993a).
Nonetheless, these studies did confirm that resistance to infection correlated
with reduced amounts of IL4 mRNA and smaller numbers of cells producing
IL4 (Morris et al ., 1993b).
The influence of L. major-specific Thl - and Th2-type CD4+ T cells on
pathogenesis has been assessed by studying the effect of adoptive transfer of
differentiated T-cell lines into SCID mice.  SCID mice reconstituted with Thl-
like T-cell lines were able to restrict parasite growth, whereas mice
reconstituted with Th2-like cell lines developed exacerbated disease (Holaday et
al., 1991).  These results indicate that differentiated Thi and Th2 cells
respectively are capable of mediating resistance and susceptibility to infection
with L. major.
IFNγ is an important anti-L. major effector molecule because of its
macrophage activating properties (reviewed in Liew and O'Donnell, 1993),
while IL4 has been reported to block the activation of murine macrophages by
IFNγ in vitro (Liew et al., 1991).  Similar observations have been made with
human monocyte-derived macrophages infected with L. amazonensis (Lehn et
al., 1989; Ho, 1992).  Evidence for a role of IL4 in susceptibility also derives
from observations that resistant mice are rendered susceptible to infection by the
expression of transgenic IL4 (Leal et al., 1993).  However, although unable to
clear the infection, these mice exhibited lesions that were significantly smaller
than those developing in genetically susceptible mice.
EVIDENCE THAT THE PROTECTIVE CAPACITY OF SOME LEISHMANIA
MAJOR SPECIFIC CD4+ THI T CELLS DEPENDS UPON THEIR
SPECIFICITY
Some L. major-specific CD4+ T-cell lines and clones, in spite of expressing a
functional Thl-type phenotype, exacerbate disease in mice infected with L.
major (Muller et al ., 1989).  These parasite-specific Thl-type cells induced
exacerbation in a dose-dependent manner when transferred into synagenic
recipient mice, even when these were rendered T-cell and B-cell deficient
before reconstitution (Titus et al ., 1991).  Ovalbumin-specific Thl cells also
exacerbated disease, but only if the cognate antigen, i.e. ovalbumin, was co-
injected with the parasites.  Following transfer into infected mice, these
parasite-specific Thl cells migrate preferentially to the site of lesions.  These
results suggest that the major signal for exacerbation of disease by Thl-type
CD4+ T cells is their activation in situ.  The observation that enhanced L. major
growth in lesions of irradiated mice, which occurs as soon as four days after
transfer of these Thl-like cells and simultaneous infection, is dependent on the
administration of bone marrow cells as a source of circulating monocytes,
indicates that this exacerbation of disease requires an interaction between Th l
cells (or their products) and macrophages (Mendonea et al ., 1990).
   Th1 -type CD4+ cells capable of enhancing lesions were selected by in vitro
restimulation with a lysate of promastigotes, the extracellular form of the
parasite.  In contrast, other parasite-specific Thl-like cells, recognizing only
living parasites (Muller and Louis, 1989), protected normal mice against
infectious challenge.  These results highlighted key differences between Thl-
type CD4+ cells that recognize living parasites and those responding to dead
parasite products in their effects on disease.  The inability of non-proteetive
parasite-specific Th1-type CD4+ T cells to recognize their epitope on the surface
of infected macrophages may result in their failure to focus the IFNγ on the
infected cell and so restrict parasite growth (Locksley and Louis, 1992).
    Two reasons might explain the failure of L. major-infected macrophages to
present specific epitopes to CD4+ T cells specific for antigen(s) present in a
lysate of L. major promastigotes.  The antigenic composition of the L. major
amastigote intracellular form differs from that of the extracellular promastigote
used to derive 'exacerbating' Th1-type CD4+ T cells.  In addition, even if similar
antigens are present on both stages, their presentation to T cells by macrophages
may be altered by the presence of living parasites in the compartment in which
processing for the MHC-class II pathway of antigen presentation occurs.
   The second possibility has been tested by studying the influence L. major
inside macrophages on their antigen-presenting function.  Bone marrow-derived
macrophages infected with L. major have a greatly reduced ability to present
non-parasite antigens to specific T cells.  However, the ability of infected
macrophages to present peptide epitopes to specific T-cell hybridomas was
normal (Fruth et al., 1993).  Thus, the impaired ability of parasitized
macrophages to present epitopes from erogenous protein antigens to T cells was
not related to a lack of membrane MHC class II molecules for binding to newly
formed peptides.  Neither did this inhibition of presentation of protein antigen
by parasitized macrophages result from a decrease either in the antigen uptake
or its intracellular degradation.  These data suggest that parasites in
macrophages interfere with the intracellular loading of MHC class II molecules
with antigenic peptides derived from exogenously added antigens.  Interestingly,
using a T-cell hybridoma specific for epitopes in a lysate of L. major
promastigotes, it was shown that infected macrophages are profoundly affected
in their ability to present exogenously added antigens of L. major to specific T
cells (Louis et al ., 1993; Fruth et al ., 1993).  These results could explain why
'exacerbating' Th1-type CD4+ T cells specific for antigen(s) present in a lysate
of L. major do not recognize their specific epitope at the surface of macrophages
parasitized with L. major.
REGULATION OF CD4+ T-CELL SUBSET DIFFERENTIATION DURING
INFECTION WITH LEISHMANIA MAJOR
Differentiated Th1 - and Th2-type CD4+ T cells arise from a common lineage
(Rocken et al ., 1992; Seder et al ., 1992).  The specificity of the T-cell receptor
is not important in determining the pathway of CD4+ T-cell precursor
differentiation (Reiner et al ., 1993).  Although it is becoming clear that several
factors may influence the T-cell subset that predominates following antigenic
stimulation, the precise understanding of the mechanisms involved in the
initiation of Thl or Th2 CD4+ T-cell development from naive precursors remains
an important and not fully resolved issue.
   Results from in vivo and in vitro studies strongly suggest that cytokines
present at the initiation of infection with L. major play a crucial role in the
differentiation of naive CD4+ T cells towards one or other functional phenotype.
Administration of anti-IFNγ MAb at the time of parasite inoculation abrogated
the natural resistance of C3H mice to infection (Belesovicetal., 1989). This
treatment ablated the Thl-cell response normally seen during infection of these
mice and promoted a Th2-type response (Scott, 1991).  A role for IFNγ in
driving the early CD4+ T-cell response towards a Th l -type functional
phenotype was also revealed by injecting recombinant IFNγ into susceptible
BALB/c mice along with the infective inoculum; the cytokine profile was
indeed altered towards a Th l -type response (Scott, 1991).  The observation of
an IFNγ response in lymph nodes draining the infection site of resistant mice as
soon as 72 hours after infection supports the role of IFNγ in directing early
CD4+ Th1-type response.  Natural killer (NK) cells have been shown to be the
major source of IFNγ early during infection (Sharton and Scott, 1993).
Similarly, the differentiation of adoptively transferred CD4+ T cells towards a
Th1 phenotype in infected SCID mice and the associated resistance of these
mice to infection has been attributed to IFNγ produced by NK cells (Varkila et
al., 1993).  However, IFNγ does not support a sustained Th1 response, since
administration of IFNγ to susceptible BALB/c mice for up to six weeks after
infection did not modify the outcome of disease (Sadick et al ., 1990).
Furthermore, infection of BALB/c mice with parasites transfected with the
murine IFNγ gene, led to the development of severe lesions and did not modify
the polarized Th2-type response (Tobin et al ., 1993).  These findings suggest
that, in the murine model of infection with L. major, IFNγ alone is not sufficient
either to promote a sustained differentiation of Th l cells in resistant mice or to
impede Th2 cell maturation in susceptible mice.  Recently, observations made in
IFNγ-deficient C57B2/6 mice have revealed that these mice, in contrast to wild
type control mice, develop a Th2-type response following infection with L.
major, without evidence of a Thl-type response, supporting a role for IFNγ in
the differentiation of Thl-type CD4+ T cells (Wang et al ., 1994).  In contrast,
recent results showing that mice lacking the ligand binding chain of the Il.PNy
receptor (IFNγR-/-) still mount a polarized IFNγ-producing CD4+ T-cell
response without evidence for the expansion of IL4-producing CD4+ T cells
indicate that IFNγ-mediated signals are not necessary for the differentiation of
CD4+ T-cell precursors towards a Th l phenotype (Swihart et al ., 1995).  The
reasons for this difference in the type of CD4+ T-cell response triggered in
IFNγR-/- and IFNγ-knockout mice following infection with L. major are not
known.  However, since the IFNγ and IFNγR-1- mice were derived on
genetically different backgrounds, it is possible that the influence of IFNγ on the
differentiation of T-cell subsets may vary in different mouse strains.
   IL12 is a cytokine produced by macrophages and B cells (Trinchieri et al .,
1993) that stimulates the production of IFNγ by T and NK cells.  Therefore,
inasmuch as the early IFNγ-producing NK cell response observed in resistant
mice has been implicated in the development of a polarized Thl response
(Sharton and Scott, 1993), it was logical to consider that IL 12 plays a major
role in Th1 cell differentiation in the model of infection with L. major
Administration of IL12 during the first week of infection with L. major cured
BALB/c mice.  This treatment also favoured a Thl-type response and prevented
a deleterious Th2-type response (Heinzel et al ., 1993).  Furthermore, treatment
with anti-IL 12 polyclonal antibody, for 25 days from the time of infection
significantly exacerbated disease in resistant mice (Sypeck et al ., 1993).  These
data show that IL12 plays an important role in the development of Th1-type
response following infection with L. major.
   Treatment of BALB/c mice with anti-IL4 MAb at the initiation of infection
renders them resistant, inhibits the expansion of Th2 cells and leads to the
development of a Th1 response (Sadick et al., 1990; Tobin et al, 1993).
Administration of IL4 to resistant mice at the time of parasite inoculation
enhanced the development of a Th2-type CD4+ response but this change from
the normally observed pattern of response was only transient (Chatelain et al,
1992).  Results recently obtained in our laboratory also strongly support the role
for IL4 in the differentiation of L. major specific T-cell precursors towards a
Th2 functional phenotype.  CD4+ T cells isolated from mice seven days after
infection with L. major produced small amounts of IFNγ and IL4 upon specific
restimulation in vitro.  After a few cycles of specific restimulation, the amount
of IFNγ produced by these CD4+ T cells decreased progressively, whereas the
release of IL4 increased steadily.  After six cycles of restimulation, these cells
produced almost exclusively IL4 and no IFNγ.  Addition of soluble IL4
receptors (provided by M. Widmer, Immunex Corp., Seattle, USA) to the
cultures led to the differentiation of T cells producing large amounts of IFNγ
and almost no IL4 (manuscript in preparation).  However, it was also reported
that despite the administration of IL4 for three weeks following infection,
resistant mice resolved their lesions (Sadick et al ., 1990).  Thus, although IL4
might be required for the development of polarized Th2 response following
infection with L. major, other factors might also be necessary.
CONCLUDING REMARKS
Infection of inbred mice with L. major remains one of the best experimental
systems for the study of the complex interactions between intracellular
pathogens and their hosts.  Using this model system, basic research aimed at the
identification of host factors that lead to or circumvent the development of an
effective immune response has already greatly contributed to the demonstration
of host-protective (Thl-type) and disease promoting (Th2-type) CD4+ cell
responses.  The dramatic effects of these functionally distinct CD4+ T cells on
the disease processs has already been clearly related to the lymphokines that
they produce.
   This experimental model of infection provides a unique system for defining
the rules that control maturation and activation of distinct CD4+ T-cell subsets
during antigenic stimulation in vivo.  This not yet fully resolved issue has
profound implications not only for the field of leishmaniasis, but also for a
number of other diseases with an immunological basis.
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INTRODUCTION
There is strong evidence that cattle immunized against Theileria parva by
infection and treatment clear the parasite through the deployment of class I
MHC-restricted parasitespecific CD8+ cytotoxic T lymphocytes (CTL)
(McKeever et al., 1994).  The induction of these responses is crucial to the
development of an improved vaccine for T. parva and work is in progress to
identify parasite antigens that elicit them.  However, the factors involved in the
generation and maintenance of these responses in vivo are poorly understood.
Conflicting data from murine and human systems suggest that CD8+ CTL
specific for certain antigens can be induced in vivo and in vitro with or without
help from CD4+ cells (Sprent et al ., 1986.. Buller et al ., 1987).  Other
requirements such as the nature of antigen-presenting cells (APC), their surface
molecules and secreted factors have also been shown to be important (Huang et
al ., 1994).
We have used highly purified (96-99%) populations of CD4+ and CD8+ T cells
co-cultured with autologous lymphocytes transformed with the Muguga stock of
T. parva (TpM) to examine the activation requirements of naive and immune
CD8+ T cells in vitro.  We have observed that CD4+ T cells and their secreted
products are crucial to the induction of naive and parasite-specific bovine
memory CD8+ CTL (Table 1).  Cultures of naive or immune CD8+ T cells with
TpM in the presence of immune CD4+ T cells generated CD8+ CTL activity
comparable to that of unfractionated cells.  In addition, specific stimulation of
CD4+ T cells primed with an unrelated antigen, the variable surface
glycoprotein (VSG) of Trypanosoma brucei, in similar co-cultures generated
help for the activation of parasite-specific CD8+ CTL from immune but not
naive CD8+ T cells.  This activity was higher when antigen-pulsed and fixed
monocytes presented the VSG (four-cell cluster) than when the parasitized cell
line was used as APC (three-cell cluster).
To characterize helper signals delivered to CD8+ T cells in these experiments,
a supernatant of T-cell growth factors (TCGF) derived from Concanavalin A-
stimulated lymphocytes or recombinant bovine interleukin-2 (rBoIL-2) were
added  to  co-cultures of  naive or immune CD8+ T cells  with TpM.  Significant
Table 1. Activation of Theileria-immune and naive CDS+ T cells is dependent on help
from antigen-specific CD4+ T cells.
____________________________________________________________________
Culture components    Killing activity2
____________________________________________________________________
iPBM1 + TpM +++
nPBM + TpM   +
iCD8 + TpM   +
iCD8 + iCD4 + TpM +++
iCD8 + nCD4 + TpM   +
nCD8 + iCD4 + TpM +++
 nCD8 + iCD4 + TpM   +
____________________________________________________________________
1. i = immune, n = naïve, M  = periipheral blood monocytes.
2. + = <10%, ++ = 10-25%, +++ = >25-55%.
Table 2. Antigen-primed CD4+ T cells need not be Theileria-specific in order to provide
helper function to parasite-specific CTL.
____________________________________________________________________
Culture components Killing activity2
____________________________________________________________________
VSG-specific CD4 + iCD81 + TpM + VSG +++
VSG-specific CD4 + iCD8 + TpM + MO + VSG +++
VSG-specific CD4 + nCD8 + TpM + VSG  ++
VSG-specific CD4 + nCD8 + TpM + MO + VSG   +
____________________________________________________________________
1.  i = immune, n = naïve, M  = periipheral blood monocytes.
2. + = <10%, ++ = 10-25%, +++ = >25-55%.
Table 3. Role of contact signals and soluble factors from antigen-specific CD4+ T cells
in the provision of helper function to immune and naive CD8+ T cells.
____________________________________________________________________
    Inner chamber Outer chamber Killing activity2
____________________________________________________________________
    iCD41 + TpM iCD8 + TpM +++
    iCD4 + TpM nCD8 + TpM   +
    None      iCD41 + nCD8 + TpM +++
    TCGF + medium iCD8 + TpM +++
    TCGF + medium nCD8 + TpM   +
    rBoIL-2 + medium iCD8 + TpM +++
    rBoIL-2 + medium nCD8 + TpM   +
____________________________________________________________________
1.  i = immune, n = naïve, M  = periipheral blood monocytes.
2. + = <10%, ++ = 10-25%, +++ = >25-55%.
   CTL activity, comparable to that obtained with immune CD8+ T cells
stimulated by TpM in the presence of immune CD4+ T cells, was detected in
cultures containing primed CD8+ T cells but not in those containing naive cells.
 To determine whether contact between parasite-specific CD4+ T cells and
CD8+ T cells is an essential requirement for helper function, additional
experiments were performed using two-chamber culture plates incorporating
semi-porous membranes.  TpM were co-cultured with naive or immune CD8+ T
cells in the outer chamber and with immune CD4+ T cells in the inner chamber.
Cytotoxic activity was observed in cultures containing primed CD8+ T cells but
was undetectable in those containing naive CD8+ T cells.  This observation
suggests that while soluble factors derived from activated CD4+ T helper cells
are sufficient for the activation of memory CTL, naive CD8+ T cells require
actual cell contact.  Whether this signifies the involvement of receptor-ligand
interactions or is a reflection of a requirement for defined local cytokine
concentrations is not clear.
SUMMARY
It is evident from these results that Theileria-immune and naive CD8+ T cells
require help from activated antigen-specific CD4+ T cells to generate parasite-
specific cytotoxic activity.  The CD4+ T cells need not be Theileria-specific,
although this bystander effect is operative for primed CD8+ T cells only.  While
TCGF or rBoIL-2 can replace the requirement of primed CD8+ T cells for
CD4+ T cell help, these factors cannot induce CTL activity in naive CD8+ T
cells cultured with autologous parasitized lymphoblasts.  The results further
suggest that contact signals from immune CD4+ T cells are important for the
specific activation of naive CD8+ cells.
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T cells bearing the γδ antigen receptor can constitute up to 50% of T cells in
peripheral blood and lymphoid organs of calves below six months of age.  This
observation prompted us to investigate the involvement of γδ T cells in the
immune response of young calves against Theileria parva (Muguga).
A limiting dilution analysis of γδ T cells sorted from peripheral blood of one
calf was conducted to examine the frequency of proliferating γδ T cells changes
during the course of a primary infection.  Three different stimulator cell
populations, namely autologous Con A blasts, autologous heat-stressed (HS)
Con A blasts and autologous T. parva-infected cell lines (TpM) were used in the
assay.  This analysis revealed that T. parva-specific γδ T cells were present at
measurable frequencies prior to immunization, while those responding to Con A
blasts or HS Con A blasts were not detectable.  Frequencies of proliferating γδ
T cells responding to HS Con A blasts and TpM increased dramatically during
immunization and dropped after clearance of the infection.
To investigate the basis of the reactivity of bovine γδ T cells for autologous
infected cell lines, a panel of γδ T-cell clones has been generated.  The
phenotype of these T-cell clones is CD3+, CD2+, CD4-, GB21A+ and CC15+,
and a proportion express the CD8 specificity.  These T-cell clones proliferate
specifically in the presence of autologous and allogeneic TpM.  The
proliferative response can be increased in some clones by heat shocking the
TpM.  This reactivity can be blocked by monoclonal antibodies against the
bovine γδ T-cell receptor (GB21A) and CD2 (IL-A 43).  Some γδ T-cell clones
can be activated by fixed autologous TpM, although to a lower degree.  Both IL-
2 and IL-4 are required for proliferation of these clones in the presence of TpM.
Since it has been established that a proportion of γδ T cells in mouse and
human are activated by stress proteins, we examined the possibility that T.
parva-specific γδ T cells recognize stress proteins by characterizing the
expression of the hsp70 family of stress proteins in T. parva-infected cell lines.
A rat polyclonal sera has been raised against the T. parva-derived hsp70 and
gives rise to intense punctate staining of the schizont cytoplasm in
immunofluorescence analysis of infected cells; staining of the host cell cytosol
is variable and of lower intensity.  The latter observation is probably the result
of cross-reactive epitopes located on bovine and parasitic stress proteins, since
hsp70 proteins are known to be highly conserved.  Staining of the schizont is
markedly intensified by prior incubation of the infected cells at 42 'C for 3 h.
Host cytoplasm staining is unaffected by this treatment.
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INTRODUCTION
Techniques for in vivo depletion of lymphocytes using monoclonal antibodies
have been well documented for murine systems.  This model has played an
important role in analysing the involvement of various lymphocyte subsets in
several immune mechanisms.  In mice 600 µg of Ab are generally injected
intraperitoneally once a week.  In order to study bovine specific immune
mechanisms we have attempted to adapt this technology to cattle.
RESULTS AND DISCUSSION
Previous studies indicated that intravenous inoculation of cattle with MAb
specific for bovine T-cell markers resulted in depletion of the appropriate T-cell
subsets in peripheral blood (Howard et al., 1989, 1992).  However, it was
observed that, with this dose of MAb, T-cell depletion of other lymphoid organs
was not complete.  Furthermore, intravenous inoculation of these quantities of
MAb was occasionally accompanied by shock-like symptoms.  Since it has been
observed that the depletion blood can be complete in less than two hours, the
latter may be related to massive agglutination and lysis of the target cell
population.  We modified the inoculation regime by administering only a small
dose of MAb in the first injection.  In studies that focused on CD4+ and CD8+ T
cells, reconstitution of the blood with the depleted population was observed
overnight, presumably the result of migration of T cells from lymphoid organs.
The treatment was continued by injection of small amounts of antibodies in the
morning followed by a high dose in the afternoon (Table 1).  Using this protocol
the majority of the animals did not show adverse reactions, although some did
show transient mild reactions.  Complete depletion of peripheral blood was
achieved and animals could be maintained on this regime for up to four weeks.
After this period CD8+ T cells reappeared in the blood even under continuous
antibody treatment.  This is most likely due to the formation of anti-mouse Ig
antibodies in cattle.  Indeed, bovine anti-mouse-Ig antibodies can be detected in
serum of treated animals as early as one week after the first injection.  These
antibodies may be involved in clearing the active mouse monoclonal antibodies
but may also contribute to aggregation of T cells.
  We have performed an immunohistological analysis of the extent of depletion
in lymphoid tissues in one animal sacrificed after complete depletion of CD8+ T
cells in peripheral blood.  Considerable variation in the extent of the depletion
was observed in different immune compartments.  Using FACS analysis of cell
suspensions, extensive CD8+ T-cell depletion was observed in the blood and
lymph node but not in spleen.  By immunohistology, CD8+ positive cells were
shown to be present in the lymph node, spleen and thymus.
Table 1. In vivo depletion of bovine T-cell subsets using monoclonal antibodies.
____________________________________________________________________
Day of inoculation Morning Afternoon
____________________________________________________________________
Day 1 0.5 mg 0.5 mg
Day 2 0.5 mg 2.0 mg
Day 3 2.0 mg 20.0 mg
Day 4 2.5 mg 20.0 mg
________________________________________
To investigate the functional significance of the remaining CD8+ T cells, an in
vitro restimulation assay was performed on different tissues, based on reactivity
to T. parva, to which the animal was immune.  Lymphocytes were co-cultured
with irradiated T. parvainfected stimulator cells for one week and analysed for
their capacity to kill parasitized target cells (Goddeeris et al ., 1986).  It was
observed that lytic activity could be detected in cells derived from lymph node,
spleen and even peripheral blood (data not shown).  Since only very small
numbers of CD8+ T cells were detectable in these populations by FACS analysis
prior to stimulation, it is clear that the in vitro restimulation assay is much more
sensitive.  This might be related to the expected expansion of CD8+ cells during
the one week in vitro culture in the presence of T. parva-infected cells.
Moreover, these experiments show that cell suspensions such as those that
might be collected in aspirated lymph node biopsies are not representative of
total lymph node.
In an attempt to target antibodies more directly to the lymph node we
administered MAb to one cow subcutaneously.  At the first inoculation large
amounts of antibodies (5 mg) were very well tolerated and no side effects were
recorded.  Three days after injection of anti-CD8+ antibodies very good
depletion was observed in the blood.  However, depletion in both blood and
lymph node were not complete by day 10.  Interestingly, no chancre formation
was observed when this animal was infected with T. congolense  through bites
of infected tsetse flies.  Since the chancre formation is mainly the result of
infiltrating lymphocytes, this may suggest that the level of T-cell depletion in
the skin can influence the response of cattle to the bite of an infected tsetse fly
(Table 2).
To determine whether T-cell memory is affected by cell depletion, we
examined the capacity of cattle that had been allowed to recover blood T-cell
numbers following complete depletion.  We reasoned that if all T cells were
depleted, a memory response would not be present in the reconstituting
population.  Foot and Mouth Disease virus (FMDV) antigen constituted an ideal
system for this investigation since all of our animals had been immunized
against this virus.  Animals were treated with MAb specific for CD8 or both
CD4 and CD8 for one week and allowed to reconstitute the depleted
population(s).  After 36 days of reconstitution proliferative activity against
FMDV antigen was measured in peripheral blood of (i) normal, (ii) CD8+ T cell-
depleted and (iii) CD4+ and CD8+ T cell-depleted animals (Table 3).  In two
animals depleted of both CD4+ and CD8+ T cells, no FMDV-specific T-cell
proliferation could be observed (Table 3).  The control animals and the CD8+ T-
cell depleted animals showed normal T-cell proliferation.
Table 2. Chancre formation in a CD8+ T cell-depleted animal on day 10 after feeding of
infected tsetse fly bites.  Average skin thickness (mm) around five bite sites.
____________________________________________________________________
Normal skin Chancres
_______________________________________
Control                      CDS+/CD4+ T cell-depleted
__________________________________________________________________________
                                                  8  8
                                                 14 11
                                                 16 11
                                                 18 11
                                                 18 11
                                                 18 12
__________________________________________________________________________
Spontaneous recovery of specific T-cell activity in one of the calves depleted
of both CD4+ and CD8+ T cells might have been the result of residual vaccine
antigen present during reconstitution.  This antigen could prime naive T cells
leaving the thymus.  However, it cannot be excluded that memory CD4+ T cells
escaped the depletion and only entered the peripheral circulation in the later
stages of reconstitution.  Both animals recovered normal proliferative responses
after re-immunization with the antigen of interest, suggesting that a normal
immune response is possible in animals that have recovered  from immune cell
depletion, and that only T-cell memory is affected by this treatment.  Taken
together these results provide preliminary indications that in vivo depletion of
CD4+ T-cell memory in peripheral blood is possible.
Table 3. FMDV-specific proliferation of PBM from animals depleted for specific T-cell subsets and allowed to
reconstitute normal cell numbers.  Figures represent average counts of duplicate wells adjusted for background.
________________________________________________________________________________________
Days of                              Intact              ____         Depleted CD4+ and CD8+ T cells     Depleted CD8+ T cells
reconstitution BK 66 BK 68 BK 69 BK 70 BK 71 BK 72
________________________________________________________________________________________
36 34706 6528 78 46 30224 2911
43 24226 14026 265 868 59671 2438
59 4987 2994 0 4242 11695 1493
69 9056 9342 0 5485 76599 3592
78 IMMUNIZATION WITH FMDV
85 2188 4700 7931 20317 25897         1395
91 28196 14419 37821 31291 62137       11472
________________________________________________________________________________________
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Summary of discussion
Chairperson: J. Naessens
Rapporteurs: N. McHugh and C. Wells
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The session opened with an overview by F. Cox of the roles of cytokines and T-
cell subsets in the immunity and immunopathology of protozoan parasitic
diseases.  J. Louis then described the current perception of immunity of mice to
Leishmania major infection, which is the most extensively studied model of Thl
and 712 subsets and the cytokines that they produce.  Some observations on the
inductive requirements of bovine CD8+ cytotoxic T cells were presented by E.
Taracha and preliminary data on the involvement of γδ T cells in T. parva and
trypanosome infections of cattle were discussed by C. Daubenberger and M.
Sileghem respectively.  In the final presentation of the session, J-P Scheerlinck
described attempts to deplete bovine T-cell subsets in vivo by treatment with
lineage-specific monoclonal antibodies.
In the discussion that followed it was observed that in spite of the clear cut
dichotomy between Thl and Th2 CD4+ T-cell responses in protection of mice
against Leishmania major, no such distinction exists in many diseases.  Indeed
in leprosy the best prognosis is for those patients with a mixed Thl/Th2
response.  It was suggested that, since immune responses occur within discrete
microenvironments, the generation of a specific Thl response to an antigenic
challenge need not preclude the development of a Th2 response in another
location.  There was some debate on the importance of both antigen type and
route of administration in the generation of Th1 and Th2 responses.  The initial
antigen presentation event was considered to be a major factor in determining
the direction of the response, although it was observed that individual peptide
antigens can elicit distinct responses when administered through different routes
of inoculation.  The significance of the latter finding was questioned on the
basis that the peptides involved were not targets for protective immune
responses.
There was some discussion on the ability of Leishmania major to access the
MHC class I antigen processing pathway, since the parasite survives within a
phagolysosome.  It was suggested that the mechanisms responsible for
translocating peptides from the cytosol to the phagolysosome might be
reversible and allow peptides or proteins to exit to the cytosol and become
available for MHC class I processing.
The mechanism by which T. parva peptides might be presented to specific
CD4+ T cells to elicit help for naive and primed CD8+ T cells was discussed.
The possibility was raised that CD8+ T cells may be capable of presenting
antigen in association with class II MHC, and so elicit their own help.  It was
pointed out that activated T cells in cattle express class II MHC and that
activated bovine CD8+ T cells have been shown to present trypanosomal
variable surface glycoprotein to specific CD4+ T-cell clones.  However, it was
observed that the basis of class II MHC-associated antigen presentation in the T.
parva system was still under investigation.
Possible mechanisms whereby γδ T cells recognize antigen were discussed and
it was observed that in man heat shock proteins (hsp) have been shown to be
presented to γδ T cells by non-classical class I MHC molecules.  It was
suggested that hsp antigens may be involved in activation of γδ T cells in both
ECF and trypanosomiasis.  It was however stressed that the study of bovine γδ T
cells is at a preliminary stage and that their precise function and mechanisms
responsible for their control remain to be elucidated.
A lengthy discussion focused on the in vivo depletion of bovine T-cell subsets
using monoclonal antibodies.  Two major concerns that arose were the extent of
depletion that was possible in cattle and, given the complicated nature of ECF
and trypanosomiasis, whether the results of depletion experiments in these
systems could be interpreted accurately.  The extent of depletion was considered
to be critical since failure to remove precursor cell populations completely could
compromise the interpretation of results.  Suggestions were made on how
greater levels of depletion might be obtained; osmotic pumps or hybridoma cell
lines encapsulated in sodium arsenate and poly-L-lysine to allow persistent
levels of antibody might improve the extent of depletion.  However, it was
pointed out that the possibility of hypersensitivity and the accumulation of large
amounts of host antibodies to mouse Ig would still be possible sources of
complication.  Although it was generally agreed that good depletion data would
complement adoptive transfer studies, it was felt that the complex nature of T.
parva infections, where T-cell depletion would be removing both parasitized
host cells and immune effector populations, would seriously complicate the
interpretation of results.  However, it was suggested that the technique might be
applicable in the study of levels of T-dependent antibody production in Boran
and N'Dama cattle undergoing infection with trypanosomes, where even partial
depletion of target cell populations would be sufficient to produce a measurable
result.
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INTRODUCTION
Pathogenic organisms are often capable of stimulating a range of humoral and
cell-mediated immune responses, only some of which are relevant in mediating
recovery from infection and subsequent immunity to challenge.  Indeed, in some
infections, components of the immune response have been shown to contribute
to disease, and the balance of the immune responses determines whether the
outcome of infection is recovery or enhanced disease (Scott and Kauffmann,
1991).  This is particularly well-documented for a number of parasitic infections
where the outcome is determined by the profile of cytokines produced by CD4+
T cells (Scott et al., 1989).  Recently, evidence has emerged that similar
phenomena operate in viral infections (Clerici and Shearer, 1993; Alwan and
Oppenshaw, 1993).  In considering approaches to vaccination against such
organisms, the identification of both the beneficial and harmful elements of the
immune response and definition of their antigenic specificities are necessary
steps toward choice of antigens and appropriate antigen delivery systems.
Because of the relatively simple antigenic structure of viruses and the
availability of detailed information on genome sequences, the immune responses
elicited by viruses are particularly amenable to detailed dissection.  This
presentation will summarize current information on the nature and antigenic
specificity of immune responses to respiratory syncytial virus (RSV) and
consider their role in control of infection and in the pathogenesis of pulmonary
lesions.
RESPIRATORY SYNCYTIAL VIRUS
Bovine RSV infects the epithelium of upper and lower respiratory tract and is an
important cause of pneumonia in housed calves (Stott and Taylor, 1985).
Outbreaks occur annually during the winter months with greatest mortality
being observed during the first six months of life, when maternal antibody is
often still present.  Reinfection is common although the severity of disease
usually decreases with subsequent infections.  RSV is a pneumovirus of the
Paramyxoviridae family and contains a negative sense single-stranded RNA
encoding ten proteins seven of which are incorporated in the virion.  The
attachment (G) and fusion (F) glycoproteins are expressed on the outer aspect of
the viral envelope.  The bovine virus is structurally and antigenically related to
human RSV and the epidemiology and pathogenesis of the diseases they cause
are very similar.  A number of vaccines of variable efficacy have been produced
for human and bovine RSV.  A vaccine consisting of glutaraldehyde-fixed
infected cells has proved to be particularly effective in calves (Stott et al .,
1984; Howard et al ., 1987).  However, with some of the vaccines there have
been reports of enhanced pathology following natural challenge of vaccinated
individuals (Kimman et al ., 1989; Kim et al ., 1969).  This was a particular
problem with a human vaccine that employed formalin-fixed virus.  These
observations highlight the need for a clearer understanding of the mechanisms
of immunity against RSY.
   In contrast to bovine RSV, which is not infectious for mice, human RSV
readily infects mice and causes pneumonia (Prince et al ., 1979; Taylor et al .,
1984a).  While the murine model has proved to be a valuable system for
exploring the nature and specificity of immune responses induced by the virus,
there is evidence that the relative contribution of the components of the immune
response to immunity and enhanced pathology differ from that in the natural
hosts.  The information presented herein is drawn from studies of the human
virus in the murine model and the bovine virus in cattle.
IMMUNOGENICITY OF VIRAL GLYCOPROTEINS
Studies of the immunogenicity of human RSV proteins have been carried out in
mice using biochemically purified viral proteins (Routledge et al ., 1988) or
recombinant vaccinia viruses expressing individual proteins (Stott and Taylor,
1989).  In both instances, only the G and F glycoproteins stimulated significant
protection in the lung against RSV challenge; in mice immunized with these
recombinant vaccinia viruses, titres of virus in the lungs following challenge
were reduced by more than log102.5 plaque-forming units compared with
controls.  Both glycoproteins induced neutralizing antibodies.  Although
vaccinated mice were protected against RSV infection, they developed more
severe lung lesions after RSV challenge than control animals (Stott et al ., 1987;
Openshaw et al ., 1992).
   Preliminary experiments in calves indicate that immunization with
recombinant vaccinia viruses expressing the F, G or N proteins result in reduced
levels of virus replication in the lung.  In contrast to the findings in mice, there
was a marked reduction in the extent of lung lesions in vaccinated calves
following RSV challenge compared with controls.
PROTECTIVE PROPERTIES OF GLYCOPROTEIN-SPECIFIC ANTIBODIES
The role of antibodies in immunity has been studied by examining the protective
activity of monoclonal antibodies (MAbs) specific for RSV proteins.  The
MAbs comprised a panel of reagents raised in mice against human RSV and 12
bovine MAbs, all specific for the F glycoprotein, produced by heterohybridomas
generated from cattle immunized with bovine RSV.  The MAbs were
administered either intraperitoneally or intravenously to mice 24 h prior to
intranasal challenge with human RSV.  Protection, as judged by reduction in
virus growth, was achieved only with MAbs specific for the F and G
glycoproteins (Taylor et al ., 1984b; Kennedy et al ., 1988).  Not all MAbs
specific for these antigens were protective and the level of protection varied for
different antibodies.  When tested against a number of different strains of both
human and bovine RSV, the protective F-specific MAbs were cross-reactive,
recognizing all the human and bovine viruses studied.  In contrast, G-specific
MAbs were either strain-specific or specific for the subgroup of human or
bovine RSY When the properties of protective and non-protective MAb specific
for the F protein were compared there was no correlation between protection
and the antibody isotype, the capacity to facilitate complement-mediated lysis or
in vitro neutralizing activity (although all protective antibodies neutralized).
However, a consistent correlation was found between the ability of the
antibodies to inhibit fusion and syncytia formation by infected cells and
protective activity (Taylor et al ., 1984b, 1992).  That the protective activity of
these MAbs was independent of their Fc domains was demonstrated by the
finding that Fab fragments of the MAb were able to mediate protection.
Protective MAbs specific for the F glycoprotein were also tested for
therapeutic activity by administering them to mice four days after infection with
RSV, when high titres of virus are found in the lungs.  Somewhat surprisingly,
this treatment was found to reduce virus titres in the lungs to undetectable levels
within 24 hours and again was independent of the Fc domain.  A similar result
was obtained in athymic nude mice indicating that the effect did not depend on
primed T cells.  Furthermore, virus did not reappear in the lungs of passively
immunized athymic mice, even when the antibody had declined below levels
previously shown to be protective.  In contrast, administration of protective G-
specific MAb to infected nude mice resulted in a more gradual decline in virus
titres.  The results of these studies indicate that antibodies specific for the F
glycoprotein exert their protective effect directly as a result of binding to
functional sites on the molecule.  Presumably they are capable of preventing
spread of virus from cell to cell, as well as clearing free virus.  Whether the
antibodies have additional effects on infected cells that result in inhibition of
viral growth has yet to be investigated.
Since the F-specific MAbs reacted with both human and bovine RSV it has
been possible to examine the protective activity of these antibodies in calves.
Intra-tracheal administration of fusion-inhibiting bovine MAbs that were
protective against RSV infection in mice, 24 h prior to challenge with bovine
RSV, resulted in significant reduction in virus replication in the lung and a
reduction in the severity of pneumonic lesions, indicating that these antibodies
are also protective in cattle.
These studies have shown that certain antibodies to the F protein of RSV are
highly effective both at preventing and clearing RSV infection.  Furthermore,
antibody appears to either protect against lung lesions or have no effect on their
development.
A combination of techniques has identified two sites on the F glycoprotein
recognized by protective antibodies (Taylor et al ., 1992).  By sequence analysis
of the F protein gene from antibody-escape mutants selected with the protective
MAb, these areas have been located to amino acid residues 255-275 and the
region around amino acid 429 of the F protein (Arbiza et al ., 1992).  These
findings indicate that there are two immunodominant sites on the F protein
recognized by protective antibodies.  It is of note that the murine and bovine
MAb reacted with the same sites on the molecule.
T-CELL RESPONSES IN MICE
Antigen-specific T-cell proliferative responses and MHC-restricted cytotoxic T
cells have been demonstrated in mice infected with RSV (Taylor et al ., 1985;
Openshaw et al ., 1988, 1990).  A range of cytokines, including IL-2, IL-4 and
IL-5, are produced by T cells from previously infected mice after restimulation
with RSV in vitro (Alwan and Openshaw, 1993).  Similar studies conducted in
mice immunized with recombinant vaccinia viruses expressing the F or G
glycoproteins have revealed a marked difference in the T-cell responses
stimulated by the two antigens (Alwan and Openshaw, 1993).  The F
glycoprotein induced readily detectable CTL, abundant IL-2 production and low
levels of IL-4 and IL-5.  In contrast, the G glycoprotein induced a response
characteristic of Th2 cells, namely the absence of detectable CTL and
production of IL-4 and IL-5 but little if any IL-2.  Similarly, F-specific cell
lines, maintained by repeated stimulation with RSV, showed a Th1 pattern of
cytokines whereas G-specific lines had a Th2 pattern of cytokine production
(Alwan et al ., 1993).  Although mice recover from primary infection with RSV
or infection with vaccinia recombinants expressing the F or G glycoproteins
control virus replication following challenge with RSV, such animals develop
enhanced lung pathology compared with animals undergoing primary infection
(Stott et al ., 1987; Openshaw et al ., 1992).  The lung lesions are particularly
pronounced in mice immunized with the G glycoprotein and include infiltrates
of eosinophils, a feature associated with IL-5 production.
   These findings provide important clues to the basis of the enhanced pathology
that is sometimes observed after natural human and bovine infections of
vaccinated animals.  In particular, they suggest a role for Th2 T-cell responses.
However, the observation of pathological lesions following secondary infection
of mice with RSV is not a feature of experimental challenge infections in cattle
and highlights the shortcomings of the murine model.
THE ROLE OF T-CELL RESPONSES IN RECOVERY FROM INFECTION
IN CATTLE
The precise nature of the T-cell responses induced by RSV in cattle has not yet
been investigated.  However, the role of T-cell subsets in recovery from primary
infections has been examined by monitoring the course of infection in calves
transiently depleted of T-cell subpopulations.  Depletion of the CD4+ or CD8+
subsets of T cells was achieved by intravenous administration of specific MAbs.
Although depletion of CD4+ T cells resulted in a delay in the onset of RSV-
specific antibody production, the course of infection was similar to that in
untreated controls.  By contrast, animals depleted of CD8+ T cells exhibited a
significant delay in clearance of virus from nasal secretions and the lungs.
Thus, despite the evidence that antibodies play a prominent role in control of
RSV the results of this study indicate that CD8+ T cells are of critical
importance in recovery from infection.  The apparent failure of antibody
produced in CD8-depleted calves to clear the virus perhaps suggests that the
primary antibody response may be qualitatively defective These findings
contrast with those in mice depleted of T-cell subsets, where failure to clear
RSV only occurred in mice depleted of both CD4+ and CD8+ T cells (Graham et
al ., 199 1).  Current studies are aimed at defining the nature and antigenic-
specificity of the CD8+ T-cell response.
   In summary, these studies indicate that the F protein is the major protective
antigen of RSV, providing protection against different strains of virus.  Fusion-
inhibiting antibody is highly protective, although, at least in cattle, CD8+ T-cell
responses appear to be essential for recovery from primary infections.
Furthermore, in contrast with the failure of antibody to potentiate disease, there
is evidence that Th2 responses may contribute to the pathology of RSV disease.
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INTRODUCTION
Theileria parva, a protozoan parasite of cattle, causes a disease called East
Coast fever (ECF) (reviewed by Irvin and Morrison, 1987).  The disease is of
economic importance because it causes high morbidity and mortality and limits
the development of the cattle industry (Mukhebi et al., 1991).  Recent estimates
have shown that 20 million cattle are at risk in eastern, central and southern
Africa and indicate that in 1989 alone almost US$ 168 million were lost due to
deaths and debilitation (Mukhebi et al., 1991).  The parasite is transmitted by
the brown ear tick, Rhipicephalus appendiculatus. lie infective stage for cattle,
the sporozoite, develops in the salivary glands of the tick vector and it is
introduced into the mammalian host during tick feeding.  Sporozoites are
released into the host where they enter lymphocytes by receptor mediated
endocytosis (Fawcett et al., 1982; Shaw et al., 1991).  CD4+ and CD8+ T-
lymphocytes are the major target cells although B-Iymphocytes and y8 T cells
can also be infected (Baldwin et al., 1988).  Within lymphocytes, sporozoites
differentiate into the pathogenic schizont stage, an event that is associated with
the transformation and clonal expansion of the parasitized cells.  Schizonts
undergo merogony to produce merozoites which are released upon rupture of
the host cells.  Merozoites invade erythrocytes where they differentiate into the
piroplasm stage, the infective stage to ticks.
East Coast fever is characterized by pyrexia, generalized lymphadenopathy
and severe leucopaenia and is usually fatal (Irvin and Mwamachi, 1983).
However, animals that recover spontaneously or due to drug intervention are
resistant to re-infection with the same stock of parasite (Radley, 1981), an
indication that vaccination against the disease is possible.
The only available method for immunization against ECF is by infection with
live sporozoites and simultaneous treatment with a long acting oxytetracycline
(Radley, 1981).  The method is not yet widely used because the immunity
engendered is parasite strainspecific and because of cold chain and delivery
problems related to poor infrastructure in ECF endemic areas.  In addition, there
are risks of transmitting other tick-borne pathogens.  A subunit vaccine is
therefore an attractive alternative for the control of ECF.
MECHANISMS OF PROTECTION AGAINST EAST COAST FEVER
The infection-and-treatment method of immunization gives rise to a transient parasitosis
which is followed by the appearance of genetically restricted cellular responses directed
against the schizont-infected cells.  It is believed that this response is the major
protective mechanism in immune cattle due to the observation that it appears in
animals at the time of remission of the infection (Eugui and Emery, 1989) and
that the immunity can be transferred using thoracic duct lymphocytes (Emery,
198 1).  The T cells which are responsible for this activity have been cloned and
shown to belong to CD8+ subset of T-lymphocytes (Goddeeris et al., 1986).
The role played by these cells has recently been confirmed using transfer
experiments which have clearly demonstrated that CD8+ T cells can confer
protection against a lethal challenge with T. parva sporozoites (McKeever et al.,
1994).  However, recent evidence suggests that immune mechanisms directed
against the sporozoite may also be protective.  Sera from cattle in endemic areas
or those immunized repeatedly with sporozoite lysates can neutralize the
infectivity of sporozoites in vitro (Musoke et al., 1984).  Similar results have
been obtained using monoclonal antibodies (MAbs) raised against surface
antigen of T. parva sporozoites (Musoke et al, 1984; Dobbelaere et al., 1984).
In addition sera from animals immunized with one parasite stock are capable of
neutralizing sporozoites from another stock (Musoke et al., 1984).  These sera
and MAbs recognize a 67 kilodalton (kDa) stage-specific antigen (p67) in
immunoblots (Nene et al., 1992).  Immunogold labelling studies using MAbs
and immune sera have confirmed that p67 antigen is located on the surface of
the sporozoites (lams et al., 1990; Musoke et al., 1993).
   Further analysis with MAbs indicated that at least two B-cell epitopes are
present on p67 and that these are conserved among the sporozoites of different
parasite stocks (Musoke et al., 1984).  A vaccine based on p67 could therefore
circumvent the stock specificity of the responses engendered by the infection-
and-treatment method of immunization.  Since the severity of the disease is
dose-dependent (Jarret et al., 1969), such a vaccine could still be effective even
if only partial neutralization was achieved.
CLONING AND EXPRESSION OF P67
The isolation and characterization of the gene encoding p67 has been described
previously (Nene et al., 1992).  The single copy gene, containing an intron of 29
base pairs, is transcribed only in the sporozoites, and encodes 709 amino acid
residues.  The predicted amino acid sequence incorporates a signal sequence at
the N-terminus, seven sites for N-linked glycosylation and a hydrophobic C-
terminus.  The gene is present in all stocks of T. parva and has a high degree of
homology with the gene encoding SPAG1, a T.annulata sporozoite surface
antigen (Nene et al., 1992).  The primary amino acid sequences suggest that p67
is a membrane protein with a predicted molecular mass of 75 kDa.  The protein
does not contain multiple short amino acid sequence repeats that characterize
several antigens of other protozoan parasites (Enea et al., 1984).
   The p67 gene has been expressed as a C-terminal fusion protein with the
Schistosoma japonicum antigen, Sj-26, using the PGEX expression vector
system (Nene et al., 1992).  Rat anti-serum raised against the purified Sj26-
fusion protein neutralized sporozoite infectivity in vitro (Nene et al., 1992), but
the fusion protein was highly unstable.  On testing alternative expression
systems, the plasmid PMGI, a derivative of the pAS expression system, was
found to be more suitable.  PMGI gives rise to the expression of recombinant
antigens as C-terminal fusion proteins with NS1(Young et al., 1983), a non-
structural protein of influenza virus A. The translational fusion was created by
cloning a repaired 2.3 kbp BamHI fragment containing the p67 gene into the
HpaI site of pMG1.  Transcription of the hybrid gene is regulated by a
temperature-sensitive mutant of the cI repressor gene of bacteriophage lambda
and is driven by the P promoter of lambda.  Expression of the fusion protein is
induced by heat shock and the insoluble protein, termed NSI-p67, contains the
first 85 amino acid residues of NSI, two residues encoded by a DNA linker
sequence and all 709 residues of p67 (Musoke et al, 1992).
IMMUNIZATION AND CHALLENGE OF CATTLE
The antigen for immunization was prepared as described previously (Musoke et
al., 1992).  Nine Boran (Bos indicus) cattle aged between six and eight months,
which were serologically negative for antibodies to T. parva and had been
maintained under strict acaricidal control, were used.  The nine animals were
immunized by subcutaneous inoculation wiTh1 mg of the antigen preparation,
equivalent to 600 µg of NS1-p67, formulated in 3% saponin (Merck).  A control
group, comprising four animals immunized wiTh1 mg of antigen preparation
expressing NS1 and six uninoculated cattle, was included.  The nine cattle as
well as the four controls received further inoculations of the appropriate antigen
at monthly intervals for four months.  Ten days after the final boost all the cattle
were challenged with one LD68 of a T. parva (Muguga) sporozoite stabilate
3087.
Pre-challenge sera from the nine NS1-p67 immunized animals contained
specific antibody titres in excess of 1:62,000 when analysed by sandwich-
ELISA (Katende et al., 1990) using both the native and recombinant antigens
and recognized both antigens as well as several Escherichia coli proteins on
immunoblots (Musoke et al., 1992).  The sera had neutralizing antibody titres
greater than 1:200 in an in vitro sporozoite infectivity neutralization assay
(Musoke et al., 1992).
On challenge, six of the nine cattle immunized with NS1-p67, were protected
against challenge with only two of them showing evidence of infection.  The
remaining three animals underwent severe clinical reactions and were
euthanized.  Total neutralization of the challenge by the four non-reactors was
indicated by the absence of schizont antibodies for 60 days after challenge.
Furthermore, the day 9 lymph-node biopsies of two of the non-reactors were
negative for the presence of T. parva DNA when tested using the polymerase
chain reaction described by Saiki et al., (1988), suggesting that elimination of
the parasites occurred before schizonts were established.  In another group of 11
animals, immunized as described above, six were protected against a
heterologous stock of T. parva.  This result confirmed our earlier observations
that stocks of T. parva sporozoites posses a common conserved neutralization
sensitive epitope(s).
B-CELL EPITOPE MAPPING
The clinical reactions vary, on challenge, from complete protection with no
evidence of disease to severe reactions with fatalities.  The degree of protection
could not be correlated with the titres of antibody as measured by ELISA or the
capacity of the sera to effect neutralization of sporozoites.  In search of a
correlate, we reasoned that animals that exhibit complete protection may
recognize different epitopes than those undergoing severe reactions.  To address
this question, overlapping peptides covering the entire sequence of the p67
molecule were made using pin technology (Chiron Mimotopes).  The peptides
were 15 amino acids in length and overlapped by seven residues.  The peptides
were tested in an ELISA system using neutralizing monoclonal antibodies
(MAbs) generated against recombinant and native p67 antigens, as well as
bovine sera from animals immunized with NS1-p67.  The neutralizing MAbs
recognized four distinct peptides, with three being recognized by MAbs raised
against recombinant p67 and one by TpM12, which was raised against the
native molecule.
   The bovine immune sera recognized only one of the peptides reactive with the
MAbs.  The rest of the peptides recognized by bovine sera lay at either end of
the molecule and none were recognized strongly in the middle of the molecule.
CONCLUDING REMARKS
The recombinant form of p67 protected 60-70% of the immunized cattle on
challenge with an LD68 of T. parva sporozoites.  That protection of the
immunized animals was due to the NS 1 -p67 antigen is indicated by the total
susceptibility of the animals immunized with a lysate of E. coli expressing NS1.
In addition, more recent experiments (data not shown) have shown that the
purified form of the antigen can induce a much higher level of protection.  The
immune mechanisms responsible for protection in the immunized animals have
not been fully elucidated.  The failure of the parasites to establish infection in
the four non-reactors in first experiment suggests that the effect is directed
either against free sporozoites or recently infected cells.  It is likely that the high
antibody titres present in the immunized cattle prior to challenge were involved
in this effect.  However, quantity of the antibody in the immunized cattle did not
correlate with protection, suggesting that the efficiency of neutralization may
have been influenced strongly by the antibody affinity.  It is also possible that T-
cell responses directed at the recently infected cell are involved in the
protection.  There is evidence that p67 is shed by the sporozoite during its entry
into the lymphocyte (Webster et al., 1985).  It is possible that the shed p67
enters the MHC class II antigen presentation pathway, and renders the recently
infected cells susceptible to cytolytic or cytokine-mediated effector function of
CD4+ T cells.  An influence of cytokines on parasite multiplication in vitro has
recently been demonstrated (Preston et al., 1992).  It is of interest to note that in
the closely related Plasmodium, both humoral and cell-mediated responses to
the circumsporozoite antigen have been shown to confer protection (Tsuji et al.,
1990; Orego and Facer, 1993).
For reasons that are not clear, p67-specific T-cell proliferative activity was not
consistently detected in immunized animals up to the time of challenge.
However, T-cell responses have been detected in other animals immunized with
the native p67, and some T-cell clones from these animals recognize the NSI-
p67 molecule.  We are currently investigating this anomaly by measuring
cytokines in supematants from cultures of cells derived from NS1-p67-
immunized animals.
   An efficacious vaccine against a parasite with several stages in the
mammalian host should ideally stimulate protective responses against all its
stages.  Partial neutralization of sporozoites may therefore be a desirable feature
of a sporozoite-based vaccine against T. parva since limited breakthrough of
infection will allow generation of protective responses against the schizont stage
of the parasite.  This was observed to be the case in this study; animals that
showed mild clinical reactions as the result of partial neutralization of
sporozoites generated potent cytotoxic responses against schizont-infected
lymphocytes and were solidly immune to re-challenge with an LD,00.
Since our protocol did not induce protection in all immunized cattle, alternative
delivery systems need to be explored. Nevertheless, our results clearly
demonstrate that it is possible to induce protective immunity to ECF in cattle
with the recombinant p67 sporozoite antigen.
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INTRODUCTION
Infection of livestock with African trypanosomes leads to haematological
changes such as anaemia and pancytopenia (Dargie, 1980; Murray and Dexter,
1988) and to immune defects, including suppression of T-cell responsiveness
(Sileghem and Flynn, 1992) and an excessive increase in the CDS+ B-cell
population in blood and spleen (Naessens and Williams, 1992).  It has been
shown that certain breeds of cattle have evolved mechanisms to reduce the
effects of trypanosome infections (Murray and Dexter, 1988; Paling et al.,
1991b).  At ILRAD, trypanosome-specific immune responses of trypanotolerant
N'Dama cattle (Bos taurus) are being compared with those of trypanosusceptible
Boran (Bos indicus) cattle.  The molecular and cellular basis of trypanotolerance
are poorly defined, but preliminary data suggest that differences exist between
these breeds at the level of T and B-cell responses to trypanosome antigens
during infection.  Clear differences have been reported between N'Dama and
Boran cattle in the quantity, quality and specificity of antibodies produced
following trypanosome infection (Paling et al., 1991a, 1991b; Authie et al.,
1993a, 1993b).  Further characterization of these differences and evaluation of
their role in trypanotolerance will require the availability of reagents for the
analysis of bovine cytokine responses.
INTERLEUKIN-4
Studies in human and murine systems have shown that IL-4, originally described
as B-cell growth and differentiation factor, stimulates the proliferation of T cells
and mast cells and is an important regulator for immunoglobulin isotype switch
(for review, see Paul, 1991).  A cDNA encoding bovine IL-4 (Heussler et al.,
1992) was kindly provided by Dr. D. Dobbelaere.  The sequences encoding the
mature IL-4 molecule were subcloned into the pGEX-3X vector (Smith and
Johnson, 1988) and the fusion protein, termed IL-4-glutathione S-transferase
(GST), was produced in Escherichia coli with typical yields of 3 mg/l bacterial
culture.  Recombinant IL-4-GST (rIL-4-GST) was tested for biological activity
in an assay based on T-cell growth factor activity of IL-4 (TCGF assay).
Proliferative responses are determined by measuring incorporation of 125IUDR
into concanavalin A-activated bovine peripheral blood lymphocytes cultured for
three days in the presence of rIL-4-GST.  Maximum proliferation occurred with
50 ug/ml rIL-4-GST while no responses are induced by the GST carrier alone.
The rEL-4-GST was used to immunize mice in order to raise polyclonal and
monoclonal antibodies (MAb).  Eight hybridomas were selected that recognized
rIL-4-GST but not GST in ELISA screening.  All eight MAbs are of the IgG l
isotype and their ability to block the biological activity of rIL-4-GST is being
tested.  The availability of recombinant bovine IL-4 and specific antibodies
provides useful reagents to investigate T- and B-cell interactions in immune
response to infectious diseases in cattle.
TUMOUR NECROSIS FACTOR
In addition to its tumouricidal and immunoregulatory functions, tumour necrosis
factoi alpha (TNFα) plays an important role in the control and pathogenesis of
infectious diseases.  Specific reagents have been developed at IILRAD to study
the role of TNFα in the pathogenesis of African trypanosomiasis.  Recombinant
bovine TNFα (rTNFα), obtained from Ciba-Geigy SA, Switzerland, was used to
raise polyclonal and monocional antibodies and these fortn the basis of a
bioassay and an immunoassay for TNFα (Sileghem et al., 1992).  In addition,
the full-length coding region of bovine TNFα has been cloned and expressed in
E. coli at ILRAD.  Biologically active RTNFα and the assays specific for TNFα
will be of great value in elucidating the involvement of TNFα in the pathology
associated with diseases such as African trypanosomiasis.
HAEMOPOIETIC CYTOKINES/GROWTH FACTORS
Anaemia is a prominent feature of many chronic inflammatory diseases.  In
livestock, infection with trypanosomes causes a profound decrease in the
numbers of circulating erythrocytes and all other blood cell types.  The
haematological changes during trypanosome-infections have been well
characterized and ILRAD scientists have reported differences between
trypanotolerant N'Dama and trypanosusceptible Boran cattle in the control of
the anaemia (Andrianarivo et al, 1993).  In contrast, the mechanisms that cause
pancytopaenia in trypanosomiasis are poorly understood.  One approach to a
better understanding of these mechanisms is to study the role of cytokines in the
regulation of haemopoiesis.  It is possible that the action of some cytokines
within the bone marrow of infected animals may adversely affect haemopoiesis.
In humans and mice, cytokine-mediated down regulation of bone marrow has
been attributed to TNFα, transforming growth factor-beta (TGFβ) and
interferon gamma (IFNγ).  Conversely, erythropoietin is one of the most
important positive regulators of erythropoiesis (for review, see Koury and
Bondurant, 1992).
   To gain a better understanding of the mechanisms controlling ineffective
haemopoiesis in trypanosomiasis, we have started to clone the genes for bovine
haemopoietic factors.
Stem Cell Factor
Stem cell factor (SCF), also known as c-kit ligand, mast cell growth factor or
steel factor, is an essential regulator for normal haemopoiesis, melanogenesis,
gametogenesis and mast cell growth and development.  In humans and mice it
has been shown that SCF exists in both membrane and soluble forms (Anderson
et al., 1990).  To clone the bovine cDNA portion encoding soluble SCF, primers
were designed based on interspecies homologies.  RNA was isolated from bone
marrow mononuclear cells of Boran cattle and reverse transcribed into cDNA
for use as a template for the PCR reaction.  After subcloning and sequencing of
various PCR fragments, a cDNA clone was selected with an open reading frame
complete to the terminal amino acid residue 174.  A 25-residue leader peptide
similar to that of human SCF is present and homology with human SCF at
amino acid and nucleotide level is 85 and 90%, respectively.  Preservation of
cysteine residues at positions 4, 43, 89 and 139 most likely results in disulphide
bridging identical to that seen in the rodent and primate SCFS.  The   predicted
amino acid sequence of the bovine molecule contains an additional residue at
position 130 that is not present in humans or rodents, but is present in the canine
analog.  Experiments are in progress to express a truncated bovine cDNA
encoding soluble SCF, up to alanine residue 165.
Interleukin-3
Interleukin-3 (IL-3) is produced by activated T cells, activated mast cells and
granulocytes.  This cytokine acts on early progenitors to produce cells of all
haemopoietic lineages and modulates the growth and effector functions of
mature cells such as macrophages, lymphocytes and mast cells.  IL-3 is highly
species-specific in its activity.  Complementary DNA sequences of human and
mouse IL-3 show very low homology: 29% at amino acid level and 45% at the
nucleotide level.  We have amplified and cloned a 533 bp DNA fragment from
cDNA derived from PHA/PMA-stimulated bovine peripheral blood
lymphocytes (PBL) using primers based on 5' and 3' untranslated regions of the
ovine IL-3 cDNA (McInnes et al., 1993).  The bovine cDNA clone contains an
open reading frame of 432 bp encoding a protein of 144 residues.  Homology
with the ovine IL-3 sequence is 85 and 90.5% at amino acid and nucleotide
levels, respectively.  Experiments are under way to produce recombinant
protein, and to identify the biological activity in bovine clonogenic assays.
Erythropoietin
The hormone erythropoietin (EPO) is an important regulator of terminal
erythroid differentiation.  A blunted EPO response is implicated in many
chronic inflammatory diseases (Means and Krantz, 1992) and may also
contribute to the chronic anaemia that is characteristic of trypanosomiasis.  To
address this issue, a cDNA clone containing the complete open reading frame of
bovine EPO has been isolated from Boran kidney tissue.  Recombinant protein
will be produced using an eukaryotic expression system, since glycosylation of
human and mouse EPO has been shown to be essential for biological activity.
ANALYSIS OF BOVINE CYTOKINE RNA EXPRESSION
Because techniques for detection of cytokines at the protein level are sometimes
not sensitive enough, measurement of cytokine RNA expression can be a useful
alternative for the characterization of immune responses in vitro or in vivo.
While assays such as Northern blot and dot blot hybridization are in use at
ILRAD, quantities of RNA are often a limiting factor, so we have also installed
the semi-quantitative reverse transcription PCR (RT-PCR) technique for a
number of bovine cytokines.
   Oligonucleotide primers for the amplification of bovine IL-1α, IL-1β, IL-2,
IL-3, IL-4, IL-6, IL-7, GM-CSF, IFNγ, TGFβ, TNFα, TNFβ and EPO have been
generated.  These primer sets are being used for amplification of cDNA derived
from total RNA.  We have tested several published methods for isolating RNA
from small numbers of cells and have selected the guanidine thiocyanate-
phenol-chloroform extraction method of Chomczynski and Sacchi (1987).  In
order to compare the level of gene expression between different samples,
aliquots are taken during the exponential phase of amplification and products
are hybridized on Southern blots with appropriate digoxigenin-labelled internal
oligonucleotides.  To ensure that equal amounts of cDNA have been used an
amplification with beta actin primers is included.
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INTRODUCTION
Recent information on the effects of cytokines (CK) in vitro and in vivo and
their significance in pathogenesis and immunity has ensured that CK research
will be at the center of future prophylactic and therapeutic developments.  The
practical applications of this accumulated knowledge are now being explored.
One area of application that we believe shows great promise is the use of
selected CK to improve immune responses to vaccine antigens.  The use of CK
in this context has already been explored in cattle by testing the adjuvant
potential of interleukin-1 (IL-1), interleukin-2 (IL-2), and interferon gamma
(IFNγ) in selected antigen systems.  However, this application has not reached
clinical practice due to a variety of problems intrinsic to the use of these potent
biological-response modifiers, including difficulties in formulation and
secondary effects that are often associated with their systemic administration.
This paper will address the research developments that have led us to the
approaches currently being used to exploit adjuvant properties of CK.  In
addition, some concepts will be discussed that might assist in the design of more
rational application of these mediators to improved vaccination strategies.
PROPHYLACTIC EFFECTS OF SINGLE-DOSE, SINGLE-CK
ADMINISTRATIONS
Early assessments of the potential clinical use of CK examined the prophylactic
potential of single-CK, single-dose administrations.  It was observed that
treatment of cattle with IFNγ or IFNα (Barbiuk et al., 1985, 1987, 1991) prior to
sequential challenge with BHV-1 and Pasteurella haemolytica reduced the
severity of clinical signs and mortality.  Virus isolation and immunological
studies suggested that the beneficial effects obtained after IFN administration
were due to immunoregulatory properties rather than the anti-viral activity of
these CK (Barbiuk et al., 1985, 1987, 1991; Bielefeldt Ohmann and Martinod,
1990).
   Exploitation of the immunoregulatory properties of IFNs to ameliorate clinical
manifestations of disease has also been demonstrated in several other
experimental models.  Treatment of calves with IFN  (5 mglanimal) prior to
crowding reduced the incidence of crowding disease (Bielefeldt Ohmann and
Martinod, 1990) and administration of IFNγ prior to Haemophilus somnus
challenge of dexamethasone immunosuppressed calves resulted in reduction of
the severity of pneumonias (Chiang et al., 1990).  In addition, intramuscular
administration of IFNγ to calves prior to infection with Salmonella typhimurium
reduced the degree of septicaemia (Peel et al, 1990) and intramammary infusion
of IFNγ 24 hours prior to challenge with Escherichia coli reduced the number of
infected quarters, prevented death, diminished clinical signs and shortened the
duration of infection (Sordillo and Babiuk, 1991).  More recently the
prophylactic capacity of single-CK, single-dose administrations has also been
demonstrated for IL-1, IL-2, and GM-CSF.  All three CK were shown to protect
mammary glands from the subsequent challenge with Staphylococcus aureus
(Daley et al., 1991).
All of these examples clearly demonstrate the prophylactic effect of CK
administration in a single-dose regimen under experimental conditions where
timing and exposure can be controlled.  However, examples of effective
prophylaxis under field conditions, where these parameters are uncontrollable,
are not as readily available.  In one instance where steers were treated with 5 mg
IFNα at feedlot entry, the effects of treatment were not as striking as those
observed in experimental situations (Babiuk et al, 1991).  Results such as these
suggest that prophylactic approaches using single-dose CK administration
regimes require the use of formulation technologies that allow slow- or pulse-
release of CK to cater for different windows of disease susceptibility.  However,
initial attempts to extend the prophylactic effect of CK using a sustained release
formulation or repeated injections have not been successful.  Administration of
IFNα or IFNγ in consecutive injections failed to protect animals from clinical
manifestions and mortality in the BHV-1/Pasteurella haemolytica model
(authors' unpublished observations), and administration of IFNα in a slow-
release formulation was able to sustain levels of 2'5'A synthetase but failed to
induce a sustained change in flow cytometric profiles associated with IFNα
immunoregulatory properties (authors' unpublished observations).  Thus, it
appears that the immunoregulatory properties of single-dose CK administrations
can only be maintained by careful dosage and timing regimens that cannot be
achieved with current formulation technologies.
These experiences, along with many others described in the literature, suggest
that exploitation of the immunoregulatory properties of CK under field
conditions will require careful selection of protocols designed to regulate
specific immune functions responsible for protection.  Thus CK would be
selected for incorporation in a vaccine on the basis of their capacity to enhance
a desired immune function.
POTENTIATING VACCINES USING CK
Communication between cells of the immune system is governed by a number
of recognition molecules, adhesion molecules, as well as CK.  Recognition of
antigen and engagement of adhesion molecules can be followed by polarized
secretion of CK, influencing their site and mechanism of action.  Under natural
conditions, CK act as ultra-short range mediators and should be compared more
with neurotransmitters than hormones.  From the results of an elegant series of
experiments, Mitchison (1990) proposed a general scheme for interactions
between immune cells.  Ibis scheme involves clusters of two or three cells that
incorporate either T and B cells (2-cell cluster) or T cells, B cells and
interdigitating dendritic cells (3-cell cluster).  These cell clusters facilitate the
delivery of signals for the activation of effector cells.  An excess of CK between
an effector cell and a regulatory cell may have functional significance through
the activation of bystander reactions, which may be either beneficial or
detrimental to the desired immune response.  Mitchison proposed that
administration of low doses of CK should be beneficial since only those cells
already activated by antigen recognition and appropriate second signals would
be expanded.  Conversely, high doses might activate redundant effector
mechanisms that might be ineffectual or detrimental.  We have examined the
effect of CK dose on the outcome of immunization schemes.
Most CK tested to date have shown at least a modest beneficial effect when
administered with recombinant or subunit antigens (Hughes et al., 1991, 1992a)
or with killed or modified live vaccines (Reddy et al., 1990; Nunberg et al.,
1989).  Nonetheless, CK generally exert their adjuvant effect at an optimal dose;
high doses can produce adverse effects, while low doses are ineffective.  This
has been demonstrated with IL-1, IL-2, and IFNγ in different model systems.
The adjuvant activity of IL-1 appears to be both time- and dose-dependent,
with the best activity occurring when the CK is administered at approximately
the same time as the antigen (Staruch and Wood, 1983).  The activity was first
attributed to an indirect effect, such as enhancement of IL-2 release from
antigen-driven cells, but this has been disputed in a series of experiments where
IL-1 enhanced B-cell responses in the presence of antibodies that neutralize IL-2
(Reed et al., 1989).  It is more likely that IL-1 acts through its co-stimulatory
effects on T cells following antigen recognition.  Recombinant bovine IL-1 P
has been administered to cattle in conjunction with a modified live BHV-1
vaccine (Reddy et al., 1990).  Administration enhanced the cytotoxic activity of
peripheral blood cells against BHV-1 infected targets after immunization.  This
augmented response was apparent at all doses of CK tested (33 ng/kg to 1000
ng/kg).  However, augmentation of neutralizing antibodies against the virus
occurred only at 100 ng/kg of IL-1, with higher or lower doses having no effect
when compared to the control.  Likewise, when animals were challenged with
live virus, those animals given 100 ng/kg of recombinant bovine IL-1 P shed
significantly less virus than those animals given lower or higher doses.  These
studies indicate that IL-1 can enhance both cellular and humoral mechanisms of
immunity and, further, that the dose at which this occurs is critical for optimal
effect.
   Following early studies of the adjuvant effects of IL-2, it was proposed that it
has two distinct mechanisms of action in vivo, one being to overcome genetic
low responsiveness and the other being that of a classical adjuvant, i.e. to
enhance a response to antigen.  The different activities appeared to be related to
formulation with IL-2 in oil overcoming genetic low responsiveness and
aqueous preparations providing an adjuvant effect (Heath and Playfair, 1992).
However, IL-2 has been shown to overcome Ir gene control in a manner similar
to that in which KLH can overcome genetic non-responsiveness to peptides
(Good et al., 1988).  These authors concluded that KLH induces a strong but
localized secretion of IL-2 that has a direct effect on the proliferation of peptide-
specific T cells.  They further proposed that delivering erogenous IL-2 acts in
the same way by taking the place of the KLH-induced IL-2 secretion.  Thus, the
ability of IL-2 to overcome genetic non-responsiveness was not due to
formulation; rather, it was due to a localized over-production of CK.  Few
studies have been carried out in which these diverse activities of IL-2 have been
examined simultaneously.  In all of those cases where genetic non-
responsiveness was examined, the adjuvant effects of the CK in normal
(responding) animals was not considered.  Further, in all but a few studies, the
dose of CK that was administered was extremely high (up to 1 mg/kg).  These
experiments have been adequately summarized elsewhere (Hughes and Babiuk,
1992).  Very few studies have examined a dose response effect of IL-2 in
conjunction with vaccines.  However, in those instances where this has been
done, it is clear that high doses of IL-2 can induce suppression of the specific
response, whereas lower doses induce an adjuvant effect.  An appropriate dose
of IL-2 can induce up to a 25-fold increase in the immune response to killed
rabies vaccine (Nunberg et al., 1989).  When extremely low doses of IL-2 (0.5
µg/Kg) were given in a multiple dose regimen to cattle following vaccination
with authentic glycoprotein D (gD) isolated from BHV-1, there was a 25-fold
increase in the immune response to the antigen (Hughes et al., 1991).  At this
dose of IL-2, no other detectable biological effect can be determined (Campos et
al., 1992).  This may indicate that the desired effect, enhanced specific
activation in the absence of a non-specific bystander response, is being
achieved.
A similar trend has been observed with the use of IFNγ in vaccination
protocols.  In a series of studies, Heath and Playfair have demonstrated that
there is a strict optimum dose for the adjuvant effect of IFNγ.  When IFNγ was
administered in excess, there was either no effect or suppression of the response
(Playfair and DeSouza, 1987).
As mentioned earlier, initial work in the use of CK as adjuvants was based on
the principle that the CK should be present simultaneously with antigen to
ensure that antigen reactive cells were driven to respond.  Repeated
administration of IL-2 improved the efficacy of a HSV-2 gD vaccine when IL-2
was given throughout the course of the 17-day vaccination schedule (Nunberg et
al., 1989).  Realization of the impracticality of this type of schedule led several
investigators to prolong the presence of the IL-2 through encapsulation, PEG-
modification or incorporation in liposomes (Heath and Playfair, 1992).  The last
two approaches were shown to be effective as adjuvants in vaccine
formulations.  The PEG IL-2 formulation was effective in providing protection
to mice from rabies at a lower dose (0.05 versus 0.1 µg) and with fewer
injections (1 dose/day versus 2 doses/day) but the CK still needed to be
administered for five days (Nunberg et al., 1989).  A liposomebased IL-2
formulation also provided protection in mice against challenge with influenza A
virus, suggesting that both cellular and humoral responses can be effectively
stimulated using this approach (Heath and Playfair, 1992).  In addition,
improvement of antigen-specific humoral responses has been observed after
administration of IL-2 in an emulsion formulation that is believed to extend the
lifetime of the entrapped IL-2 (Heath and Playfair, 1992).  It is possible that
liposomes and emulsions activate phagocytic cells and cause the local release of
other CK capable of acting in synergy or counteracting the administered IL-2.
Therefore, the results of these studies may not be solely due to the effect of
administered IL-2.  The examples provided above demonstrate the benefits of
prolonging the CK effects through formulation.  However, extending the
circulating lifetime of the CK does not limit its activity to a specific location
such as a regional lymph node.  The CK may still stimulate inappropriate
immune responses in potentiating the response to the vaccine.
When doses and localization of CK are uncontrolled, there is a danger that
bystander reactions could lead to autoimmune disease.  This has been observed
in an experimental model as well as in patients who have been given large doses
of CK (IL-2 or IFNα) for treatment of renal cell carcinoma and melanoma
(Scaizo et al., 1990).  These data have indicated that IL-2 may have the ability
to overcome tolerance to auto-antigens, with resulting autoimmune disease.
Indeed, IL-2 has been termed a 'pro-autoimmune' lymphokine (Kroemer and
Martinez, 1992).  These observations have led investigators to associate the CK
with antigen through chemical linkage or by co-expression in live vectors to
guarantee delivery of the CK to the same local environment as the vaccine
antigen.  This approach not only ensures that CK and antigen reach the correct
destination at the same time, but it also allows the dose of CK to be optimized
by this method so that activation of bystander reactions does not occur.  Results
from virus challenge following immunization with CK/antigen-double vaccinia
recombinants demonstrated that there was no reduction in immunogenicity of
either the vaccinia antigens or the recombinant antigen in the case of IL-
2/HSV/vaccinia and IL-2/influenza/vaccinia constructs.  However, co-
expression of the CK did not provide any improvement in protection when
compared to the expression of antigen alone (Heath and Playfair, 1992).
Therefore, direct linkage of antigen with a CK may hold the greatest promise for
the development of vaccines that use the CK as immune potentiators.
Association of CK with antigens has been accomplished through chemical
coupling, genetic fusion, or the formation of ternary complexes such as CK-
biotin-avidin.  The CK used in these formulations have been an IL-1 β
nonapeptide, IL-2, IFNγ, and GM-CSE
The initial attempts to associate CK with non-viable antigens used an IFNγ-
biotinavidin complex as an immunogen without additional adjuvant.  This
complex induced increased anti-avidin antibody titres and significantly
improved the DTH response to avidin as measured by ear swelling.  These data
suggested that the expected Thl response was induced.  However when the anti-
avidin antibody responses of Gl and G2a subclasses were examined, there was
no statistical difference between the group immunized with the complex and the
control group.
Fusions or chimaeric molecules incorporating antigen and CK components
have provided interesting results.  It has been shown in vitro that the bioactivity
of IL-1, IL-2, and GM-CSF in such molecules is retained, providing
encouragement for their potential in vivo effects.  IL-2 has been genetically
fused to the HSV-1 gD and the lktA gene product from Pasteurella haemolytica
and used to immunize animals (Hughes et al., 1992a; Hazama et al., 1993a).  In
the latter study cattle were immunized with the chimera in combination with an
emulsion adjuvant, using a multiple step immunization schedule.  No
improvement of either the humoral or cellular immune response was observed
when compared to that induced by the IktA antigen alone.  However, the
adjuvant used in these studies was a strong inducer of immune responses to
lktA, so that detection of an IL-2-related improvement was difficult.
In the HSV-1 gD study, the fusion protein was administered to mice either
parenterally or intranasally, without other adjuvants (Hazama et al., 1993a,
1993b).  Following subcutaneous immunization with the gD-IL-2, specific
antibody titres, DTH responses and protection were equal to that induced by the
gD formulated in complete Freud's adjuvant.  The adjuvant effect of the fused
IL-2 was not extended to an additional antigen incorporated in the inoculum.
The use of the same IL-2-gD protein administered intranasally was also
examined.  The chimera was a better primary immunogen than gD or a mixture
of IL-2 and gD and induced significant protection to intranasal challenge with
HSV-2.
An alternative approach for the generation of immunogenic chimaeric
molecules used peptide synthesis to link a nonapeptide derived from IL-1β and
hepatitis B S1 antigen (Kanury and Nayak, 1990).  Immunization with this
synthetic chimaera adsorbed on aluminum hydroxide improved the number of
mice with anti-peptide antibodies following primary immunization and
increased the final anti-peptide titre when compared to those in mice immunized
with a mixture of antigen and CK.  The enhanced antibody response was seen in
mice of four different haplotypes.  A separate study examined the effect of
genetic insertion of the same IL-1β peptide into the immunizing proteins
(Beckers et al., 1993).  The immunogenicity of these recombinant proteins was
evaluated in the absence of other adjuvants.  Specific responses were
significantly greater to the chimaera than to control proteins over the period
form day 4-38 after primary immunization.
It is clear that CK are effective adjuvants and that the delivery of antigen and
CK to the same cell or micro location can further improve the immune response
while limiting untoward stimulation of other immune cells.  The use of other
adjuvant compounds in some of the studies has made analysis of the exact role
of the CK in these vaccine formulations difficult.  However, in most cases it
appears that the addition of the CK to antigens improves both humoral and
cellular responses.  The results do not conform to the current paradigm for the
role of CK in directing immune responses to exclusive pathways.  It was
originally thought that administration of a Th1 CK such as IL-2 or INFY would
result in a Th1 -type responses against the immunizing antigen.  Similarly, it
was assumed that incorporation of Th2 CK such as IL-4 or EL-5 in a vaccine
would enhance certain type of antibody responses.  While the Thl-Th2 paradigm
is clearly significant in the pathogenesis of certain diseases and may be relevant
to the use of CK therapy in a limited number of infectious diseases (Yamamura
et al., 1991), it appears that it does not apply to the use of CK as immunological
adjuvants with vaccines.  We have observed that when IL-2 is administered with
a subunit antigen, it does not appear to influence the isotype specificity of the
humoral response or to shift the response towards cellular or humoral elements
(Hughes et al., 1991, 1992b).  Indeed, all responses were equally enhanced.
Similarly, administration of IL-1 enhanced both humoral and cellular immunity
against a modified live B HV-1 vaccine (Reddy et al, 1990).  Furthermore, when
a HSV gD-IL-2 chimeric molecule was administered intranasally, there was an
enhanced lgA production in the lungs of mice.  In this case, a Thl CK was
apparently enhancing a Th2 response (Hazama et al., 1993b).  Other workers
immunized mice with liposomes containing antigen and IL-2 or IL-4 and,
contrary to the current paradigm for mucosal T-cell help, observed that only the
IIL-2-containing liposomes enhanced antigen-specific lgA responses (Abraham
and Shah, 1992).  Ibus the use of CK as immunological adjuvants depends on
many factors including the nature of the antigen, the dose of CK, the route of
administration, and the formulation used.  All of these factors may be as
important to the outcome of the immunization as the CK itself.
With the exception of the viral vectors, the formulations described above do
not target antigen to either pathway for association with MHC molecules.  The
use of formulations based on acid-sensitive liposomes (Reddy et al., 1992),
iscoms (Taskahashi et al., 1991), or certain adjuvants (Wu et al., 1992) that
allow antigen association with MHC class I molecules in conjunction with CK
has not been reported to date.  Use of CK in association with these delivery
systems might alter the broad immune enhancement so far observed with CK.
This approach may allow more predictable specific induction of a desired
immune response.  Thus it may be possible in the future to use a CK associated
with neutral liposomes containing an antigen to induce an IgGI response, while
a different CK associated with acid-sensitive liposomes containing an antigen
might induce a strong DTH and CTL response, with neither formulation
enhancing the alternative response.
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_______________________________________________________________
Summary of discussion
Chairperson: D.J.L. Williams
Rapporteurs: S. Morzaria and K. Taylor
_______________________________________________________________
This session dealt with how appropriate immune responses can be enhanced
through the design system.  Four papers were presented that described how
different responses of the immune system to the same challenge can influence
the outcome of infection or immunization with regard to pathogenesis or
protection.  The issue of influencing the outcome of an immune response
through the use of defined delivery systems and cytokine reagents was also
addressed.
The plasticity of the immune response received some discussion.  To identify
the mechanisms involved in protective immune responses, it was clear that
detailed analysis of the roles of different components of the immune system is
necessary.  The use of in vivo experiments based on gene knockouts, cytokine
treatment, administration of neutralizing antibody and depletion of immune cell
subsets has yielded valuable information on the role of various immune cell
types in protection and pathogenesis in a number of experimental systems.
However, it should be noted that compensatory mechanisms can be invoked
through the experimental removal of the major arm of the normal responses to a
given immunological challenge, and so results of these experiments must be
interpreted with care.  It was clear from the experiences at ILRAD with the use
of in vivo depletion techniques in cattle that the application of these
methodologies in this species is still subject to a number of technical problems.
The group focused for a period on the significance of the fine specificity of
antibody responses to the outcome of immunizations and infections.  In
particular, a distinction was made between the epitope specificities of NIAB and
those of polyclonal antisera raised by immunization.  The distinction was
highlighted by an observation made in the murine malaria system where a MAb
that recognizes a 3 amino acid epitope of the circumsporozoite protein
neutralizes sporozoite infectivity, whereas immunization with the full length
protein fails to protect.  This may reflect steric hindrance of this neutralizing
epitope by other antibodies, but does highlight the importance of immunizing
against the protective epitope.
Emphasis was placed on the importance of antigen delivery to the outcome of
immunization.  Events occurring at the point of delivery determine the nature of
the resulting immune response.  Great care must therefore be taken in the
selection of the site of inoculation and the delivery system or adjuvant
preparation to be used.
It was pointed out that experiences in the respiratory syncitial virus (RSV)
system indicate that the manner in which individuals are immunized can also
profoundly affect the outcome of a challenge infection, with certain
immunization regimes being associated with enhanced lung pathology.  The
latter appears to relate to a Th-2 type response.
Considerable discussion focused on the results of immunizations performed at
ILRAD with the p67 surface antigen of T. parva sporozoites.  Levels of
protection already achieved in the face of needle challenge were considered
highly promising, and the discussion turned to possible ways in which this could
be improved.  It was agreed that future research should aim towards identifying
immunological parameters that correlate with protection and generating a
challenge dose that will mimic field challenge.
   A final point was made that ILRAD should continue to develop new reagents
necessary for immunological research in cattle rather than restricting its efforts
to areas determined by available reagents.
_______________________________________________________________
Concluding discussion
_______________________________________________________________
The concluding discussion was organized around summary statements prepared
by the chairperson of each session of the meeting, which identified the key
themes and questions that arose from the session.
SESSIONS I AND II
Initial discussion of this part of the programme focused on whether it was
actually necessary to complement a p67-based vaccine with antigens that would
provoke cytotoxic T lymphocyte responses.  It was pointed out that the
combined complexities of Theileria parva and the bovine MHC might pose
severe problems to the design of a vaccine that would stimulate different arms
of the immune response against distinct stages of the parasite, and that it might
therefore be more prudent in the short term to explore further the potential of
the p67 antigen.
The discussion then turned to the state of knowledge of the bovine MHC and
the value of peptide stripping as opposed to screening of cDNA libraries for the
identification of antigens that constitute targets for CTL.  Examples of the
identification of such antigens in virus systems were considered too simple and
possibly invalid in the context of T. parva, and it was suggested that tumours
were perhaps more analogous to this system.  The predominant concern was that
technologies for the isolation of CTL peptides were very new and had yielded
only limited numbers of peptides that might have promise as vaccine candidates.
It was nonetheless recognized that CTL had been demonstrated to provide
protection against T. parva, and that the technologies for peptide isolation and
cDNA screening were now established at ILRAD with collaborations in place
with the leading laboratories in the area.  All of these elements should maximize
the likelihood of identifying candidate antigens.  It was also pointed out that the
number of schizont transcripts was estimated at no more than 4000 and that
there had been important developments in the study of bovine class I and II
MHC that would complement the search for antigens.  A general consensus was
reached that ILRAD should continue its search for CTL epitopes using peptide
stripping in conjunction with other approaches.
A point about the value of mouse models and the use of knock-out mice in
identifying protective responses led to a lively discussion on their possible use
in the systems of relevance to URAD. 7lis was largely driven by the report of
difficulties encountered in eliminating all cells of a particular population during
depletion experiments in cattle. here was no question of the value of mouse
models in establishing mechanisms of immunity; the example of helper T-cell
responses in Leishmania was a good one in that a set of rules had been
established that could be extrapolated to other species.  However, it was not
considered realistic for ILRAD to become involved in in-depth studies in mice
in the context of trypanosomiasis research.  Large numbers of quality cattle of
defined breed and genetic background and the capacity to work with
monozygous and chimaeric twins were perceived as a major resource of the
Institute that confer considerable comparative advantage.
SESSIONS III, IV AND V
Discussion on the search for a vaccine against trypanosomiasis focused on both
anti-parasite and anti-disease approaches.  Differences between Boran and
N'Dama cattle in their responses to infection were listed (Table 1) as an aid to
discussion and major areas of debate were the role of parasite load in the
pathogenesis of the disease and the significance of the failure of the more
susceptible Boran cattle to effect isotype switching during their response.
It was observed that the endocrinological failure described in trypanosomiasis
closely resembles that seen in malaria, where Plasmodium antigens disturb the
insulin signalling pathway.  The possibility was raised that trypanosome
antigens might induce a similar perturbation, perhaps resulting in pituitary
dysfunction.  A role for cytokines or hormonal reactions in metabolic and
physiological disturbances can be investigated, even in such a complicated
disease as trypanosomiasis.  It was suggested that a single mechanism might
control parasite load, so that an anti-disease approach could complement an
anti-parasite approach.
It was stressed that the more we can learn about cytokines, the more we will
learn about immunology and disease.  Massive disturbances of the immune
system occur in both trypanosomiasis and ECF, and few, if any, investigations
are being conducted elsewhere on the involvement of cytokines under such
circumstances.  The capacity at ILRAD to explore bovine cytokine function was
perceived as impressive and of great value in dissecting the relative roles of
TNF, IFNγ and IL-1 in damage associated with acute phase responses.  This
information is important for determining whether the pathology of these
diseases arises from the parasite or the host response.  It was pointed out that the
striking differences in immunoglobulin responses between Boran and N'Dama
cattle may be related to immune memory as well as isotype switching; this will
be reflected in the cytokines produced by T cells and other regulatory cells in
response to challenge, and will become apparent as the investigations progress.
It was proposed that the trypanosome cysteine protease, a molecule that might
induce pathogenic effects, could be used as a tool to investigate the disturbances
in the immune response.  The possibility that degradation products of antigens
such as this might be responsible for the pathology should not be ruled out.
Table 1. Differences between N'Dama and Boran cattle in their responses to infection with
Trypanosoma congolense.
_____________________________________________________________________
Clinical parameter                                                                  N'Dama                           Boran
_____________________________________________________________________
Parasitaemia lower                          higher
Anaemia (PCV) less severe
Neutropaenia less severe
_____________________________________________________________________
Antibody responses Igm IgGI IgG2 Igm IgGI             IgG2
_____________________________________________________________________
Congopain + ++   - +     -            -
BiP (hsp70) + ++   -   ++ +                  -
VSG (cryptic) + ++   - + +                   -
SEE-VSG + +   + + +                 +
β-Galactosidase - - -   ++ -                            -
_____________________________________________________________________
Macrophage Function
IL-1/1L-6 Activity + earlier peak +
Trypanosome phagocytosis + earlier peak +
Erythrophagocytosis +
_____________________________________________________________________
T-cell proliferation ++ +
CD5+ B-cells + +
Serodeme-specific acquired immunity ++ +
_____________________________________________________________________
While the functional role of γδ T cells is still poorly understood, it was
acknowledged that the results of studies at ILRAD complements those emerging
from other laboratories.  Considerable numbers of these cells occur in the
spleens and peripheral blood of young cattle and since young animals are the
principal target for improved vaccines, elucidation of the role of this population
in bovine immunity is an important goal.  A thorough investigation of their role
in trypanosomiasis and ECF was considered justified.  It was pointed out that
cytotoxicity was not the only mechanism of controlling intracellular parasites.
There are many examples of protection being mediated by inhibition of growth,
evidence for this has been presented for both trypanosomiasis and Theileria
parasites.  Hence, γδ T cells need not necessarily act through cytotoxicity but
could exert their function by inhibition of growth.
The issue of reversed age resistance in which young cattle can tolerate or
control parasite infection and develop immunity in the absence of disease was
raised, and it was speculated that γδ T cells may be involved in this
phenomenon.  It was also asked whether natural killer (NK) cells might be
involved.  These cells are present in cattle and have a CD2+ phenotype but do
not express CD3, CD4 or CD8.  They are present in very low numbers in blood
and are readily activated to kill by cytokines.  A minor role has been attributed
to them in killing T. parva-infected cells.
A brief discussion on the plasticity of the immune response ensued despite
some confusion as to its definition.  The meeting concluded that the research
programmes at ILRAD should focus on the major effector mechanisms in the
target animal population and the identification of the parasite antigens that
provoke them.
It was emphasized that development of the p67 antigen of T. parva as a
vaccine will proceed in conjunction with a commercial partner.  The mandate of
ILRAD is to identify protective antigens and confirm their vaccine potential by
presenting them effectively to the target the animal.  Vaccine production and
quality control will be the responsibility of the commercial partner.
Finally, it was indicated that studies in the field of cell biology would
contribute to the search for antigens through enhanced knowledge of the
parasite and its interactions with the host.  This information could highlight
those molecules that are likely to constitute targets for CTL and so reduce the
number of antigens to be screened for vaccine potential.
_______________________________________________________________
Conclusions and recommendations
• The p67 antigen of Theileria parva is an extremely promising vaccine
candidate antigen and its potential should be explored vigorously.
Although the first promising candidate antigen may not prove to be a
successful vaccine, these efforts will considerably enhance the capacity of
the laboratory in vaccine development so that further antigens will be
exploited rapidly.
• The search for schizont antigens should be pursued through peptide
stripping, cDNA screening and other approaches.  A successful vaccine for
T. parva may require stimulation of different compartments of the immune
response by antigens of different stages of the parasite.
• Existing studies of bovine MHC should be continued and expanded to
provide enhanced support for immunological studies and immunization
trials, and for the identification of protective antigens.
• Investigations of the role of cytokines in immunity, parasite control and
pathology should be expanded in studies of both T. parva and trypanosome
infections.
• The search for a trypanosome vaccine should focus on both anti-parasite
and anti-disease strategies.
• Studies of the cell biology of both T. parva and trypanosomes should be
expanded to provide fundamental information towards a better
understanding of the parasites and host-parasite interactions and greater
opportunities for identifying potentially protective antigens.
_______________________________________________________________
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